

* * * * * STN Columbus * * * * *

FILE 'HOME' ENTERED AT 07:00:59 ON 15 MAY 2007

=> fil reg

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

0.21

0.21

FILE 'REGISTRY' ENTERED AT 07:01:12 ON 15 MAY 2007

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2007 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 14 MAY 2007 HIGHEST RN 934733-40-1

DICTIONARY FILE UPDATES: 14 MAY 2007 HIGHEST RN 934733-40-1

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH December 2, 2006



Please note that search-term pricing does apply when conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

<http://www.cas.org/support/stngen/stndoc/properties.html>

=>

Uploading C:\Program Files\Stnexp\Queries\QUERIES\10511691.str



chain nodes :

13 14 25

ring nodes :

1 2 3 4 5 6 7 8 9 10 11 12 15 16 17 18 19 20

chain bonds :

1-25 13-14 14-15

ring bonds :

1-2 1-6 2-3 3-4 4-5 5-6 7-8 7-12 8-9 9-10 10-11 11-12 15-16 15-20
16-17 17-18 18-19 19-20

exact/norm bonds :

1-2 1-6 1-25 2-3 3-4 4-5 5-6 13-14 14-15

normalized bonds :

7-8 7-12 8-9 9-10 10-11 11-12 15-16 15-20 16-17 17-18 18-19 19-20

Match level :


1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:Atom
11:Atom 12:Atom 13:CLASS 14:CLASS 15:Atom 16:Atom 17:Atom 18:Atom 19:Atom
20:Atom 23:Atom 24:Atom 25:CLASS

L1 STRUCTURE UPLOADED

=> d

L1 HAS NO ANSWERS

L1 STR



Structure attributes must be viewed using STN Express query preparation.

=> s l1

SAMPLE SEARCH INITIATED 07:02:15 FILE 'REGISTRY'

SAMPLE SCREEN SEARCH COMPLETED - 63 TO ITERATE

100.0% PROCESSED 63 ITERATIONS

3 ANSWERS

SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**

BATCH **COMPLETE**

PROJECTED ITERATIONS: 784 TO 1736

PROJECTED ANSWERS: 3 TO 163

L2 3 SEA SSS SAM L1

=> s l1 full

FULL SEARCH INITIATED 07:02:19 FILE 'REGISTRY'

FULL SCREEN SEARCH COMPLETED - 1039 TO ITERATE

100.0% PROCESSED 1039 ITERATIONS

7 ANSWERS

SEARCH TIME: 00.00.01

L3 7 SEA SSS FUL L1

=> s l3 and caplus/lc
54188266 CAPLUS/LC
L4 7 L3 AND CAPLUS/LC

| COST IN U.S. DOLLARS | SINCE FILE ENTRY | TOTAL SESSION |
|----------------------|------------------|---------------|
| FULL ESTIMATED COST | 177.50 | 177.71 |

FILE 'CAPLUS' ENTERED AT 07:02:26 ON 15 MAY 2007
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2007 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 15 May 2007 VOL 146 ISS 21
FILE LAST UPDATED: 14 May 2007 (20070514/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply. They are available for your review at:

<http://www.cas.org/infopolicy.html>

=> s l4
L5 12 L4

| COST IN U.S. DOLLARS | SINCE FILE ENTRY | TOTAL SESSION |
|----------------------|------------------|---------------|
| FULL ESTIMATED COST | 0.94 | 178.65 |

FILE 'REGISTRY' ENTERED AT 07:03:47 ON 15 MAY 2007
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2007 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 14 MAY 2007 HIGHEST RN 934733-40-1
DICTIONARY FILE UPDATES: 14 MAY 2007 HIGHEST RN 934733-40-1

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH December 2, 2006



Please note that search-term pricing does apply when conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

<http://www.cas.org/support/stngen/stndoc/properties.html>

=>

Uploading C:\Program Files\Stnexp\Queries\QUERIES\10511691.str



chain nodes :

13 14 25

ring nodes :

1 2 3 4 5 6 7 8 9 10 11 12 15 16 17 18 19 20

chain bonds :

1-25 13-14 14-15

ring bonds :

1-2 1-6 2-3 3-4 4-5 5-6 7-8 7-12 8-9 9-10 10-11 11-12 15-16 15-20
16-17 17-18 18-19 19-20

exact/norm bonds :

1-2 1-6 1-25 2-3 3-4 4-5 5-6 13-14 14-15

normalized bonds :

7-8 7-12 8-9 9-10 10-11 11-12 15-16 15-20 16-17 17-18 18-19 19-20

Match level :


1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:Atom
11:Atom 12:Atom 13:CLASS 14:CLASS 15:Atom 16:Atom 17:Atom 18:Atom 19:Atom
20:Atom 23:Atom 24:Atom 25:CLASS

L6 STRUCTURE UPLOADED

=> d

L6 HAS NO ANSWERS

L6 STR



Structure attributes must be viewed using STN Express query preparation.

=> s l6

SAMPLE SEARCH INITIATED 07:04:06 FILE 'REGISTRY'

SAMPLE SCREEN SEARCH COMPLETED - 13700 TO ITERATE

14.6% PROCESSED 2000 ITERATIONS
INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)
SEARCH TIME: 00.00.01

2 ANSWERS

FULL FILE PROJECTIONS: ONLINE **COMPLETE**
BATCH **COMPLETE**

PROJECTED ITERATIONS: 266988 TO 281012

PROJECTED ANSWERS: 52 TO 496

L7 2 SEA SSS SAM L6

=> s l6 full

FULL SEARCH INITIATED 07:04:11 FILE 'REGISTRY'

FULL SCREEN SEARCH COMPLETED - 271382 TO ITERATE

100.0% PROCESSED 271382 ITERATIONS
SEARCH TIME: 00.00.04

386 ANSWERS

L8 386 SEA SSS FUL L6

=> s l8 and caplus/lc

54188266 CAPLUS/LC

L9 380 L8 AND CAPLUS/LC


=> s l8 not l9

L10 6 L8 NOT L9

=> d l10 1-6

L10 ANSWER 1 OF 6 REGISTRY COPYRIGHT 2007 ACS on STN
 RN 789486-69-7 REGISTRY
 ED Entered STN: 28 Nov 2004
 CN 2H-1,2,3-Triazole-4-methanamine, 5-[[[(2R,3S)-2-[(1R)-1-[3,5-bis(trifluoromethyl)phenyl]ethoxy]-3-(4-fluorophenyl)-4-morpholinyl]methyl]-N,N-dimethyl-, rel- (9CI) (CA INDEX NAME)
 FS STEREOSEARCH
 MF C26 H28 F7 N5 O2
 CI COM
 SR CA


Relative stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L10 ANSWER 2 OF 6 REGISTRY COPYRIGHT 2007 ACS on STN
 RN 781611-04-9 REGISTRY
 ED Entered STN: 16 Nov 2004
 CN 2H-1,2,3-Triazole-4-methanamine, 5-[[[(2S,3R)-2-[(1S)-1-[3,5-bis(trifluoromethyl)phenyl]ethoxy]-3-(4-fluorophenyl)-4-morpholinyl]methyl]-N,N-dimethyl-, (9CI) (CA INDEX NAME)
 FS STEREOSEARCH
 MF C26 H28 F7 N5 O2
 CI COM
 SR CA


Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L10 ANSWER 3 OF 6 REGISTRY COPYRIGHT 2007 ACS on STN
 RN 740065-61-6 REGISTRY
 ED Entered STN: 05 Sep 2004
 CN 3H-1,2,4-Triazol-3-one, 5-[[[2-[[1-[(3,5-bis(trifluoromethyl)phenyl)ethoxy]-3-(4-fluorophenyl)-4-morpholinyl]methyl]-2,4-dihydro-4-(phosphonooxy)-, [2R-[2α(R*),3α]]-, (9CI) (CA INDEX NAME)
 FS STEREOSEARCH
 MF C23 H22 F7 N4 O7 P
 CI COM
 SR CA


Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L10 ANSWER 4 OF 6 REGISTRY COPYRIGHT 2007 ACS on STN
 RN 557088-45-6 REGISTRY
 ED Entered STN: 30 Jul 2003
 CN Benzeneethanol, β-[[[(2R,3S)-3-(4-fluorophenyl)-4-(1H-1,2,4-triazol-3-ylmethyl)-2-morpholinyl]oxy]-3,5-bis(trifluoromethyl)-, (R,S)-rel- (9CI) (CA INDEX NAME)
 FS STEREOSEARCH
 MF C23 H21 F7 N4 O3
 CI COM
 SR CA


Relative stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT


L10 ANSWER 5 OF 6 REGISTRY COPYRIGHT 2007 ACS on STN
 RN 265121-02-6 REGISTRY
 ED Entered STN: 17 May 2000
 CN Phosphonic acid,
 [3-[[[(2S,3S)-2-[[3,5-bis(trifluoromethyl)phenyl]methoxy]-
 3-phenyl-4-morpholinyl]methyl]-2,5-dihydro-5-oxo-1H-1,2,4-triazol-1-yl]-
 (9CI) (CA INDEX NAME)
 FS STEREOSEARCH
 MF C22 H21 F6 N4 O6 P
 CI COM
 SR CA

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L10 ANSWER 6 OF 6 REGISTRY COPYRIGHT 2007 ACS on STN
 RN 171298-04-7 REGISTRY
 ED Entered STN: 13 Dec 1995
 CN 1,2,3-Triazolidine-4-methanamine, 5-[[[2-[[1-[3,5-
 bis(trifluoromethyl)phenyl]ethoxy]-3-phenyl-4-morpholinyl]methyl]-N-ethyl-
 1(2 or 3)-methyl-N-(1-methylethyl)- (9CI) (CA INDEX NAME)
 MF C30 H41 F6 N5 O2
 CI IDS, COM
 SR CA



D1-Me

=> fil caplus
COST IN U.S. DOLLARS

| SINCE FILE | TOTAL |
|------------|---------|
| ENTRY | SESSION |
| 189.20 | 367.85 |

FULL ESTIMATED COST

FILE 'CAPLUS' ENTERED AT 07:05:03 ON 15 MAY 2007
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2007 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 15 May 2007 VOL 146 ISS 21
FILE LAST UPDATED: 14 May 2007 (20070514/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply. They are available for your review at:

<http://www.cas.org/infopolicy.html>

=> d his

(FILE 'HOME' ENTERED AT 07:00:59 ON 15 MAY 2007)

FILE 'REGISTRY' ENTERED AT 07:01:12 ON 15 MAY 2007

| | |
|----|----------------------|
| L1 | STRUCTURE UPLOADED |
| L2 | 3 S L1 |
| L3 | 7 S L1 FULL |
| L4 | 7 S L3 AND CAPLUS/LC |

FILE 'CAPLUS' ENTERED AT 07:02:26 ON 15 MAY 2007

| | |
|----|---------|
| L5 | 12 S L4 |
|----|---------|

FILE 'REGISTRY' ENTERED AT 07:03:47 ON 15 MAY 2007

| | |
|-----|------------------------|
| L6 | STRUCTURE UPLOADED |
| L7 | 2 S L6 |
| L8 | 386 S L6 FULL |
| L9 | 380 S L8 AND CAPLUS/LC |
| L10 | 6 S L8 NOT L9 |

FILE 'CAPLUS' ENTERED AT 07:05:03 ON 15 MAY 2007

=> s 19

| | |
|-----|--------|
| L11 | 237 L9 |
|-----|--------|

=> s l11 and 15

| | |
|-----|---------------|
| L12 | 11 L11 AND L5 |
|-----|---------------|

=> s l12 not 15

| | |
|-----|--------------|
| L13 | 0 L12 NOT L5 |
|-----|--------------|

=> s l5 not l12
L14 1 L5 NOT L12

=> d ibib abs hitstr

L14 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2003:361810 CAPLUS

DOCUMENT NUMBER: 139:159162

TITLE: Kinetic analysis and subambient temperature on-line

on-column derivatization of an active aldehyde

LoBrutto, R.; Bereznitski, Y.; Novak, T. J.;

DiMichele, L.; Pan, L.; Journet, M.; Kowal, J.;

Grinberg, N.

CORPORATE SOURCE: RY818-C220, Merck Research Laboratories, Rahway, NJ,

07065-0914, USA

SOURCE: Journal of Chromatography, A (2003), 995(1-2), 67-78

CODEN: JCRAEY; ISSN: 0021-9673

PUBLISHER: Elsevier Science B.V.

DOCUMENT TYPE: Journal

LANGUAGE: English

AB The chromatog. anal. of aldehydes under typical reversed-phase conditions may be a challenging task due to an equilibrium process giving a gem diol species regardless of acidic or basic conditions. Initially, a reversed-phase HPLC gradient elution was developed to determine the amount of an

acetylenic aldehyde in a reaction mixture. Significant fronting was observed

under acidic and basic conditions even at -5°. In order to circumvent this problem, a reversed-phase HPLC gradient method on a C18 column at subambient temperature was developed using diethylamine as a

mobile

phase additive for online on-column derivatization of the aldehyde

moiety.

The online on-column reaction rate for the derivatization of the aldehyde

with diethylamine was determined as a function of column temperature. An

Arrhenius

plot was constructed and the activation energy was calculated. The

chromatog.

behavior of the derivatized acetylenic aldehyde and products formed

in-situ in the chromatog. system were studied at various temps. ranging

from -10 to 60°C. The reaction products could be controlled by

adjusting the column temperature. Different reaction pathways were

identified as

a function of temperature. The products and the reaction pathways were

characterized by NMR, LC-MS and UV spectra.

IT 571146-82-2

RL: FMU (Formation, unclassified); PRP (Properties); FORM (Formation,

nonpreparative)

(kinetic anal. and subambient temperature online on-column

derivatization of


acetylenic aldehyde using diethylamine as mobile phase additive)

RN 571146-82-2 CAPLUS

CN 2-Butyne-1,1-diamine, 4-[(2R,3S)-2-[(1R)-1-[3,5-bis(trifluoromethyl)phenyl]ethoxy]-3-(2-fluorophenyl)-4-morpholinyl]-N,N,N',N'-tetraethyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L14 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



REFERENCE COUNT: 23 THERE ARE 23 CITED REFERENCES AVAILABLE FOR
THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE
FORMAT

=> d his

(FILE 'HOME' ENTERED AT 07:00:59 ON 15 MAY 2007)

FILE 'REGISTRY' ENTERED AT 07:01:12 ON 15 MAY 2007

L1 STRUCTURE UPLOADED
L2 3 S L1
L3 7 S L1 FULL
L4 7 S L3 AND CAPLUS/LC

FILE 'CAPLUS' ENTERED AT 07:02:26 ON 15 MAY 2007

L5 12 S L4

FILE 'REGISTRY' ENTERED AT 07:03:47 ON 15 MAY 2007

L6 STRUCTURE UPLOADED
L7 2 S L6
L8 386 S L6 FULL
L9 380 S L8 AND CAPLUS/LC
L10 6 S L8 NOT L9

FILE 'CAPLUS' ENTERED AT 07:05:03 ON 15 MAY 2007

L11 237 S L9
L12 11 S L11 AND L5
L13 0 S L12 NOT L5
L14 1 S L5 NOT L12

=> d ibib abs hitstr l12 1-11

L12 ANSWER 1 OF 11 CAPLUS COPYRIGHT 2007 ACS on STN
 ACCESSION NUMBER: 2007:402185 CAPLUS
 DOCUMENT NUMBER: 146:401980
 TITLE: A process for producing aprepitant using a highly pure intermediate, (2R,3S)-4-benzyl-3-(4-fluorophenyl)morpholin-2-yl 3,5-bis(trifluoromethyl)benzoate
 INVENTOR(S): Nath, Asok; Mehta, Hiten Sharadchandra; Prasad, Mohan
 PATENT ASSIGNEE(S): Ranbaxy Laboratories Limited, India
 SOURCE: PCT Int. Appl., 24pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---|------|----------|-----------------|----------|
| WO 2007039883 | A2 | 20070412 | WO 2006-1853649 | 20061005 |
| W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BE, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GN, GR, GU, HK, IL, IN, IS, JP, KE, KG, KH, KR, KP, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW | | | | |
| RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GL, HR, KE, MG, MN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM | | | | |

PRIORITY APPLN. INFO.: IN 2005-DE2679 A 20051005

OTHER SOURCE(S): CASREACT 146:401980
 GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB The invention relates to processes and intermediates for preparation of aprepitant (I) or pharmaceutically acceptable salts thereof. The intermediates include (2R,3S)-4-benzyl-3-(4-fluorophenyl)morpholin-2-yl 3,5-bis(trifluoromethyl)benzoate (II), useful in the manufacture of I. For instance, II was prepared in a highly pure form (HPLC purity 99.94%) by reduction of compound III using L-selectride followed by substitution with 3,5-bis(trifluoromethyl)benzoyl chloride. Olefination of the ester carbonyl in II using dimethyltitanocene, followed by hydrogenation, substitution with N-(methoxycarbonyl)-2-chloroacetamido, and heterocyclization, gave I with a purity of 99.81. Claims cover a variety of processes, as well as the antiemetic use of highly pure I, i.e., $\geq 99.5\%$ by HPLC.

IT 170729-80-3P, Aprepitant
 RL: IMF (Industrial manufacture); PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (drug intermediate; preparation of high-purity aprepitant via L-selectride)


L12 ANSWER 2 OF 11 CAPLUS COPYRIGHT 2007 ACS on STN
 ACCESSION NUMBER: 2004:1040445 CAPLUS
 DOCUMENT NUMBER: 142:411306
 TITLE: The syntheses of [14C] and [13C2,15N3]aprepitant
 AUTHOR(S): Elmore, Charles S.; Dean, Dennis C.; Zhang, Yong; Mellillo, David G.
 CORPORATE SOURCE: Department of Drug Metabolism, Merck Research Laboratories, Rahway, NJ, 07065, USA
 SOURCE: Journal of Labelled Compounds & Radiopharmaceuticals (2004), 47(12), 837-846
 CODEN: JLCRD4; ISSN: 0362-4803
 PUBLISHER: John Wiley & Sons Ltd.
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 OTHER SOURCE(S): CASREACT 142:411306

AB In support of a program to develop a treatment for chemotherapy-induced nausea and vomiting, two isotopically labeled forms of neurokinin-1 receptor antagonist aprepitant have been synthesized. A [14C]-labeled version was synthesized for use in metabolism studies, while a [13C2,15N3]-labeled version was synthesized for use in a study to determine the bioavailability of the final market image. Both syntheses utilized labeled chloroacetamide which was synthesized in two steps from labeled potassium cyanide.

IT 850354-58-4P 850354-60-8P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (syntheses of [14C] and [13C2,15N3]aprepitant)

RN 850354-58-4 CAPLUS
 CN Hydrazine-15N2-carboxylic acid, 2-[2-[(2R,3S)-2-[(1R)-1-[3,5-bis(trifluoromethyl)phenyl]ethoxy]-3-(4-fluorophenyl)-4-morpholinyl]-1-iminoethyl-1-14C]-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 850354-60-8 CAPLUS
 CN Hydrazine-15N2-carboxylic acid, 2-[2-[(2R,3S)-2-[(1R)-1-[3,5-bis(trifluoromethyl)phenyl]ethoxy]-3-(4-fluorophenyl)-4-morpholinyl]-1-iminoethyl-1-14C]-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L12 ANSWER 1 OF 11 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
 Edn. of morpholinone deriv.)
 RN 170729-80-3 CAPLUS
 CN 3H-1,2,4-Triazol-3-one, 5-[[[(2R,3S)-2-[(1R)-1-[3,5-bis(trifluoromethyl)phenyl]ethoxy]-3-(4-fluorophenyl)-4-morpholinyl]methyl]-1,2-dihydro- (CA INDEX NAME)


Absolute stereochemistry. Rotation (+).




IT 219821-37-1P
 RL: IMF (Industrial manufacture); RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (intermediate; preparation of high-purity aprepitant via L-selectride reduction of morpholinone derivative)

RN 219821-37-1 CAPLUS
 CN 4-Morpholineethanimidic acid, 2-[[[(1R)-1-[3,5-bis(trifluoromethyl)phenyl]ethoxy]-3-(4-fluorophenyl)-2-(methoxycarbonyl)hydrazide, (2R,3S)- (CA INDEX NAME)

Absolute stereochemistry.




L12 ANSWER 2 OF 11 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



IT 850261-31-3P 850261-38-0P
 RL: SPN (Synthetic preparation); PREP (Preparation)
 (syntheses of [14C] and [13C2,15N3]aprepitant)


RN 850261-31-3 CAPLUS
 CN 3H-1,2,4-Triazol-3-one-5-13C-1,2,4-15N3, 5-[[[(2R,3S)-2-[(1R)-1-[3,5-bis(trifluoromethyl)phenyl]ethoxy]-3-(4-fluorophenyl)-4-morpholinyl]methyl]-13C]-1,2-dihydro- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 850261-38-0 CAPLUS
 CN 3H-1,2,4-Triazol-3-one-5-14C, 5-[[[(2R,3S)-2-[(1R)-1-[3,5-bis(trifluoromethyl)phenyl]ethoxy]-3-(4-fluorophenyl)-4-morpholinyl]methyl]-1,2-dihydro- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 16 THERE ARE 16 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE

FORMAT

ACCESSION NUMBER: 2003:855926 CAPLUS
DOCUMENT NUMBER: 139:350741
TITLE: Intramolecular cyclocondensation process for the preparation of 5-[(2(R)-[1(R)-[3,5-bis(trifluoromethyl)phenyl]ethoxy]-3(S)-(4-fluorophenyl)-4-morpholinyl)methyl]-1,2-dihydro-3H-1,2,4-triazol-3-one
INVENTOR(S): Huffman, Mark; Kaba, Mahmoud S.; Payack, Joseph F.; Nanda, David
PATENT ASSIGNEE(S): Merck & Co., Inc., USA; Merck Sharp & Dohme Limited
SOURCE: PCT Int. Appl., 15 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|--|------|----------|-----------------|------------|
| WO 2003089429 | A1 | 20031030 | WO 2003-US11956 | 20030417 |
| W: | | | | |
| AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW | | | | |
| RM: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GM, GQ, GW, ML, MR, NE, SN, TD, TG | | | | |
| CA 2482466 | A1 | 20031030 | CA 2003-2482466 | 20030417 |
| AU 2003228578 | A1 | 20031103 | AU 2003-228578 | 20030417 |
| EP 1499611 | A1 | 20050126 | EP 2003-726338 | 20030417 |
| R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK | | | | |
| BR 2003009277 | A | 20050222 | BR 2003-9277 | 20030417 |
| CN 1646525 | A | 20050727 | CN 2003-808446 | 20030417 |
| JP 2005529881 | T | 20051006 | JP 2003-586150 | 20030417 |
| US 2005215786 | A1 | 20050929 | US 2004-511591 | 20041014 |
| NO 2004005001 | A | 20041117 | NO 2004-5001 | 20041117 |
| PRIORITY APPLN. INFO.: | | | US 2002-373734P | P 20020418 |
| | | | WO 2003-US11956 | W 20030417 |


GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB The present invention is concerned with a novel process for the preparation of the compound
5-[(2(R)-[1(R)-[3,5-bis(trifluoromethyl)phenyl]ethoxy]-3(S)-(4-fluorophenyl)-4-morpholinyl)methyl]-1,2-dihydro-3H-1,2,4-triazol-3-one
(I)
is prepared by the intramol. cyclocondensation reaction of (II).
IT 219821-37-1P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT


(Reactant or reagent)
(intramol. cyclocondensation process for the prepn. of
5-[(2(R)-[1(R)-[3,5-bis(trifluoromethyl)phenyl]ethoxy]-3(S)-(4-fluorophenyl)-4-morpholinyl)methyl]-1,2-dihydro-3H-1,2,4-triazol-3-one)
RN 219821-37-1 CAPLUS
CN 4-Morpholineethanimidic acid,
2-[(1R)-1-[3,5-bis(trifluoromethyl)phenyl]ethoxy]-3-(4-fluorophenyl)-, 2-(methoxycarbonyl)hydrazide, (2R,3S)- (CA INDEX NAME)

Absolute stereochemistry.



IT 170729-80-3P
RL: SPN (Synthetic preparation); PREP (Preparation)
(intramol. cyclocondensation process for the preparation of
5-[(2(R)-[1(R)-[3,5-bis(trifluoromethyl)phenyl]ethoxy]-3(S)-(4-fluorophenyl)-4-morpholinyl)methyl]-1,2-dihydro-3H-1,2,4-triazol-3-one)
RN 170729-80-3 CAPLUS
CN 3H-1,2,4-Triazol-3-one, 5-[(2(R,3S)-2-[(1R)-1-[3,5-bis(trifluoromethyl)phenyl]ethoxy]-3-(4-fluorophenyl)-4-morpholinyl)methyl]-1,2-dihydro- (CA INDEX NAME)


Absolute stereochemistry. Rotation (+).



REFERENCE COUNT: 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE


FORMAT

ACCESSION NUMBER: 2003:74903 CAPLUS
 DOCUMENT NUMBER: 139:255173
 TITLE: Efficient Synthesis of NK1 Receptor Antagonist Aprepitant Using a Crystallization-Induced Diastereoselective Transformation
 AUTHOR(S): Brands, Karel M. J.; Payack, Joseph F.; Rosen, Jonathan D.; Nelson, Todd D.; Candelario, Alexander; Huffman, Mark A.; Zhao, Matthew M.; Li, Jing; Craig, Bridgette; Song, Zhiguo J.; Tachaen, David M.; Hansen, Karl; Devine, Paul N.; Pye, Philip J.; Rossen, Kai; Dormer, Peter G.; Reamer, Robert A.; Welch, Christopher J.; Mathre, David J.; Tsou, Nancy N.; McNamara, James M.; Reider, Paul J.
 CORPORATE SOURCE: Department of Process Research, Merck Research Laboratories, Rahway, NJ, 07065, USA
 SOURCE: Journal of the American Chemical Society (2003), 125(8), 2129-2135
 CODEN: JACSAT; ISSN: 0002-7863
 PUBLISHER: American Chemical Society
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 OTHER SOURCE(S): CASREACT 139:255173
 GI




AB An efficient stereoselective synthesis of the orally active NK1 receptor antagonist Aprepitant (I) is described. A direct condensation of N-benzyl ethanolamine with glyoxylic acid yielded a 2-hydroxy-1,4-oxazin-3-one which was activated as the corresponding trifluoroacetate. A Lewis acid mediated coupling with enantiopure (R)-1-(3,5-bis(trifluoromethyl)phenyl)ethan-1-ol afforded a 1:1 mixture of acetal diastereomers which was converted into a single isomer via a novel crystallization-induced asym. transformation. The resulting 1,4-oxazin-3-one was converted via a unique and highly stereoselective one-pot process to the desired α -(4-fluorophenyl)morpholine derivative. Interesting and

unexpected [1,2]-Wittig and [1,3]-sigmatropic rearrangements were identified during the optimization of these key steps. In the final step, a triazolinone side chain was appended to the morpholine core. The targeted clin. candidate was thus obtained in 55% overall yield over the longest linear sequence.
 IT 219821-37-1P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (stereoselective preparation of Aprepitant via crystallization induced asym. transformation of intermediate benzyl[bis(trifluoromethyl)phenyl]ethoxy oxazinone)
 RN 219821-37-1 CAPLUS
 CN 4-Morpholineethanimidic acid, 2-[(1R)-1-[3,5-bis(trifluoromethyl)phenyl]ethoxy]-3-(4-fluorophenyl)-, 2-(methoxycarbonyl)hydrazide, (2R,3S)- (CA INDEX NAME)
 Absolute stereochemistry.



IT 170729-80-3P
 RL: SPN (Synthetic preparation); PREP (Preparation)
 (stereoselective preparation of Aprepitant via crystallization induced asym. transformation of intermediate benzyl[bis(trifluoromethyl)phenyl]ethoxy oxazinone)
 RN 170729-80-3 CAPLUS
 CN 3H-1,2,4-Triazol-3-one, 5-[[[(2R,3S)-2-[(1R)-1-[3,5-bis(trifluoromethyl)phenyl]ethoxy]-3-(4-fluorophenyl)-4-morpholinyl]methyl]-1,2-dihydro- (CA INDEX NAME)
 Absolute stereochemistry. Rotation (+).



REFERENCE COUNT: 70 THERE ARE 70 CITED REFERENCES AVAILABLE FOR THIS
 FORMAT RECORD. ALL CITATIONS AVAILABLE IN THE RE

ACCESSION NUMBER: 1999:48712 CAPLUS
 DOCUMENT NUMBER: 130:129971
 TITLE: Polymorphic form of the tachykinin receptor antagonist
 2-(R)-[(1-(R)-[(3,5-bis(trifluoromethyl)phenyl)ethoxy]-3-(S)-(4-fluorophenyl)-4-(3-(5-oxo-1H,4H-1,2,4-triazol-3-yl)methyl)morpholine
 INVENTOR(S): Crocker, Louis; McCauley, James
 PATENT ASSIGNEE(S): Merck & Co., Inc., USA
 SOURCE: PCT Int. Appl., 66 pp.
 CODEN: PIKXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:


| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---|------|----------|------------------|------------|
| WO 9901444 | A1 | 19990114 | WO 1998-US13766 | 19980701 |
| W: AL, AM, AU, AZ, BA, BB, BG, BR, BY, CA, CN, CU, CZ, EE, GE, GW, HR, HU, ID, IL, IS, JP, KG, KR, KZ, LC, LK, LR, LT, LV, MD, MG, MK, MN, MX, NO, NZ, PL, RO, RU, SG, SI, SK, SL, TJ, TM, TR, TT, UA, US, UZ, VN, YU | | | | |
| RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG | | | | |
| CA 2293836 | A1 | 19990114 | CA 1998-2293836 | 19980701 |
| AU 9882833 | A | 19990125 | AU 1998-82833 | 19980701 |
| AU 735230 | B2 | 20010705 | | |
| ZA 9805765 | A | 19990804 | ZA 1998-5765 | 19980701 |
| EP 994867 | A1 | 20000426 | EP 1998-933088 | 19980701 |
| R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE, SI, LT, LV, FI, RO | | | | |
| TR 9903299 | T2 | 20000721 | TR 1999-3299 | 19980701 |
| EE 9900603 | A | 20000815 | EE 1999-603 | 19980701 |
| EE 4152 | B1 | 20031015 | | |
| JP 2000513383 | T | 20001010 | JP 1999-507368 | 19980701 |
| BR 9810360 | A | 20010130 | BR 1998-10360 | 19980701 |
| NZ 501589 | A | 20011026 | NZ 1998-501589 | 19980701 |
| HU 200004008 | A2 | 20020228 | HU 2000-4008 | 19980701 |
| HR 980370 | B1 | 20021031 | HR 1998-370 | 19980701 |
| CN 1106390 | B | 20030423 | CN 1998-806703 | 19980701 |
| IL 133357 | A | 20031210 | IL 1998-133357 | 19980701 |
| TW 577887 | B | 20040301 | TW 1998-87110655 | 19980701 |
| CZ 295410 | B6 | 20050817 | CZ 1999-4777 | 19980701 |
| PL 191496 | B1 | 20060531 | PL 1998-337579 | 19980701 |
| SK 285644 | B6 | 20070503 | SK 1999-1872 | 19980701 |
| US 6096742 | A | 20000801 | US 1998-212511 | 19981215 |
| US 6229010 | B1 | 20010508 | US 1999-458168 | 19991209 |
| BG 104010 | A | 20010831 | BG 1999-104010 | 19991214 |
| BG 64703 | B1 | 20051230 | | |
| NO 9906549 | A | 20000301 | NO 1999-6549 | 19991229 |
| NO 316893 | B1 | 20040614 | | |
| HK 1029345 | A1 | 20040206 | HK 2001-100223 | 20010109 |
| US 2001041702 | A1 | 20011115 | US 2001-850370 | 20010507 |
| US 6432953 | B2 | 20020813 | | |
| US 2003027825 | A1 | 20030206 | US 2002-219386 | 20020812 |
| US 6583142 | B2 | 20030624 | | |
| PRIORITY APPLN. INFO.: | | | US 1997-51600P | P 19970702 |

L12 ANSWER 5 OF 11 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
GB 1998-216 A 19980107
US 1998-108567 B1 19980701
WO 1998-US13766 W 19980701
US 1998-212511 A3 19981215
US 1999-450168 A3 19991209
US 2001-850370 A3 20010507

AB This invention is concerned with a novel polymorphic form of the compound 2-(R)-(1-(R)-(3,5-bis(trifluoromethyl)phenyl)ethoxy)-3-(S)-(4-fluorophenyl)-4-(3-(5-oxo-1H,4H-1,2,4-triazolo)methyl)morpholine (I) which is a tachykinin receptor antagonist useful in the treatment or prevention of disorders of the central nervous system, inflammatory diseases, pain or migraine, asthma, and emesis. This polymorphic form has advantages over the other known forms of I in terms of thermodyn. stability and suitability for inclusion in pharmaceutical formulations. I was synthesized in a series of steps starting from 2-(R)-(1-(R)-(3,5-bis(trifluoromethyl)phenyl)ethoxy)-3-(S)-(4-fluorophenyl)morpholine. Different polymorphic forms of I were prepared. Dry filled capsules containing 5 mg drug/capsule were prepared containing lactose 194 and Mg stearate 1 mg.
IT 170729-80-3P
RL: PRP (Properties); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses) (preparation of polymorphic forms of tachykinin receptor antagonist)

bis(trifluoromethyl)phenylethoxy(fluorophenyl)oxotriazolomethylmorpholinol
RN 170729-80-3 CAPLUS
CN 3H-1,2,4-Triazol-3-one, 5-[[[(2R,3S)-2-[[[(1R)-1-[3,5-bis(trifluoromethyl)phenyl]ethoxy]-3-(4-fluorophenyl)-4-morpholinyl]methyl]-1,2-dihydro- (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



IT 219821-37-1


L12 ANSWER 6 OF 11 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 1998:146563 CAPLUS
DOCUMENT NUMBER: 128:192658
TITLE: Morpholine and thiomorpholine tachykinin receptor antagonists
INVENTOR(S): Dorn, Conrad P.; Finke, Paul E.; Hale, Jeffrey J.; MacCoss, Malcolm; Mills, Sander G.; Shah, Shrenik K.; Chambers, Mark Stuart; Harrison, Timothy; Ladduwahetty, Tamara; Williams, Brian John
PATENT ASSIGNEE(S): Herck and Co., Inc., USA
SOURCE: U.S., 86 pp., Cont.-in-part of U.S. Ser. No. 169,889, abandoned.
CODEN: USXXAM
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 3
PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|------------------------|------|----------|-----------------|-------------|
| US 5719147 | A | 19980217 | US 1995-525259 | 19950908 |
| ZA 9304624 | A | 19940620 | ZA 1993-4624 | 19930628 |
| AU 9346561 | A | 19940124 | AU 1993-46561 | 19930629 |
| CN 1087902 | A | 19940615 | CN 1993-109517 | 19930629 |
| CN 1049431 | B | 20000216 | | |
| PL 174506 | B1 | 19980831 | PL 1993-306840 | 19930629 |
| RO 114448 | B1 | 19990430 | RO 1994-2095 | 19930629 |
| RU 2140914 | C1 | 19991110 | RU 1994-46364 | 19930629 |
| SK 281093 | B6 | 20001107 | SK 1994-1600 | 19930629 |
| BG 62963 | B1 | 20001229 | BG 1994-99274 | 19941219 |
| FI 9406133 | A | 19941228 | FI 1994-6133 | 19941228 |
| FI 111363 | B1 | 20030715 | | |
| NO 9405064 | A | 19950228 | NO 1994-5064 | 19941228 |
| NO 303698 | B1 | 19990712 | | |
| US 5637659 | A | 19970610 | US 1995-445489 | 19950522 |
| US 5872116 | A | 19980216 | US 1997-959393 | 19971028 |
| US 5922706 | A | 19990713 | US 1997-969685 | 19971113 |
| US 6048859 | A | 20000411 | US 1999-251190 | 19990216 |
| US 6235735 | B1 | 20010522 | US 2000-526843 | 20000316 |
| PRIORITY APPLN. INFO.: | | | US 1992-905976 | B2 19920629 |
| | | | US 1992-971448 | B2 19921104 |
| | | | US 1993-61914 | B2 19930519 |
| | | | US 1993-169889 | B2 19931217 |
| | | | WO 1993-US6181 | A 19930629 |
| | | | WO 1994-US14497 | A2 19941213 |
| | | | US 1995-525259 | A3 19950908 |
| | | | US 1997-959393 | A3 19971028 |
| | | | US 1999-251190 | A3 19990216 |

OTHER SOURCE(S): MARPAT 128:192658
GI


L12 ANSWER 5 OF 11 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
RL: RCT (Reactant); RACT (Reactant or reagent) (prepn. of polymorphic forms of tachykinin receptor antagonist)
bis(trifluoromethyl)phenylethoxy(fluorophenyl)oxotriazolomethylmorpholinol
RN 219821-37-1 CAPLUS
CN 4-Morpholineethanimidic acid, 2-[(1R)-1-[3,5-bis(trifluoromethyl)phenyl]ethoxy]-3-(4-fluorophenyl)-, 2-(methoxycarbonyl)hydrazide, (2R,3S)- (CA INDEX NAME)

Absolute stereochemistry.




REFERENCE COUNT: 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RECORD.
FORMAT

L12 ANSWER 6 OF 11 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



AB Title compds. I [R1 = H, alkyl, OH, Ph, etc.; R2, R3 = H, alkyl, OH, Ph, etc.; R6, R7, R8, R11, R12, R13 = H, alkyl, alkoxy, = (un)substituted Ph, etc.; X = O, S, SO, SO2; Y = O, S, CO, CH2, etc.; Z = alkyl] were prepared as tachykinin receptor antagonists (no data). Thus, treating a solution of 1-phenyl-2-hydroxy-4-(3,5-bis(trifluoromethyl)phenyl)-3-butenamine with NaH, followed by ClCH2CO2Et, gave 55% 2-(2-(3,5-bis(trifluoromethyl)phenyl)ethoxy)-3-(4-fluorophenyl)-5-oxomorpholine.
IT 170729-80-3P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses) (preparation of morpholine and thiomorpholine tachykinin receptor antagonists)
RN 170729-80-3 CAPLUS
CN 3H-1,2,4-Triazol-3-one, 5-[[[(2R,3S)-2-[[[(1R)-1-[3,5-bis(trifluoromethyl)phenyl]ethoxy]-3-(4-fluorophenyl)-4-morpholinyl]methyl]-1,2-dihydro- (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



IT 159706-38-4P 159706-39-5P 159706-63-5P
159706-64-6P 159706-67-9P 159706-68-0P
159706-75-9P 159706-90-8P 170729-76-7P
170729-82-5P 170729-84-7P 170902-79-1P
170902-81-5P 171242-94-7P 172673-23-3P
172673-24-4P 172673-32-4P 172673-33-5P
172673-34-6P 172673-35-7P 172673-36-8P

L12 ANSWER 6 OF 11 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)


172673-37-9P 172673-38-0P 172673-39-1P
172673-40-4P 172673-41-5P 172673-51-7P
172673-52-8P 172673-53-1P 172673-56-2P
172673-57-3P 172673-58-4P 172673-59-5P
172673-60-8P 172673-61-9P 172673-62-0P
172673-63-1P 172673-66-4P 172673-67-5P
172673-68-6P 172673-69-7P 172673-70-0P
172673-71-1P 172673-72-2P 172673-73-3P
172673-83-5P 172673-84-6P 172673-87-9P
172673-88-0P 172674-11-2P 172674-12-3P
172674-15-6P 172674-16-7P 172674-39-4P
172674-40-7P 172674-43-0P 172674-44-1P
172674-67-8P 172674-68-9P 172674-71-4P
172674-72-5P 172674-95-2P 172674-96-3P
172674-99-6P 172675-00-2P 172675-23-9P
172675-24-0P 172675-27-3P 172675-50-2P
172675-51-3P 172675-54-6P 172675-55-7P
172675-77-3P 172675-78-4P 172675-80-8P
172675-81-9P 172675-86-4P 172675-87-5P
172675-89-7P 172675-90-0P 172675-92-2P
172675-93-3P 172675-95-5P 172675-96-6P
172675-98-8P 172676-00-5P 172676-01-6P
172676-03-8P 172676-04-9P 172676-06-1P
172676-07-2P 172676-09-4P 172676-10-7P
172676-12-9P 172676-13-0P 172676-15-2P
172676-17-4P 172676-18-5P 172676-20-9P
172676-21-0P 172676-23-2P 172676-24-3P
172676-26-5P 172676-27-6P 172676-29-8P
172676-30-1P 172676-32-3P 172676-33-4P
172676-35-6P 172676-36-7P 172676-38-9P
172676-39-0P 172676-38-3P 172676-59-4P
172676-61-8P 172676-62-9P 172676-67-4P
172676-68-5P 172676-70-9P 172676-71-0P
172676-73-2P 172676-74-3P 172676-76-5P
172676-77-6P 172676-79-8P 172676-80-1P
172676-82-3P 172676-83-4P 172676-85-6P
172676-86-7P 172676-88-9P 172676-89-0P
172676-91-4P 172676-92-5P 172676-94-7P
172676-95-8P 172676-97-0P 172676-98-1P
172677-00-8P 172677-01-9P 172677-03-1P
172677-04-2P 172677-06-4P 172677-08-6P
172677-10-0P 172677-12-2P 172677-14-4P
172677-16-6P 172677-18-8P 172677-20-2P
172677-22-4P 172677-24-6P 172677-26-8P
172677-28-0P 172677-30-4P 172677-32-6P
172677-34-8P 172677-36-0P 172677-38-2P
172677-40-6P 172822-03-6P 172822-04-7P
172822-05-9P 172822-07-0P 172822-08-1P
172822-09-2P 172822-10-5P 172822-11-6P
172822-12-7P 172822-28-5P 172822-29-6P
173405-07-7P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses) (prepn. of morpholine and thiomorpholine tachykinin receptor antagonists)

RN 159706-38-4 CAPLUS
CN Morpholine, 2-[[3,5-bis(trifluoromethyl)phenyl]methoxy]-3-phenyl-4-(1H-1,2,4-triazol-3-ylmethyl)-, (2S,3R)- (9CI) (CA INDEX NAME)


L12 ANSWER 6 OF 11 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
methyl-3-phenyl-4-morpholinylmethyl]-1,2-dihydro-, (2S-(2a,3a,6b))- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 159706-67-9 CAPLUS
CN Morpholine, 2-[[3,5-bis(trifluoromethyl)phenyl]methoxy]-3-phenyl-4-(1H-1,2,4-triazol-3-ylmethyl)-, (2S,3R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 159706-68-0 CAPLUS
CN 3H-1,2,4-Triazol-3-one, 5-[[2-[[3,5-bis(trifluoromethyl)phenyl]methoxy]-3-phenyl-4-morpholinylmethyl]-1,2-dihydro-, (2S-trans)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 159706-75-9 CAPLUS
CN 3H-1,2,4-Triazol-3-one, 5-[[2-[[3,5-dichlorophenyl]methoxy]-3-phenyl-4-


L12 ANSWER 6 OF 11 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

Absolute stereochemistry.




RN 159706-39-5 CAPLUS
CN 3H-1,2,4-Triazol-3-one, 5-[[2-[[3,5-bis(trifluoromethyl)phenyl]methoxy]-3-phenyl-4-morpholinylmethyl]-1,2-dihydro- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 159706-63-5 CAPLUS
CN Morpholine, 2-[[3,5-bis(trifluoromethyl)phenyl]methoxy]-6-methyl-3-phenyl-4-(1H-1,2,4-triazol-3-ylmethyl)-, (2S-(2a,3a,6b))- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 159706-64-6 CAPLUS
CN 3H-1,2,4-Triazol-3-one, 5-[[2-[[3,5-bis(trifluoromethyl)phenyl]methoxy]-6-


L12 ANSWER 6 OF 11 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
morpholinylmethyl]-1,2-dihydro-, (2S-cis)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 159706-90-8 CAPLUS
CN 3H-1,2,4-Triazol-3-one, 5-[[2-[[3,5-bis(trifluoromethyl)phenyl]methoxy]-3-phenyl-4-morpholinylmethyl]-1,2-dihydro- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 170729-76-7 CAPLUS
CN 3H-1,2,4-Triazol-3-one, 5-[[2-[[3,5-bis(trifluoromethyl)phenyl]methoxy]-3-phenyl-4-morpholinylmethyl]-1,2-dihydro- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



L12 ANSWER 6 OF 11 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)


RN 170729-82-5 CAPLUS
CN 3H-1,2,4-Triazol-3-one, 1,2-dihydro-5-[[[(2R,3S)-3-phenyl-2-[(1R)-1-[3-(trifluoromethyl)phenyl]ethoxy]-4-morpholinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 170729-84-7 CAPLUS
CN 3H-1,2,4-Triazol-3-one, 5-[[[(2R,3S)-2-[(1R)-1-[3-fluoro-5-(trifluoromethyl)phenyl]ethoxy]-3-phenyl-4-morpholinyl]methyl]-1,2-dihydro- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 170902-79-1 CAPLUS
CN 3H-1,2,4-Triazol-3-one, 5-[[[(2R,3S)-2-[(1S)-1-[3,5-bis(trifluoromethyl)phenyl]ethoxy]-3-phenyl-4-morpholinyl]methyl]-1,2-dihydro- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 170902-81-5 CAPLUS


L12 ANSWER 6 OF 11 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 172673-24-4 CAPLUS
CN Carbonic acid, 2-[[3-[[2-[(1-[3,5-bis(trifluoromethyl)phenyl]ethoxy]-3-(4-fluorophenyl)-4-morpholinyl]methyl]-1,5-dihydro-5-oxo-4H-1,2,4-triazol-4-yl]-1-methylethyl ethyl ester (9CI) (CA INDEX NAME)



RN 172673-32-4 CAPLUS
CN Morpholine, 2-[[3-[[3-bis(trifluoromethyl)phenyl]methoxy]-3-phenyl-4-(1H-1,2,4-triazol-3-ylmethyl)- (9CI) (CA INDEX NAME)




RN 172673-33-5 CAPLUS
CN 3H-1,2,4-Triazol-3-one, 5-[[[2-[[3,5-bis(trifluoromethyl)phenyl]methoxy]-3-phenyl-4-morpholinyl]methyl]-1,2-dihydro- (9CI) (CA INDEX NAME)

L12 ANSWER 6 OF 11 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)


CN 3H-1,2,4-Triazol-3-one, 5-[[[2-[[3,5-bis(trifluoromethyl)phenyl]ethoxy]-3-(4-fluorophenyl)-4-morpholinyl]methyl]-1,2-dihydro-, [2R-[2a(S*),3a]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 171242-94-7 CAPLUS
CN Morpholine, 2-[[1R)-1-[3,5-bis(trifluoromethyl)phenyl]ethoxy]-3-(4-fluorophenyl)-4-(1H-1,2,4-triazol-3-ylmethyl)-, (2R,3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 172673-23-3 CAPLUS
CN 3H-1,2,4-Triazol-3-one, 5-[[[2-[[3,5-bis(trifluoromethyl)phenyl]ethoxy]-3-(4-fluorophenyl)-4-oxido-4-morpholinyl]methyl]-1,2-dihydro-, [2R-[2a(R*),3a]]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.




L12 ANSWER 6 OF 11 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 172673-34-6 CAPLUS
CN Morpholine, 2-[[3-[[3-bis(1,1-dimethylethyl)phenyl]methoxy]-3-phenyl-4-(1H-1,2,4-triazol-3-ylmethyl)- (9CI) (CA INDEX NAME)




RN 172673-35-7 CAPLUS
CN 3H-1,2,4-Triazol-3-one, 5-[[[2-[[3,5-bis(1,1-dimethylethyl)phenyl]methoxy]-3-phenyl-4-morpholinyl]methyl]-1,2-dihydro- (9CI) (CA INDEX NAME)




RN 172673-36-8 CAPLUS
CN Morpholine, 2-[[3-[[3-bis(1,1-dimethylethyl)-5-methylphenyl]methoxy]-3-phenyl-4-(1H-1,2,4-triazol-3-ylmethyl)- (9CI) (CA INDEX NAME)




L12 ANSWER 6 OF 11 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
 RN 172673-37-9 CAPLUS
 CN 3H-1,2,4-Triazol-3-one, 5-[[2-[[3-(1,1-dimethylethyl)-5-methylphenyl]methoxy]-3-phenyl-4-morpholinyl]methyl]-1,2-dihydro- (9CI) (CA INDEX NAME)



RN 172673-38-0 CAPLUS
 CN Morpholine, 2-[[3-methyl-5-(trifluoromethyl)phenyl]methoxy]-3-phenyl-4-(1H-1,2,4-triazol-3-ylmethyl)- (9CI) (CA INDEX NAME)




RN 172673-39-1 CAPLUS
 CN 3H-1,2,4-Triazol-3-one, 1,2-dihydro-5-[[2-[[3-methyl-5-(trifluoromethyl)phenyl]methoxy]-3-phenyl-4-morpholinyl]methyl]- (9CI) (CA INDEX NAME)



RN 172673-40-4 CAPLUS
 CN Morpholine, 2-[[3-(1,1-dimethylethyl)-5-(trifluoromethyl)phenyl]methoxy]-3-phenyl-4-(1H-1,2,4-triazol-3-ylmethyl)- (9CI) (CA INDEX NAME)




L12 ANSWER 6 OF 11 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 172673-55-1 CAPLUS
 CN 3H-1,2,4-Triazol-3-one, 5-[[2-[[1-(3-chloro-5-(trifluoromethyl)phenyl)ethoxy]-3-phenyl-4-morpholinyl]methyl]-1,2-dihydro-, [2R-[2α(R*),3α]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 172673-56-2 CAPLUS
 CN 3H-1,2,4-Triazol-3-one, 5-[[2-[[1-(3,5-dimethylphenyl)ethoxy]-3-phenyl-4-morpholinyl]methyl]-1,2-dihydro-, [2R-[2α(R*),3α]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 172673-57-3 CAPLUS
 CN 3H-1,2,4-Triazol-3-one, 5-[[2-[[1-(3-fluoro-5-methylphenyl)ethoxy]-3-phenyl-4-morpholinyl]methyl]-1,2-dihydro-, [2R-[2α(R*),3α]]- (9CI)

L12 ANSWER 6 OF 11 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 172673-41-5 CAPLUS
 CN 3H-1,2,4-Triazol-3-one, 5-[[2-[[3-(1,1-dimethylethyl)-5-(trifluoromethyl)phenyl]methoxy]-3-phenyl-4-morpholinyl]methyl]-1,2-dihydro- (9CI) (CA INDEX NAME)



RN 172673-51-7 CAPLUS
 CN Morpholine, 2-[[3,5-bis(trifluoromethyl)phenyl]methoxy]-5,6-dimethyl-3-phenyl-4-(1H-1,2,4-triazol-3-ylmethyl)-, 4-oxide, [2R-(2α,3β,5α,6α)]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 172673-52-8 CAPLUS
 CN 3H-1,2,4-Triazol-3-one, 5-[[2-[[3,5-bis(trifluoromethyl)phenyl]methoxy]-5,6-dimethyl-3-phenyl-4-oxido-3-phenyl-4-morpholinyl]methyl]-1,2-dihydro-, [2R-(2α,3β,5α,6α)]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




L12 ANSWER 6 OF 11 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
 (CA INDEX NAME)

Absolute stereochemistry.




RN 172673-58-4 CAPLUS
 CN 3H-1,2,4-Triazol-3-one, 5-[[2-[[1-(3-chloro-5-methylphenyl)ethoxy]-3-phenyl-4-morpholinyl]methyl]-1,2-dihydro-, [2R-[2α(R*),3α]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 172673-59-5 CAPLUS
 CN 3H-1,2,4-Triazol-3-one, 5-[[2-[[1-(3-bromo-5-methylphenyl)ethoxy]-3-phenyl-4-morpholinyl]methyl]-1,2-dihydro-, [2R-[2α(R*),3α]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 172673-60-8 CAPLUS

L12 ANSWER 6 OF 11 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

CN 3H-1,2,4-Triazol-3-one, 1,2-dihydro-5-[[2-[1-[3-(1-methylethyl)phenyl]ethoxy]-3-phenyl-4-morpholinyl]methyl]-, [2R-[2 α (R*),3 α]]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 172673-61-9 CAPLUS

CN 3H-1,2,4-Triazol-3-one, 1,2-dihydro-5-[[2-[1-[3-(1-methylethyl)-5-(trifluoromethyl)phenyl]ethoxy]-3-phenyl-4-morpholinyl]methyl]-, [2R-[2 α (R*),3 α]]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 172673-62-0 CAPLUS

CN 3H-1,2,4-Triazol-3-one, 5-[[2-[1-[3-chloro-5-(1-methylethyl)phenyl]ethoxy]-3-phenyl-4-morpholinyl]methyl]-1,2-dihydro-, [2R-[2 α (R*),3 α]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 172673-63-1 CAPLUS

CN 3H-1,2,4-Triazol-3-one, 5-[[2-[1-[3-fluoro-5-(1-methylethyl)phenyl]ethoxy]-3-phenyl-4-morpholinyl]methyl]-1,2-dihydro-, [2R-[2 α (R*),3 α]]- (9CI) (CA INDEX NAME)

L12 ANSWER 6 OF 11 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

CN 3H-1,2,4-Triazol-3-one, 5-[[2-[1-[4-fluoro-3,5-dimethylphenyl]ethoxy]-3-phenyl-4-morpholinyl]methyl]-1,2-dihydro-, [2R-[2 α (R*),3 α]]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 172673-69-7 CAPLUS

CN 3H-1,2,4-Triazol-3-one, 5-[[2-[1-[4-chloro-3,5-dimethylphenyl]ethoxy]-3-phenyl-4-morpholinyl]methyl]-1,2-dihydro-, [2R-[2 α (R*),3 α]]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 172673-70-0 CAPLUS

CN 3H-1,2,4-Triazol-3-one, 5-[[2-[1-[4-fluoro-3,5-bis(trifluoromethyl)phenyl]ethoxy]-3-phenyl-4-morpholinyl]methyl]-1,2-dihydro-, [2R-[2 α (R*),3 α]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 172673-71-1 CAPLUS

L12 ANSWER 6 OF 11 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

CN 3-phenyl-4-morpholinyl]methyl]-1,2-dihydro-, [2R-[2 α (R*),3 α]]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 172673-66-4 CAPLUS

CN 3H-1,2,4-Triazol-3-one, 5-[[2-[1-[3-chloro-5-(1,1-dimethylethyl)phenyl]ethoxy]-3-phenyl-4-morpholinyl]methyl]-1,2-dihydro-, [2R-[2 α (R*),3 α]]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 172673-67-5 CAPLUS

CN 3H-1,2,4-Triazol-3-one, 5-[[2-[1-[3-(1,1-dimethylethyl)-5-(trifluoromethyl)phenyl]ethoxy]-3-phenyl-4-morpholinyl]methyl]-1,2-dihydro-, [2R-[2 α (R*),3 α]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 172673-68-6 CAPLUS

L12 ANSWER 6 OF 11 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

CN 3H-1,2,4-Triazol-3-one, 5-[[2-[1-[4-chloro-3,5-bis(trifluoromethyl)phenyl]ethoxy]-3-phenyl-4-morpholinyl]methyl]-1,2-dihydro-, [2R-[2 α (R*),3 α]]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 172673-72-2 CAPLUS

CN 3H-1,2,4-Triazol-3-one, 5-[[2-[1-[3,5-dichlorophenyl]ethoxy]-3-phenyl-4-morpholinyl]methyl]-1,2-dihydro-, [2R-[2 α (R*),3 α]]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 172673-73-3 CAPLUS

CN 3H-1,2,4-Triazol-3-one, 5-[[2-[1-[3,5-difluorophenyl]ethoxy]-3-phenyl-4-morpholinyl]methyl]-1,2-dihydro-, [2R-[2 α (R*),3 α]]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 172673-83-5 CAPLUS


L12 ANSWER 6 OF 11 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
 CN Morpholine, 2-[1-[2-fluoro-5-(trifluoromethyl)phenyl]ethoxy]-3-phenyl-4-(1H-1,2,4-triazol-3-ylmethyl)-, [2R-[2a(R*),3a]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 172673-84-6 CAPLUS
 CN Morpholine, 3-(4-fluorophenyl)-2-[1-[2-fluoro-5-(trifluoromethyl)phenyl]ethoxy]-4-(1H-1,2,4-triazol-3-ylmethyl)-, [2R-[2a(R*),3a]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 172673-87-9 CAPLUS
 CN 3H-1,2,4-Triazol-3-one, 5-[[2-[1-[2-fluoro-5-(trifluoromethyl)phenyl]ethoxy]-3-phenyl-4-morpholinyl]methyl]-1,2-dihydro-, [2R-[2a(R*),3a]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




L12 ANSWER 6 OF 11 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 172674-15-6 CAPLUS
 CN 3H-1,2,4-Triazol-3-one, 5-[[2-[1-[2-chloro-5-(trifluoromethyl)phenyl]ethoxy]-3-phenyl-4-morpholinyl]methyl]-1,2-dihydro-, [2R-[2a(R*),3a]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 172674-16-7 CAPLUS
 CN 3H-1,2,4-Triazol-3-one, 5-[[2-[1-[2-chloro-5-(trifluoromethyl)phenyl]ethoxy]-3-(4-fluorophenyl)-4-morpholinyl]methyl]-1,2-dihydro-, [2R-[2a(R*),3a]]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



L12 ANSWER 6 OF 11 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)


RN 172673-88-0 CAPLUS
 CN 3H-1,2,4-Triazol-3-one, 5-[[3-(4-fluorophenyl)-2-[1-[2-fluoro-5-(trifluoromethyl)phenyl]ethoxy]-4-morpholinyl]methyl]-1,2-dihydro-, [2R-[2a(R*),3a]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 172674-11-2 CAPLUS
 CN Morpholine, 2-[1-[2-chloro-5-(trifluoromethyl)phenyl]ethoxy]-3-phenyl-4-(1H-1,2,4-triazol-3-ylmethyl)-, [2R-[2a(R*),3a]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 172674-12-3 CAPLUS
 CN Morpholine, 2-[1-[2-chloro-5-(trifluoromethyl)phenyl]ethoxy]-3-(4-fluorophenyl)-4-(1H-1,2,4-triazol-3-ylmethyl)-, [2R-[2a(R*),3a]]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



L12 ANSWER 6 OF 11 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)


RN 172674-39-4 CAPLUS
 CN Morpholine, 2-[1-(3-methylphenyl)ethoxy]-3-phenyl-4-(1H-1,2,4-triazol-3-ylmethyl)-, [2R-[2a(R*),3a]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 172674-40-7 CAPLUS
 CN Morpholine, 3-(4-fluorophenyl)-2-[1-(3-methylphenyl)ethoxy]-4-(1H-1,2,4-triazol-3-ylmethyl)-, [2R-[2a(R*),3a]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 172674-43-0 CAPLUS
 CN 3H-1,2,4-Triazol-3-one, 1,2-dihydro-5-[[2-[1-(3-methylphenyl)ethoxy]-3-phenyl-4-morpholinyl]methyl]-, [2R-[2a(R*),3a]]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 172674-44-1 CAPLUS
 CN 3H-1,2,4-Triazol-3-one, 5-[[3-(4-fluorophenyl)-2-[1-(3-methylphenyl)ethoxy]-4-morpholinyl]methyl]-1,2-dihydro-, [2R-[2a(R*),3a]]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.






RN 172674-67-8 CAPLUS
CN Morphinolone, 2-[[1-(3-bromophenyl)ethoxy]-3-phenyl-4-(1H-1,2,4-triazol-3-ylmethyl)-, [2R-[2a(R*),3a]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 172674-66-9 CAPLUS
CN Morphinolone, 2-[[1-(3-bromophenyl)ethoxy]-3-(4-fluorophenyl)-4-(1H-1,2,4-triazol-3-ylmethyl)-, [2R-[2a(R*),3a]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 172674-71-4 CAPLUS
CN 3H-1,2,4-Triazol-3-one, 5-[[2-[[1-(3-bromophenyl)ethoxy]-3-phenyl-4-morpholinylmethyl]-1,2-dihydro-, [2R-[2a(R*),3a]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 172674-99-6 CAPLUS
CN 3H-1,2,4-Triazol-3-one, 5-[[2-[[1-(3-chlorophenyl)ethoxy]-3-phenyl-4-morpholinylmethyl]-1,2-dihydro-, [2R-[2a(R*),3a]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 172675-00-2 CAPLUS
CN 3H-1,2,4-Triazol-3-one, 5-[[2-[[1-(3-chlorophenyl)ethoxy]-3-(4-fluorophenyl)-4-morpholinylmethyl]-1,2-dihydro-, [2R-[2a(R*),3a]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 172675-23-9 CAPLUS
CN Morphinolone, 4-[[2-(3-dihydro-1H-1,2,4-triazol-3-ylmethyl)-3-phenyl-2-[[1-(3-(trifluoromethyl)phenyl)ethoxy]-, [2R-[2a(R*),3a]]- (9CI) (CA INDEX NAME)




RN 172674-72-5 CAPLUS
CN 3H-1,2,4-Triazol-3-one, 5-[[2-[[1-(3-bromophenyl)ethoxy]-3-(4-fluorophenyl)-4-morpholinylmethyl]-1,2-dihydro-, [2R-[2a(R*),3a]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 172674-95-2 CAPLUS
CN Morphinolone, 2-[[1-(3-chlorophenyl)ethoxy]-3-phenyl-4-(1H-1,2,4-triazol-3-ylmethyl)-, [2R-[2a(R*),3a]]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 172674-96-3 CAPLUS
CN Morphinolone, 2-[[1-(3-chlorophenyl)ethoxy]-3-(4-fluorophenyl)-4-(1H-1,2,4-triazol-3-ylmethyl)-, [2R-[2a(R*),3a]]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

Absolute stereochemistry.




RN 172675-24-0 CAPLUS
CN Morphinolone, 4-[[2-(3-dihydro-1H-1,2,4-triazol-3-ylmethyl)-3-(4-fluorophenyl)-2-[[1-(3-(trifluoromethyl)phenyl)ethoxy]-, [2R-[2a(R*),3a]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 172675-27-3 CAPLUS
CN 3H-1,2,4-Triazol-3-one, 5-[[3-(4-fluorophenyl)-2-[[1-(3-(trifluoromethyl)phenyl)ethoxy]-4-morpholinylmethyl]-1,2-dihydro-, [2R-[2a(R*),3a]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 172675-50-2 CAPLUS
CN Morphinolone, 2-[[1-(3-(1,1-dimethylethyl)phenyl)ethoxy]-3-phenyl-4-(1H-1,2,4-triazol-3-ylmethyl)-, [2R-[2a(R*),3a]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 172675-51-3 CAPLUS
 CN Morpholine, 2-[[1-[3-(1,1-dimethylethyl)phenyl]ethoxy]-3-(4-fluorophenyl)-4-(1H-1,2,4-triazol-3-ylmethyl)-, [2R-[2a(R*),3a]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 172675-54-6 CAPLUS
 CN 3H-1,2,4-Triazol-3-one, 5-[[2-[1-[3-(1,1-dimethylethyl)phenyl]ethoxy]-3-phenyl-4-morpholinyl]methyl]-1,2-dihydro-, [2R-[2a(R*),3a]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 172675-55-7 CAPLUS
 CN 3H-1,2,4-Triazol-3-one, 5-[[2-[1-[3-(1,1-dimethylethyl)phenyl]ethoxy]-3-(4-fluorophenyl)-4-morpholinyl]methyl]-1,2-dihydro-, [2R-[2a(R*),3a]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 172675-81-9 CAPLUS
 CN Morpholine, 2-[[1-[3-(methylthio)-5-(trifluoromethyl)phenyl]ethoxy]-3-phenyl-4-(1H-1,2,4-triazol-3-ylmethyl)-, [2R-[2a(R*),3a]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 172675-86-4 CAPLUS
 CN 3H-1,2,4-Triazol-3-one, 5-[[2-[1-[3,5-dimethoxyphenyl]ethoxy]-3-phenyl-4-morpholinyl]methyl]-1,2-dihydro-, [2R-[2a(R*),3a]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 172675-87-5 CAPLUS
 CN Morpholine, 2-[[1-[3,5-dimethoxyphenyl]ethoxy]-3-phenyl-4-(1H-1,2,4-triazol-3-ylmethyl)-, [2R-[2a(R*),3a]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 172675-77-3 CAPLUS
 CN 3H-1,2,4-Triazol-3-one, 1,2-dihydro-5-[[2-[1-[3-(methylthio)phenyl]ethoxy]-3-phenyl-4-morpholinyl]methyl]-, [2R-[2a(R*),3a]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 172675-78-4 CAPLUS
 CN Morpholine, 2-[[1-[3-(methylthio)phenyl]ethoxy]-3-phenyl-4-(1H-1,2,4-triazol-3-ylmethyl)-, [2R-[2a(R*),3a]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 172675-80-8 CAPLUS
 CN 3H-1,2,4-Triazol-3-one, 1,2-dihydro-5-[[2-[1-[3-(methylthio)-5-(trifluoromethyl)phenyl]ethoxy]-3-phenyl-4-morpholinyl]methyl]-, [2R-[2a(R*),3a]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 172675-89-7 CAPLUS
 CN 3H-1,2,4-Triazol-3-one, 5-[[3-(4-fluorophenyl)-2-[1-[3'-fluoro-5-(trifluoromethyl)phenyl]-3-yl]ethoxy]-4-morpholinyl]methyl]-1,2-dihydro-, [2R-[2a(R*),3a]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 172675-90-0 CAPLUS
 CN Morpholine, 3-(4-fluorophenyl)-2-[1-[3'-fluoro-5-(trifluoromethyl)[1,1'-biphenyl]-3-yl]ethoxy]-4-(1H-1,2,4-triazol-3-ylmethyl)-, [2R-[2a(R*),3a]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 172675-92-2 CAPLUS
 CN 3H-1,2,4-Triazol-3-one, 5-[[2-[1-[3'-chloro-5-(trifluoromethyl)[1,1'-biphenyl]-3-yl]ethoxy]-3-(4-fluorophenyl)-4-morpholinyl]methyl]-1,2-

Absolute stereochemistry.




RN 172675-93-3 CAPLUS
CN Morpholine, 2-([1-(3'-chloro-5-(trifluoromethyl)(1,1'-biphenyl)-3-yl)ethoxy]-3-(4-fluorophenyl)-4-(1H-1,2,4-triazol-3-ylmethyl)-, [2R-[2 α (R*),3 α]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 172675-95-5 CAPLUS
CN 3H-1,2,4-Triazol-3-one, 5-([2-([1-(3,5-dimethylphenyl)ethoxy]-3-(4-fluorophenyl)-4-morpholinyl)methyl]-1,2-dihydro-, [2R-[2 α (R*),3 α]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 172675-96-6 CAPLUS
CN Morpholine, 2-([1-(3,5-dimethylphenyl)ethoxy]-3-(4-fluorophenyl)-4-(1H-1,2,4-triazol-3-ylmethyl)-, [2R-[2 α (R*),3 α]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 172675-98-8 CAPLUS
CN 3H-1,2,4-Triazol-3-one, 5-([2-([1-(3-fluoro-5-methylphenyl)ethoxy]-3-(4-fluorophenyl)-4-morpholinyl)methyl]-1,2-dihydro-, [2R-[2 α (R*),3 α]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 172676-00-5 CAPLUS
CN 3H-1,2,4-Triazol-3-one, 5-([2-([1-(3-chloro-5-methylphenyl)ethoxy]-3-(4-fluorophenyl)-4-morpholinyl)methyl]-1,2-dihydro-, [2R-[2 α (R*),3 α]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 172676-01-6 CAPLUS
CN Morpholine, 2-([1-(3-chloro-5-methylphenyl)ethoxy]-3-(4-fluorophenyl)-4-(1H-1,2,4-triazol-3-ylmethyl)-, [2R-[2 α (R*),3 α]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 172676-03-8 CAPLUS
CN 3H-1,2,4-Triazol-3-one, 5-([2-([1-(3-bromo-5-methylphenyl)ethoxy]-3-(4-fluorophenyl)-4-morpholinyl)methyl]-1,2-dihydro-, [2R-[2 α (R*),3 α]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 172676-04-9 CAPLUS
CN Morpholine, 2-([1-(3-bromo-5-methylphenyl)ethoxy]-3-(4-fluorophenyl)-4-(1H-1,2,4-triazol-3-ylmethyl)-, [2R-[2 α (R*),3 α]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.





RN 172676-06-1 CAPLUS
CN 3H-1,2,4-Triazol-3-one, 5-[[3-(4-fluorophenyl)-2-[1-[3-methyl-5-(1-methylethoxy)phenyl]ethoxy]-4-morpholinyl]methyl]-1,2-dihydro-, [2R-[2α(R*),3α]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 172676-07-2 CAPLUS
CN Morpholine, 3-(4-fluorophenyl)-2-[1-[3-methyl-5-(1-methylethoxy)phenyl]ethoxy]-4-(1H-1,2,4-triazol-3-ylmethyl)-, [2R-[2α(R*),3α]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 172676-13-0 CAPLUS
CN Morpholine, 2-[1-[3-chloro-5-(1-methylethoxy)phenyl]ethoxy]-3-(4-fluorophenyl)-4-(1H-1,2,4-triazol-3-ylmethyl)-, [2R-[2α(R*),3α]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 172676-15-2 CAPLUS
CN Morpholine, 2-[1-[3-fluoro-5-(1-methylethoxy)phenyl]ethoxy]-3-(4-fluorophenyl)-4-(1H-1,2,4-triazol-3-ylmethyl)-, [2R-[2α(R*),3α]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 172676-09-4 CAPLUS
CN 3H-1,2,4-Triazol-3-one, 5-[[3-(4-fluorophenyl)-2-[1-[3-(1-methylethoxy)-5-(trifluoromethyl)phenyl]ethoxy]-4-morpholinyl]methyl]-1,2-dihydro-, [2R-[2α(R*),3α]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 172676-10-7 CAPLUS
CN Morpholine, 3-(4-fluorophenyl)-2-[1-[3-(1-methylethoxy)-5-(trifluoromethyl)phenyl]ethoxy]-4-(1H-1,2,4-triazol-3-ylmethyl)-, [2R-[2α(R*),3α]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 172676-12-9 CAPLUS
CN 3H-1,2,4-Triazol-3-one, 5-[[2-[1-[3-chloro-5-(1-methylethoxy)phenyl]ethoxy]-3-(4-fluorophenyl)-4-morpholinyl]methyl]-1,2-dihydro-, [2R-[2α(R*),3α]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 172676-17-4 CAPLUS
CN 3H-1,2,4-Triazol-3-one, 5-[[2-[1-[3-chloro-5-(1,1-dimethylethyl)phenyl]ethoxy]-3-(4-fluorophenyl)-4-morpholinyl]methyl]-1,2-dihydro-, [2R-[2α(R*),3α]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 172676-18-5 CAPLUS
CN Morpholine, 2-[1-[3-chloro-5-(1,1-dimethylethyl)phenyl]ethoxy]-3-(4-fluorophenyl)-4-(1H-1,2,4-triazol-3-ylmethyl)-, [2R-[2α(R*),3α]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 172676-20-9 CAPLUS
CN 3H-1,2,4-Triazol-3-one, 5-[[2-[1-[3-(1,1-dimethylethyl)-5-(trifluoromethyl)phenyl]ethoxy]-3-(4-fluorophenyl)-4-morpholinyl]methyl]-1,2-dihydro-, [2R-[2α(R*),3α]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 172676-21-0 CAPLUS
CN Morpholine,
2-[1-[3-(1,1-dimethylethyl)-5-(trifluoromethyl)phenyl]ethoxy]-
3-(4-fluorophenyl)-4-(1H-1,2,4-triazol-3-ylmethyl)-, [2R-
[2α(R*),3α]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 172676-23-2 CAPLUS
CN 3H-1,2,4-Triazol-3-one,
5-[[2-[1-(4-fluoro-3,5-dimethylphenyl)ethoxy]-3-(4-
fluorophenyl)-4-morpholinylmethyl]-1,2-dihydro-, [2R-
[2α(R*),3α]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 172676-24-3 CAPLUS
CN Morpholine,
2-[1-(4-fluoro-3,5-dimethylphenyl)ethoxy]-3-(4-fluorophenyl)-4-
[1H-1,2,4-triazol-3-ylmethyl]-, [2R-[2α(R*),3α]]- (9CI) (CA
INDEX NAME)

Absolute stereochemistry.




RN 172676-26-5 CAPLUS
CN 3H-1,2,4-Triazol-3-one,
5-[[2-[1-(4-chloro-3,5-dimethylphenyl)ethoxy]-3-(4-
fluorophenyl)-4-morpholinylmethyl]-1,2-dihydro-, [2R-
[2α(R*),3α]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 172676-27-6 CAPLUS
CN Morpholine,
2-[1-(4-chloro-3,5-dimethylphenyl)ethoxy]-3-(4-fluorophenyl)-4-
[1H-1,2,4-triazol-3-ylmethyl]-, [2R-[2α(R*),3α]]- (9CI) (CA
INDEX NAME)

Absolute stereochemistry.




RN 172676-29-8 CAPLUS
CN 3H-1,2,4-Triazol-3-one, 5-[[2-[1-(4-fluoro-3,5-
bis(trifluoromethyl)phenyl)ethoxy]-3-(4-fluorophenyl)-4-
morpholinylmethyl]-1,2-dihydro-, [2R-[2α(R*),3α]]- (9CI) (CA
INDEX NAME)

Absolute stereochemistry.




RN 172676-30-1 CAPLUS
CN Morpholine, 2-[1-(4-fluoro-3,5-bis(trifluoromethyl)phenyl)ethoxy]-3-(4-
fluorophenyl)-4-[1H-1,2,4-triazol-3-ylmethyl]-, [2R-
[2α(R*),3α]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 172676-32-3 CAPLUS
CN 3H-1,2,4-Triazol-3-one, 5-[[2-[1-(4-chloro-3,5-
bis(trifluoromethyl)phenyl)ethoxy]-3-(4-fluorophenyl)-4-
morpholinylmethyl]-1,2-dihydro-, [2R-[2α(R*),3α]]- (9CI) (CA
INDEX NAME)

Absolute stereochemistry.




RN 172676-33-4 CAPLUS
CN Morpholine, 2-[1-[4-chloro-3,5-bis(trifluoromethyl)phenyl]ethoxy]-3-(4-fluorophenyl)-4-(1H-1,2,4-triazol-3-ylmethyl)-, [2R-[2 α (R*),3 α]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 172676-35-6 CAPLUS
CN 3H-1,2,4-Triazol-3-one, 5-[[2-[1-(3,5-dichlorophenyl)ethoxy]-3-(4-fluorophenyl)-4-morpholinyl]methyl]-1,2-dihydro-, [2R-[2 α (R*),3 α]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 172676-36-7 CAPLUS
CN Morpholine, 2-[1-(3,5-dichlorophenyl)ethoxy]-3-(4-fluorophenyl)-4-(1H-1,2,4-triazol-3-ylmethyl)-, [2R-[2 α (R*),3 α]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 172676-38-9 CAPLUS
CN 3H-1,2,4-Triazol-3-one, 5-[[2-[1-(3,5-difluorophenyl)ethoxy]-3-(4-fluorophenyl)-4-morpholinyl]methyl]-1,2-dihydro-, [2R-[2 α (R*),3 α]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 172676-39-0 CAPLUS
CN Morpholine, 2-[1-[3,5-difluorophenyl]ethoxy]-3-(4-fluorophenyl)-4-(1H-1,2,4-triazol-3-ylmethyl)-, [2R-[2 α (R*),3 α]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 172676-58-3 CAPLUS
CN 3H-1,2,4-Triazol-3-one, 5-[[3-(4-fluorophenyl)-2-[1-[3-(methylthio)phenyl]ethoxy]-4-morpholinyl]methyl]-1,2-dihydro-, [2R-[2 α (R*),3 α]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 172676-59-4 CAPLUS
CN Morpholine, 3-(4-fluorophenyl)-2-[1-[3-(methylthio)phenyl]ethoxy]-4-(1H-1,2,4-triazol-3-ylmethyl)-, [2R-[2 α (R*),3 α]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 172676-61-8 CAPLUS
CN 3H-1,2,4-Triazol-3-one, 5-[[3-(4-fluorophenyl)-2-[1-[3-(methylthio)phenyl]ethoxy]-4-morpholinyl]methyl]-1,2-dihydro-, [2R-[2 α (R*),3 α]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 172676-62-9 CAPLUS
CN Morpholine, 3-(4-fluorophenyl)-2-([1-(3-methylthio)-5-(trifluoromethyl)phenyl]ethoxy)-4-(1H-1,2,4-triazol-3-ylmethyl)-, [2R-[2 α (R*),3 α]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 172676-67-4 CAPLUS
CN 3H-1,2,4-Triazol-3-one, 5-([2-[1-(3,5-dimethoxyphenyl)ethoxy]-3-(4-fluorophenyl)-4-morpholinyl]methyl)-1,2-dihydro-, [2R-[2 α (R*),3 α]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 172676-73-2 CAPLUS
CN 3H-1,2,4-Triazol-3-one, 5-([3-(4-fluorophenyl)-2-(1-phenylethoxy)-4-morpholinyl]methyl)-1,2-dihydro-, [2R-[2 α (R*),3 α]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 172676-74-3 CAPLUS
CN Morpholine, 3-(4-fluorophenyl)-2-(1-phenylethoxy)-4-(1H-1,2,4-triazol-3-ylmethyl)-, [2R-[2 α (R*),3 α]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 172676-76-5 CAPLUS
CN 3H-1,2,4-Triazol-3-one, 5-([2-[1-(3-fluorophenyl)ethoxy]-3-phenyl-4-morpholinyl]methyl)-1,2-dihydro-, [2R-[2 α (R*),3 α]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 172676-68-5 CAPLUS
CN Morpholine, 2-[1-(3,5-dimethoxyphenyl)ethoxy]-3-(4-fluorophenyl)-4-(1H-1,2,4-triazol-3-ylmethyl)-, [2R-[2 α (R*),3 α]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 172676-70-9 CAPLUS
CN 3H-1,2,4-Triazol-3-one, 1,2-dihydro-5-([3-phenyl-2-(1-phenylethoxy)-4-morpholinyl]methyl)-, [2R-[2 α (R*),3 α]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 172676-71-0 CAPLUS
CN Morpholine, 3-phenyl-2-(1-phenylethoxy)-4-(1H-1,2,4-triazol-3-ylmethyl)-, [2R-[2 α (R*),3 α]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 172676-77-6 CAPLUS
CN Morpholine, 2-[1-(3-fluorophenyl)ethoxy]-3-phenyl-4-(1H-1,2,4-triazol-3-ylmethyl)-, [2R-[2 α (R*),3 α]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 172676-79-8 CAPLUS
CN 3H-1,2,4-Triazol-3-one, 5-([3-(4-fluorophenyl)-2-[1-(3-fluorophenyl)ethoxy]-4-morpholinyl]methyl)-1,2-dihydro-, [2R-[2 α (R*),3 α]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 172676-80-1 CAPLUS
CN Morpholine, 3-(4-fluorophenyl)-2-[1-(3-fluorophenyl)ethoxy]-4-(1H-1,2,4-triazol-3-ylmethyl)-, [2R-[2 α (R*),3 α]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 172676-82-3 CAPLUS
CN 3H-1,2,4-Triazol-3-one, 5-([2-[1-(4-fluorophenyl)ethoxy]-3-phenyl-4-morpholinyl]methyl)-1,2-dihydro-, [2R-[2 α (R*),3 α]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 172676-83-4 CAPLUS
CN Morpholine, 2-[1-(4-fluorophenyl)ethoxy]-3-phenyl-4-(1H-1,2,4-triazol-3-ylmethyl)-, [2R-[2 α (R*),3 α]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 172676-85-6 CAPLUS
CN 3H-1,2,4-Triazol-3-one, 5-([3-(4-fluorophenyl)-2-[1-(4-fluorophenyl)ethoxy]-4-morpholinyl]methyl)-1,2-dihydro-, [2R-[2 α (R*),3 α]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


RN 172676-89-0 CAPLUS
CN Morpholine, 2-[1-[3,5-bis(trifluoromethyl)phenyl]ethoxy]-3-(3-fluorophenyl)-4-(1H-1,2,4-triazol-3-ylmethyl)-, [2R-[2 α (R*),3 α]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 172676-91-4 CAPLUS
CN 3H-1,2,4-Triazol-3-one, 5-([2-[1-[3,5-bis(trifluoromethyl)phenyl]ethoxy]-3-(3,4-difluorophenyl)-4-morpholinyl]methyl)-1,2-dihydro-, [2R-[2 α (R*),3 α]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 172676-92-5 CAPLUS
CN Morpholine, 2-[1-[3,5-bis(trifluoromethyl)phenyl]ethoxy]-3-(3,4-difluorophenyl)-4-(1H-1,2,4-triazol-3-ylmethyl)-, [2R-[2 α (R*),3 α]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 172676-86-7 CAPLUS
CN Morpholine, 3-(4-fluorophenyl)-2-[1-(4-fluorophenyl)ethoxy]-4-(1H-1,2,4-triazol-3-ylmethyl)-, [2R-[2 α (R*),3 α]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 172676-89-9 CAPLUS
CN 3H-1,2,4-Triazol-3-one, 5-([2-[1-[3,5-bis(trifluoromethyl)phenyl]ethoxy]-3-(3-fluorophenyl)-4-morpholinyl]methyl)-1,2-dihydro-, [2R-[2 α (R*),3 α]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 172676-94-7 CAPLUS
CN 3H-1,2,4-Triazol-3-one, 5-([2-[1-[3,5-bis(trifluoromethyl)phenyl]ethoxy]-3-(3,4-dichlorophenyl)-4-morpholinyl]methyl)-1,2-dihydro-, [2R-[2 α (R*),3 α]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 172676-95-8 CAPLUS
CN Morpholine, 2-[1-[3,5-bis(trifluoromethyl)phenyl]ethoxy]-3-(3,4-dichlorophenyl)-4-(1H-1,2,4-triazol-3-ylmethyl)-, [2R-[2 α (R*),3 α]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 172676-97-0 CAPLUS
CN 3H-1,2,4-Triazol-3-one, 5-[[2-[[1-[3,5-bis(trifluoromethyl)phenyl]ethoxy]-3-(3,4-dimethylphenyl)-4-morpholinyl]methyl]-1,2-dihydro-, [2R-[2 α (R*),3 α]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 172676-98-1 CAPLUS
CN Morpholine, 2-[[1-[3,5-bis(trifluoromethyl)phenyl]ethoxy]-3-(3,4-dimethylphenyl)-4-(1H-1,2,4-triazol-3-ylmethyl)-, [2R-[2 α (R*),3 α]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 172677-00-8 CAPLUS
CN 3H-1,2,4-Triazol-3-one, 5-[[3-(1,3-benzodioxol-5-yl)-2-[1-[3,5-bis(trifluoromethyl)phenyl]ethoxy]-4-morpholinyl]methyl]-1,2-dihydro-, [2R-[2 α (R*),3 α]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 172677-01-9 CAPLUS
CN Morpholine, 3-(1,3-benzodioxol-5-yl)-2-[1-[3,5-bis(trifluoromethyl)phenyl]ethoxy]-4-(1H-1,2,4-triazol-3-ylmethyl)-, [2R-[2 α (R*),3 α]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 172677-03-1 CAPLUS
CN 3H-1,2,4-Triazol-3-one, 5-[[2-[[1-[3,5-bis(trifluoromethyl)phenyl]ethoxy]-3-(2-naphthalenyl)-4-morpholinyl]methyl]-1,2-dihydro-, [2R-[2 α (R*),3 α]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 172677-04-2 CAPLUS
CN Morpholine, 2-[[1-[3,5-bis(trifluoromethyl)phenyl]ethoxy]-3-(2-naphthalenyl)-4-(1H-1,2,4-triazol-3-ylmethyl)-, [2R-[2 α (R*),3 α]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 172677-06-4 CAPLUS
CN Morpholine, 2-[[1-[3-fluoro-5-(trifluoromethyl)phenyl]ethoxy]-3-phenyl-4-(1H-1,2,4-triazol-3-ylmethyl)-, [2R-[2 α (R*),3 α]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 172677-08-6 CAPLUS
CN Morpholine, 2-[[1-[3-chloro-5-(trifluoromethyl)phenyl]ethoxy]-3-phenyl-4-(1H-1,2,4-triazol-3-ylmethyl)-, [2R-[2 α (R*),3 α]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 172677-10-0 CAPLUS
CN Morpholine, 2-[[1-[3,5-dimethylphenyl]ethoxy]-3-phenyl-4-(1H-1,2,4-triazol-3-ylmethyl)-, [2R-[2 α (R*),3 α]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 172677-12-2 CAPLUS
 CN Morphinolone, 2-[1-(3-fluoro-5-methylphenyl)ethoxy]-3-phenyl-4-(1H-1,2,4-triazol-3-ylmethyl)-, [2R-[2α(R*),3α]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 172677-14-4 CAPLUS
 CN Morphinolone, 2-[1-(3-chloro-5-methylphenyl)ethoxy]-3-phenyl-4-(1H-1,2,4-triazol-3-ylmethyl)-, [2R-[2α(R*),3α]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 172677-16-6 CAPLUS
 CN Morphinolone, 2-[1-(3-bromo-5-methylphenyl)ethoxy]-3-phenyl-4-(1H-1,2,4-triazol-3-ylmethyl)-, [2R-[2α(R*),3α]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 172677-24-6 CAPLUS
 CN Morphinolone, 4-[(2,5-dihydro-1H-1,2,4-triazol-3-yl)methyl]-2-[1-(3-fluoro-5-(1-methylethoxy)phenyl)ethoxy]-3-phenyl-, [2R-[2α(R*),3α]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 172677-26-8 CAPLUS
 CN Morphinolone, 2-[1-(3-chloro-5-(1,1-dimethylethyl)phenyl)ethoxy]-4-[(2,5-dihydro-1H-1,2,4-triazol-3-yl)methyl]-3-phenyl-, [2R-[2α(R*),3α]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 172677-28-0 CAPLUS
 CN Morphinolone, 4-[(2,5-dihydro-1H-1,2,4-triazol-3-yl)methyl]-2-[1-(3-(1,1-dimethylethyl)-5-(trifluoromethyl)phenyl)ethoxy]-3-phenyl-, [2R-[2α(R*),3α]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 172677-18-8 CAPLUS
 CN Morphinolone, 2-[1-(3-(1-methylethoxy)phenyl)ethoxy]-3-phenyl-4-(1H-1,2,4-triazol-3-ylmethyl)-, [2R-[2α(R*),3α]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 172677-20-2 CAPLUS
 CN Morphinolone, 2-[1-(3-(1-methylethoxy)-5-(trifluoromethyl)phenyl)ethoxy]-3-phenyl-4-(1H-1,2,4-triazol-3-ylmethyl)-, [2R-[2α(R*),3α]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 172677-22-4 CAPLUS
 CN Morphinolone, 2-[1-(3-chloro-5-(1-methylethoxy)phenyl)ethoxy]-4-[(2,5-dihydro-1H-1,2,4-triazol-3-yl)methyl]-3-phenyl-, [2R-[2α(R*),3α]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 172677-30-4 CAPLUS
 CN Morphinolone, 2-[1-(4-fluoro-3,5-dimethylphenyl)ethoxy]-3-phenyl-4-(1H-1,2,4-triazol-3-ylmethyl)-, [2R-[2α(R*),3α]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 172677-32-6 CAPLUS
 CN Morphinolone, 2-[1-(4-chloro-3,5-dimethylphenyl)ethoxy]-4-[(2,5-dihydro-1H-1,2,4-triazol-3-yl)methyl]-3-phenyl-, [2R-[2α(R*),3α]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 172677-34-8 CAPLUS
 CN Morphinolone, 4-[(2,5-dihydro-1H-1,2,4-triazol-3-yl)methyl]-2-[1-(4-fluoro-3,5-bis(trifluoromethyl)phenyl)ethoxy]-3-phenyl-, [2R-[2α(R*),3α]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 172677-36-0 CAPLUS
CN Morpholine, 2-[[1-(4-chloro-3,5-bis(trifluoromethyl)phenyl)ethoxy]-4-[(2,5-dihydro-1H-1,2,4-triazol-3-yl)methyl]-3-phenyl]-, [2R-[2α(R*),3α]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 172677-38-2 CAPLUS
CN Morpholine, 2-[[1-(3,5-dichlorophenyl)ethoxy]-4-[(2,5-dihydro-1H-1,2,4-triazol-3-yl)methyl]-3-phenyl]-, [2R-[2α(R*),3α]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 172677-40-6 CAPLUS
CN Morpholine, 2-[[1-(3,5-difluorophenyl)ethoxy]-4-[(2,5-dihydro-1H-1,2,4-triazol-3-yl)methyl]-3-phenyl]-, [2R-[2α(R*),3α]]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● 2 K

RN 172822-05-8 CAPLUS
CN Phosphonic acid, [5-[[2-[[1-(3,5-bis(trifluoromethyl)phenyl)methoxy]-3-(4-fluorophenyl)-4-morpholinyl]methyl]-2,3-dihydro-3-oxo-1H-1,2,4-triazol-1-yl]-, dipotassium salt, [2R-[2α(R*),3α]]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● 2 K


RN 172822-07-0 CAPLUS
CN Morpholine, 2-[[1-(3,5-bis(trifluoromethyl)phenyl)methoxy]-5,6-dimethyl-3-phenyl-4-(1H-1,2,4-triazol-3-ylmethyl)-, 4-oxide, [2R-[2α,3β,5β,6β]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 172822-03-6 CAPLUS
CN Phosphonic acid, [3-[[1-(2R,3S)-2-[(1R)-1-[3,5-bis(trifluoromethyl)phenyl]ethoxy]-3-(4-fluorophenyl)-4-morpholinyl]methyl]-2,5-dihydro-5-oxo-1H-1,2,4-triazol-1-yl]-, dipotassium salt (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● 2 K


RN 172822-04-7 CAPLUS
CN 1H-1,2,4-Triazol-3-ol, 5-[[2-[[1-(3,5-bis(trifluoromethyl)phenyl)methoxy]-3-(4-fluorophenyl)-4-morpholinyl]methyl]-2,3-dihydro-3-oxo-1H-1,2,4-triazol-1-yl]-, dipotassium salt (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 172822-08-1 CAPLUS
CN 3H-1,2,4-Triazol-3-one, 5-[[2-[[1-(3,5-bis(trifluoromethyl)phenyl)methoxy]-3-(4-fluorophenyl)-4-morpholinyl]methyl]-2,3-dihydro-3-oxo-1H-1,2,4-triazol-1-yl]-, dipotassium salt (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 172822-09-2 CAPLUS
CN Morpholine, 2-[[1-(3,5-bis(trifluoromethyl)phenyl)methoxy]-5,6-dimethyl-3-phenyl-4-(1H-1,2,4-triazol-3-ylmethyl)-, 4-oxide, [2S-[2α,3α,5β,6β]]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 172822-10-5 CAPLUS
CN Morpholine, 2-[[1-(3,5-bis(trifluoromethyl)phenyl)methoxy]-5,6-dimethyl-3-phenyl-4-(1H-1,2,4-triazol-3-ylmethyl)-, 4-oxide, [2S-


L12 ANSWER 6 OF 11 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
 (2 α ,3 α ,5 α ,6 α)]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 172822-11-6 CAPLUS
 CN 3H-1,2,4-Triazol-3-one, 5-[[2-[[3,5-bis(trifluoromethyl)phenyl]methoxy]-5,6-dimethyl-4-oxido-3-phenyl-4-morpholinyl]methyl]-1,2-dihydro-, [2S-(2 α ,3 α ,5 α ,6 α)]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 172822-12-7 CAPLUS
 CN 3H-1,2,4-Triazol-3-one, 5-[[2-[[3,5-bis(trifluoromethyl)phenyl]methoxy]-5,6-dimethyl-4-oxido-3-phenyl-4-morpholinyl]methyl]-1,2-dihydro-, [2S-(2 α ,3 α ,5 α ,6 α)]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




L12 ANSWER 6 OF 11 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



IT 159706-40-8P 159706-76-0P 170729-75-6P
 172678-16-9P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (preparation of morpholine and thiomorpholine tachykinin receptor antagonists)
 RN 159706-40-8 CAPLUS
 CN Hydrazinecarboxylic acid, 2-[2-[2-[[3,5-bis(trifluoromethyl)phenyl]methoxy]-3-phenyl-4-morpholinyl]-1-iminoethyl]-, methyl ester, (2S-cis)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 159706-76-0 CAPLUS
 CN Hydrazinecarboxylic acid, 2-[2-[2-[[3,5-dichlorophenyl]methoxy]-3-phenyl-4-morpholinyl]-1-iminoethyl]-, methyl ester, (2S-cis)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L12 ANSWER 6 OF 11 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)


RN 172822-28-5 CAPLUS
 CN 3H-1,2,4-Triazol-3-one, 5-[[2-[[1-[3,5-bis(trifluoromethyl)phenyl]ethoxy]-3-(4-fluorophenyl)-4-morpholinyl]methyl]-1,2-dihydro-, [2S-[2 α (S*),3 β]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 172822-29-6 CAPLUS
 CN 3H-1,2,4-Triazol-3-one, 5-[[2-[[2S,3R]-2-[(1S)-1-[3,5-bis(trifluoromethyl)phenyl]ethoxy]-3-(4-fluorophenyl)-4-morpholinyl]methyl]-1,2-dihydro- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 173405-07-7 CAPLUS
 CN 3H-1,2,4-Triazol-3-one, 5-[[2-[[1-[3-fluoro-5-(1-methylethoxy)phenyl]ethoxy]-3-(4-fluorophenyl)-4-morpholinyl]methyl]-1,2-dihydro-, [2R-[2 α (R*),3 α]]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L12 ANSWER 6 OF 11 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 170729-75-6 CAPLUS
 CN Hydrazinecarboxylic acid, 2-[2-[2-[[1-[3,5-bis(trifluoromethyl)phenyl]ethoxy]-3-phenyl-4-morpholinyl]-1-iminoethyl]-, methyl ester, [2R-[2 α (R*),3 α]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 172678-16-9 CAPLUS
 CN Morpholine, 2-[1-(3-fluoro-5-methylphenyl)ethoxy]-3-(4-fluorophenyl)-4-(1H-1,2,4-triazol-3-ylmethyl)-, [2R-[2 α (R*),3 α]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L12 ANSWER 6 OF 11 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
 REFERENCE COUNT: 47 THERE ARE 47 CITED REFERENCES AVAILABLE FOR THIS
 RECORD. ALL CITATIONS AVAILABLE IN THE RE
 FORMAT

L12 ANSWER 7 OF 11 CAPLUS COPYRIGHT 2007 ACS on STN
 ACCESSION NUMBER: 1997:761736 CAPLUS
 DOCUMENT NUMBER: 128:48231
 TITLE: Morpholine compounds are prodrugs useful as tachykinin
 INVENTOR(S): receptor antagonists
 Dorn, Conrad P.; Hale, Jeffrey J.; Maccoss, Malcolm; Mills, Sander G.
 PATENT ASSIGNEE(S): Merck and Co., Inc., USA
 SOURCE: U.S., 82 pp., Cont.-in-part of U.S. Ser. No. 206,771, abandoned.
 CODEN: USXXAM
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 2
 PATENT INFORMATION:


| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|-----------------------|------|----------|------------------|-------------|
| US 5691336 | A | 19971125 | US 1995-525870 | 19950908 |
| TW 385308 | B | 20000321 | TW 1995-84101736 | 19950224 |
| CN 1147254 | A | 19970409 | CN 1995-192860 | 19950228 |
| CN 1075812 | B | 20011205 | | |
| HU 76324 | A2 | 19970828 | HU 1996-2409 | 19950228 |
| CZ 288241 | B6 | 20010516 | CZ 1996-2588 | 19950228 |
| ES 2184794 | T3 | 20030416 | ES 1995-912667 | 19950228 |
| ZA 9501780 | A | 19951115 | ZA 1995-1780 | 19950303 |
| US 5512570 | A | 19960430 | US 1995-450507 | 19950525 |
| US 5716942 | A | 19980210 | US 1995-450198 | 19950525 |
| LV 11698 | B | 19970620 | LV 1996-355 | 19960903 |
| US 5780467 | A | 19980714 | US 1997-907738 | 19970808 |
| PRIORITY APPL. INFO.: | | | US 1994-206771 | B2 19940304 |
| | | | US 1995-525870 | A3 19950908 |

OTHER SOURCE(S): MARPAT 128:48231
 GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *


AB Title compds. [I: R = R = acyl salt-substituted azolyl; R2, R3 = H, alk(en)yl, Ph, etc; R2R3 = atoms to form a carbocyclic or heterocyclic ring; R6 = H, alkyl, OH; R7 R11 = (un)substituted Ph; Z1 = alk(en)ylene, alkynylene; Z2= bond, O, CO, CH2, etc.; p = 0 or 1] were prepared and are tachykinin receptor antagonist prodrugs (no data) useful in the treatment of inflammatory diseases, pain or migraine, asthma, and emesis. Thus II was prepared
 IT 159706-38-4P 159706-40-8P 159706-75-9P
 159706-76-0P 170729-75-6P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (for preparation of morpholine compds. as prodrugs useful as tachykinin receptor antagonists)
 RN 159706-38-4 CAPLUS
 CN Morpholine, 2-[[3,5-bis(trifluoromethyl)phenyl]methoxy]-3-phenyl-4-(1H-1,2,4-triazol-3-ylmethyl)-, (2S-cis)- (9CI) (CA INDEX NAME)

L12 ANSWER 7 OF 11 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
 Absolute stereochemistry.




RN 159706-40-8 CAPLUS
 CN Hydrazinecarboxylic acid, 2-[[2-[[3,5-bis(trifluoromethyl)phenyl]methoxy]-3-phenyl-4-(1H-1,2,4-triazol-3-ylmethyl)-1,2-dihydro-, (2S-cis)- (9CI) (CA INDEX NAME)] methyl ester, (2S-cis)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 159706-75-9 CAPLUS
 CN 3H-1,2,4-Triazol-3-one, 5-[[2-[[3,5-dichlorophenyl]methoxy]-3-phenyl-4-(1H-1,2,4-triazol-3-ylmethyl)-1,2-dihydro-, (2S-cis)- (9CI) (CA INDEX NAME)] methyl ester, (2S-cis)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 159706-76-0 CAPLUS
 CN Hydrazinecarboxylic acid, 2-[[2-[[3,5-dichlorophenyl]methoxy]-3-phenyl-4-(1H-1,2,4-triazol-3-ylmethyl)-1,2-dihydro-, (2S-cis)- (9CI) (CA INDEX NAME)] methyl ester, (2S-cis)- (9CI) (CA INDEX NAME)]


L12 ANSWER 7 OF 11 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
 morpholinyl]-1-iminoethyl]-, methyl ester, (2S-cis)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 170729-75-6 CAPLUS
 CN Hydrazinecarboxylic acid, 2-[[2-[[3,5-bis(trifluoromethyl)phenyl]ethoxy]-3-phenyl-4-(1H-1,2,4-triazol-3-ylmethyl)-1,2-dihydro-, (2S-cis)- (9CI) (CA INDEX NAME)] methyl ester, (2S-cis)- (9CI) (CA INDEX NAME)]


Absolute stereochemistry.



IT 159706-39-5P 159706-64-6P 159706-67-9P
 159706-80-8P 170729-76-7P 170729-80-3P
 170729-82-5P 170729-84-7P 170729-88-1P
 170729-95-0P 170729-96-1P 170902-79-1P
 170902-81-5P 172822-02-5P 172822-29-6P
 200000-34-6P 200000-39-1P 200000-40-4P
 200000-41-5P 200000-42-6P 200000-51-7P
 200000-52-8P 200000-53-9P
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (preparation of morpholine compds. as prodrugs useful as tachykinin receptor antagonists)
 RN 159706-39-5 CAPLUS
 CN 3H-1,2,4-Triazol-3-one, 5-[[2-[[3,5-bis(trifluoromethyl)phenyl]methoxy]-3-phenyl-4-(1H-1,2,4-triazol-3-ylmethyl)-1,2-dihydro-, (2S-cis)- (9CI) (CA INDEX NAME)] methyl ester, (2S-cis)- (9CI) (CA INDEX NAME)]


L12 ANSWER 7 OF 11 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
 hoxyl-3-phenyl-4-morpholinylmethyl]-1,2-dihydro- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 159706-64-6 CAPLUS
 CN 3H-1,2,4-Triazol-3-one,
 5-[[2-[[3,5-bis(trifluoromethyl)phenyl]ethoxy]-6-
 methyl-3-phenyl-4-morpholinylmethyl]-1,2-dihydro-, (2S-
 (2*α*,3*α*,6*β*))- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 159706-67-9 CAPLUS
 CN Morpholine, 2-[[3,5-bis(trifluoromethyl)phenyl]ethoxy]-3-phenyl-4-[(1H-
 1,2,4-triazol-3-ylmethyl)-, (2S,3R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 159706-90-8 CAPLUS
 CN 3H-1,2,4-Triazol-3-one,
 5-[[2-[(2R,3S)-2-[[3,5-bis(trifluoromethyl)phenyl]met

L12 ANSWER 7 OF 11 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 170729-82-5 CAPLUS
 CN 3H-1,2,4-Triazol-3-one, 1,2-dihydro-5-[[2-[(2R,3S)-3-phenyl-2-[(1R)-1-[3-
 (trifluoromethyl)phenyl]ethoxy]-4-morpholinylmethyl]- (9CI) (CA INDEX
 NAME)

Absolute stereochemistry.



RN 170729-84-7 CAPLUS
 CN 3H-1,2,4-Triazol-3-one, 5-[[2-[(2R,3S)-2-[(1R)-1-[3-fluoro-5-
 (trifluoromethyl)phenyl]ethoxy]-3-phenyl-4-morpholinylmethyl]-1,2-dihydro-
 (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 170729-88-1 CAPLUS
 CN 3H-1,2,4-Triazol-3-one, 5-[[3-(4-fluorophenyl)-2-[[3-fluoro-5-
 (trifluoromethyl)phenyl]ethoxy]-4-morpholinylmethyl]-1,2-dihydro-,
 [2S-[2*α*(S*),3*β*]]- (9CI) (CA INDEX NAME)


L12 ANSWER 7 OF 11 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
 hoxyl-3-[4-(4-fluorophenyl)-4-morpholinylmethyl]-1,2-dihydro- (9CI) (CA
 INDEX NAME)

Absolute stereochemistry.



RN 170729-76-7 CAPLUS
 CN 3H-1,2,4-Triazol-3-one, 5-[[2-[(2R,3S)-2-[(1R)-1-[3,5-
 bis(trifluoromethyl)phenyl]ethoxy]-3-phenyl-4-morpholinylmethyl]-1,2-
 dihydro- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 170729-80-3 CAPLUS
 CN 3H-1,2,4-Triazol-3-one, 5-[[2-[(2R,3S)-2-[(1R)-1-[3,5-
 bis(trifluoromethyl)phenyl]ethoxy]-3-(4-fluorophenyl)-4-
 morpholinylmethyl]-1,2-dihydro- (CA INDEX NAME)


Absolute stereochemistry. Rotation (+).

L12 ANSWER 7 OF 11 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
 Absolute stereochemistry. Rotation (+).




RN 170729-95-0 CAPLUS
 CN 3H-1,2,4-Triazol-3-one,
 5-[[2-[[1-[2,5-bis(trifluoromethyl)phenyl]ethoxy]-3-
 (4-fluorophenyl)-4-morpholinylmethyl]-1,2-dihydro-, [2R-
 [2*α*(R*),3*α*]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 170729-96-1 CAPLUS
 CN Morpholine, 2-[[1-[[2,5-bis(trifluoromethyl)phenyl]ethoxy]-3-(4-
 fluorophenyl)-4-[(1H-1,2,4-triazol-3-ylmethyl)-, [2R-
 [2*α*(R*),3*α*]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.





RN 170902-79-1 CAPLUS
CN 3H-1,2,4-Triazol-3-one, 5-([2R,3R]-2-([1S]-1-(3,5-bis(trifluoromethyl)phenyl)ethoxy)-3-phenyl-4-morpholinyl)methyl]-1,2-dihydro- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 170902-81-5 CAPLUS
CN 3H-1,2,4-Triazol-3-one, 5-([2S,3R]-2-([1S]-1-(3,5-bis(trifluoromethyl)phenyl)ethoxy)-3-(4-fluorophenyl)-4-morpholinyl)methyl]-1,2-dihydro-, [2R-[2a(S*),3a]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 200000-39-1 CAPLUS
CN Morpholine, 2-([3,5-bis(trifluoromethyl)phenyl]methoxy)-5,6-dimethyl-3-phenyl-4-([1H-1,2,4-triazol-3-ylmethyl])- (2R,3S)-[partial]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 200000-40-4 CAPLUS
CN 3H-1,2,4-Triazol-3-one, 5-([2-([3,5-bis(trifluoromethyl)phenyl]methoxy)-5,6-dimethyl-3-phenyl-4-morpholinyl)methyl]-1,2-dihydro-, (2R,3S)-[partial]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 200000-41-5 CAPLUS
CN Morpholine, 2-([3,5-bis(trifluoromethyl)phenyl]methoxy)-5,6-dimethyl-3-phenyl-4-([1H-1,2,4-triazol-3-ylmethyl])- (2S,3S)-[partial]- (9CI) (CA INDEX NAME)

RN 172822-02-5 CAPLUS
CN Phosphonic acid, [3-([2-([1-([3,5-bis(trifluoromethyl)phenyl]ethoxy)-3-(4-fluorophenyl)-4-morpholinyl)methyl]-1,5-dihydro-5-oxo-4H-1,2,4-triazol-4-yl])- dipotassium salt, [2R-[2a(R*),3a]]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● 2 K

RN 172822-29-6 CAPLUS
CN 3H-1,2,4-Triazol-3-one, 5-([2S,3R]-2-([1S]-1-(3,5-bis(trifluoromethyl)phenyl)ethoxy)-3-(4-fluorophenyl)-4-morpholinyl)methyl]-1,2-dihydro- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 200000-34-6 CAPLUS
CN Morpholine, 2-([3,5-bis(trifluoromethyl)phenyl]methoxy)-6-methyl-3-phenyl-4-([1H-1,2,4-triazol-3-ylmethyl])- (2S-[2a,3a,6a]]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

Absolute stereochemistry.




RN 200000-42-6 CAPLUS
CN 3H-1,2,4-Triazol-3-one, 5-([2-([3,5-bis(trifluoromethyl)phenyl]methoxy)-5,6-dimethyl-3-phenyl-4-morpholinyl)methyl]-1,2-dihydro-, (2S,3S)-[partial]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 200000-51-7 CAPLUS
CN Morpholine, 2-([3,5-bis(trifluoromethyl)phenyl]methoxy)-4-([2-oxido-1H-1,2,4-triazol-3-yl)methyl]-3-phenyl-, (2S-cis)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 200000-52-8 CAPLUS
CN Carbonic acid, 1-[3-([2-([3,5-bis(trifluoromethyl)phenyl]methoxy)-3-phenyl-

L12 ANSWER 7 OF 11 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
 4-morpholinylmethyl]-1,5-dihydro-5-oxo-4H-1,2,4-triazol-4-yl]ethyl ester,
 [2S-(2a,3a)]-[partial]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 200000-53-9 CAPLUS
 CN D-Glucitol, 1-deoxy-1-(methylamino)-, [2R-(2a(R*),3a)]-[3-[[2-
 [1-[3,5-bis(trifluoromethyl)phenyl]ethoxy]-3-(4-fluorophenyl)-4-
 morpholinyl]methyl]-1,5-dihydro-5-oxo-4H-1,2,4-triazol-4-yl]phosphonate
 (2:1) (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 172673-19-7
 CMF C23 H22 F7 N4 O6 P

Absolute stereochemistry.




CM 2

L12 ANSWER 8 OF 11 CAPLUS COPYRIGHT 2007 ACS on STN
 ACCESSION NUMBER: 1995:994556 CAPLUS
 DOCUMENT NUMBER: 124:146177
 TITLE: Preparation of morpholine tachykinin receptor
 antagonist prodrugs
 INVENTOR(S): Dorn, Conrad P.; Hale, Jeffrey J.; MacCoss, Malcolm;
 Mills, Sander G.
 PATENT ASSIGNEE(S): Merck and Co., Inc., USA
 SOURCE: PCT Int. Appl., 325 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 2
 PATENT INFORMATION:


| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---|------|-------------------|------------------|------------|
| WO 9523798 | A1 | 19950908 | WO 1995-08101736 | 19950228 |
| W: AM, AU, BB, BG, BR, BY, CA, CN, CZ, EE, FI, GE, HU, JP, KG, KR, KZ, LK, LR, LT, LV, MD, MG, MN, MX, NO, NZ, PL, RO, RU, SG, SI, SK, TJ, TT, UA, UZ | | | | |
| RW: KE, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG | | | | |
| TW 3835308 | B | 20000321 | TW 1995-08101736 | 19950228 |
| CA 2183250 | A1 | 19950908 | CA 1995-2183250 | 19950228 |
| CA 2183250 | C | 20060321 | | |
| AU 9519750 | A | 19950918 | AU 1995-19750 | 19950228 |
| AU 700611 | B2 | 19990107 | | |
| EP 748320 | A1 | 19961218 | EP 1995-912667 | 19950228 |
| EP 748320 | B1 | 20021113 | | |
| R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, NL, PT, SE | | | | |
| CN 1147254 | A | 19970409 | CN 1995-192860 | 19950228 |
| CN 1075912 | B | 20011205 | | |
| HU 76324 | A2 | 19970828 | HU 1996-2409 | 19950228 |
| BR 9507046 | A | 19970909 | BR 1995-7046 | 19950228 |
| JP 09509935 | T | 19971007 | JP 1995-523000 | 19950228 |
| JP 3073770 | B2 | 20000807 | | |
| PL 180522 | B1 | 20010228 | PL 1995-316143 | 19950228 |
| CZ 288241 | B6 | 20010516 | CZ 1996-2588 | 19950228 |
| RU 2170233 | C2 | 20010710 | RU 1996-120078 | 19950228 |
| AT 227722 | T | 20021115 | AT 1995-912667 | 19950228 |
| ES 2184794 | T3 | 20030416 | ES 1995-912667 | 19950228 |
| ZA 9501780 | A | 19951115 | ZA 1995-1780 | 19950303 |
| US 5312570 | A | 19960430 | US 1995-450507 | 19950525 |
| US 5716942 | A | 19980210 | US 1995-450198 | 19950525 |
| FI 9603450 | A | 19960903 | FI 1996-3450 | 19960903 |
| NO 9603675 | A | 19961104 | NO 1996-3675 | 19960903 |
| NO 310074 | B1 | 20010514 | | |
| LV 11688 | B | 19970620 | LV 1996-355 | 19960903 |
| PRIORITY APPLN. INFO.: | | | US 1994-206771 | A 19940304 |
| OTHER SOURCE(S): | | MARPAT 124:146177 | | |
| GI | | | WO 1995-08101736 | W 19950228 |

L12 ANSWER 7 OF 11 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
 CRN 6284-40-8
 CMF C7 H17 N O5

Absolute stereochemistry.



L12 ANSWER 8 OF 11 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



AB Title compds. [I; R = acyl salt-substituted azolyl; R2,R3 = H, alk(en)yl, Ph, etc.; R2R3 = atoms to form a carbocyclic or heterocyclic ring; R6 = H, alkyl, OH; R7,R11 = (un)substituted Ph; Z1 = alk(en)ylene, alkynylene; Z2 = bond, O, CO,CH2, etc.; p = 0 or 1] were prepared as tachykinin receptor antagonist prodrugs (no data). Thus, title compound II was prepared

IT 159706-38-4P 159706-39-5P 159706-63-5P 159706-64-6P 159706-67-9P 159706-68-0P 159706-75-9P 159706-80-8P 170729-76-7P 170729-80-3P 170729-82-5P 170729-84-7P 170902-79-1P 170902-81-5P 171242-94-7P 172673-17-5P 172673-18-6P 172673-19-7P 172673-20-0P 172673-21-1P 172673-22-2P 172673-23-3P 172673-24-4P 172673-32-4P 172673-33-5P 172673-34-6P 172673-35-7P 172673-36-8P 172673-37-9P 172673-38-0P 172673-39-1P 172673-40-4P 172673-41-5P 172673-51-7P 172673-52-8P 172673-53-9P 172673-55-1P 172673-56-2P 172673-57-3P 172673-58-4P 172673-59-5P 172673-60-8P 172673-61-9P 172673-62-0P 172673-63-1P 172673-64-2P 172673-66-4P 172673-67-5P 172673-68-6P 172673-69-7P 172673-70-0P 172673-71-1P 172673-72-2P 172673-73-3P 172673-74-4P 172673-75-5P 172673-76-6P 172673-77-7P 172673-78-8P 172673-79-9P 172673-80-2P 172673-81-3P 172673-82-4P 172673-83-5P 172673-84-6P 172673-85-7P 172673-86-8P 172673-87-9P 172673-88-0P 172674-09-8P 172674-10-1P 172674-11-2P 172674-12-3P 172674-13-4P 172674-14-5P 172674-15-6P 172674-16-7P 172674-17-8P 172674-18-9P 172674-19-0P 172674-20-1P 172674-21-2P 172674-22-3P 172674-23-4P 172674-24-5P 172674-25-6P 172674-26-7P 172674-27-8P 172674-28-9P 172674-29-0P 172674-30-1P 172674-31-2P 172674-32-3P 172674-33-4P 172674-34-5P 172674-35-6P 172674-36-7P 172674-37-8P 172674-38-9P 172674-39-0P 172674-40-1P 172674-41-2P 172674-42-3P 172674-43-4P 172674-44-5P 172674-45-6P 172674-46-7P 172674-47-8P 172674-48-9P 172674-49-0P 172674-50-1P 172674-51-2P 172674-52-3P 172674-53-4P 172674-54-5P 172674-55-6P 172674-56-7P 172674-57-8P 172674-58-9P 172674-59-0P 172674-60-1P 172674-61-2P 172674-62-3P 172674-63-4P 172674-64-5P 172674-65-6P 172674-66-7P 172674-67-8P 172674-68-9P 172674-69-0P 172674-70-1P 172674-71-2P 172674-72-3P 172674-73-4P 172674-74-5P 172674-75-6P 172674-76-7P 172674-77-8P 172674-78-9P 172674-79-0P 172674-80-1P 172674-81-2P 172674-82-3P 172674-83-4P 172674-84-5P 172674-85-6P 172674-86-7P 172674-87-8P 172674-88-9P 172674-89-0P 172674-90-1P 172674-91-2P 172674-92-3P 172674-93-4P 172674-94-5P 172674-95-6P 172674-96-7P 172674-97-8P 172674-98-9P 172674-99-0P

L12 ANSWER 8 OF 11 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

172674-93-0P 172674-94-1P 172674-95-2P
172674-96-3P 172674-97-4P 172674-98-5P
172674-99-6P 172675-00-2P 172675-21-7P
172675-22-8P 172675-23-9P 172675-24-0P
172675-25-1P 172675-26-2P 172675-27-3P
172675-48-8P 172675-49-9P 172675-50-2P
172675-51-3P 172675-52-4P 172675-53-5P
172675-54-6P 172675-55-7P 172675-77-3P
172675-78-4P 172675-80-8P 172675-81-9P
172675-83-1P 172675-84-2P 172675-86-4P
172675-87-5P 172675-89-7P 172675-90-0P
172675-92-2P 172675-93-3P 172675-95-5P
172675-96-6P 172675-98-8P 172676-00-5P
172676-01-6P 172676-03-8P 172676-04-9P
172676-06-1P 172676-07-2P 172676-09-4P
172676-10-7P 172676-12-9P 172676-13-0P
172676-15-2P 172676-17-4P 172676-18-5P
172676-20-9P 172676-21-0P 172676-23-2P
172676-24-3P 172676-26-5P 172676-27-6P
172676-29-8P 172676-30-1P 172676-32-3P
172676-33-4P 172676-35-6P 172676-36-7P
172676-38-9P 172676-39-0P 172676-41-4P
172676-42-5P 172676-44-7P 172676-45-8P
172676-46-9P 172676-47-0P 172676-49-2P
172676-50-5P 172676-52-7P 172676-53-8P
172676-55-0P 172676-56-1P 172676-58-3P
172676-59-4P 172676-61-8P 172676-62-9P
172676-64-1P 172676-65-2P 172676-67-4P
172676-68-5P 172676-70-9P 172676-71-0P
172676-73-2P 172676-74-3P 172676-76-5P
172676-77-6P 172676-79-8P 172676-80-1P
172676-82-3P 172676-83-4P 172676-85-6P
172676-86-7P 172676-88-9P 172676-89-0P
172676-91-4P 172676-92-5P 172676-94-7P
172676-95-8P 172676-97-0P 172676-98-1P
172677-00-8P 172677-01-9P 172677-03-1P
172677-04-2P 172677-06-4P 172677-08-6P
172677-10-0P 172677-12-2P 172677-14-4P
172677-16-6P 172677-18-8P 172677-20-2P
172677-22-4P 172677-24-6P 172677-26-8P
172677-28-0P 172677-30-4P 172677-32-6P
172677-34-8P 172677-36-0P 172677-38-2P
172677-40-6P 172677-42-8P 172677-44-0P
172677-46-2P 172677-48-4P 172822-01-4P
172822-02-5P 172822-03-6P 172822-04-7P
172822-05-8P 172822-07-0P 172822-08-1P
172822-09-2P 172822-10-3P

RL: BAC (Biological activity or effector, except adverse); BSU


(Biological

study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use);
BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of morpholine tachykinin receptor antagonist prodrugs)
RN 159706-38-4 CAPLUS
CN Morpholine, 2-[[3,5-bis(trifluoromethyl)phenyl]methoxy]-3-phenyl-4-(1H-
1,2,4-triazol-3-ylmethyl)-, (2S,3R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


L12 ANSWER 8 OF 11 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

Absolute stereochemistry.




RN 159706-67-9 CAPLUS
CN Morpholine, 2-[[3,5-bis(trifluoromethyl)phenyl]methoxy]-3-phenyl-4-(1H-
1,2,4-triazol-3-ylmethyl)-, (2S,3R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 159706-68-0 CAPLUS
CN 3H-1,2,4-Triazol-3-one, 5-[[2-[[3,5-bis(trifluoromethyl)phenyl]methoxy]-3-
phenyl-4-morpholinyl]methyl]-1,2-dihydro-, (2S-trans)- (9CI) (CA INDEX
NAME)

Absolute stereochemistry.




RN 159706-75-9 CAPLUS
CN 3H-1,2,4-Triazol-3-one, 5-[[2-[[3,5-dichlorophenyl]methoxy]-3-phenyl-4-
morpholinyl]methyl]-1,2-dihydro-, (2S-cis)- (9CI) (CA INDEX NAME)

L12 ANSWER 8 OF 11 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 159706-39-5 CAPLUS
CN 3H-1,2,4-Triazol-3-one, 5-[[2-[[3,5-bis(trifluoromethyl)phenyl]methoxy]-3-phenyl-4-morpholinyl]methyl]-1,2-dihydro-, (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 159706-63-5 CAPLUS
CN Morpholine, 2-[[3,5-bis(trifluoromethyl)phenyl]methoxy]-6-methyl-3-phenyl-
4-(1H-1,2,4-triazol-3-ylmethyl)-, [2S-(2a,3a,6a)]- (9CI)
(CA INDEX NAME)


Absolute stereochemistry.



RN 159706-64-6 CAPLUS
CN 3H-1,2,4-Triazol-3-one, 5-[[2-[[3,5-bis(trifluoromethyl)phenyl]methoxy]-6-
methyl-3-phenyl-4-morpholinyl]methyl]-1,2-dihydro-, [2S-
(2a,3a,6a)]- (9CI) (CA INDEX NAME)


L12 ANSWER 8 OF 11 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

Absolute stereochemistry.




RN 159706-90-8 CAPLUS
CN 3H-1,2,4-Triazol-3-one, 5-[[2-[[3,5-bis(trifluoromethyl)phenyl]methoxy]-3-
phenyl-4-morpholinyl]methyl]-1,2-dihydro-, (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 170729-76-7 CAPLUS
CN 3H-1,2,4-Triazol-3-one, 5-[[2-[[3,5-bis(trifluoromethyl)phenyl]methoxy]-3-phenyl-4-morpholinyl]methyl]-1,2-
dihydro-, (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 170729-80-3 CAPLUS

L12 ANSWER 8 OF 11 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)


CN 3H-1,2,4-Triazol-3-one, 5-[[[(2R,3S)-2-[(1R)-1-[3,5-bis(trifluoromethyl)phenyl]ethoxy]-3-(4-fluorophenyl)-4-morpholinyl]methyl]-1,2-dihydro- (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).




RN 170729-82-5 CAPLUS
CN 3H-1,2,4-Triazol-3-one, 1,2-dihydro-5-[[[(2R,3S)-3-phenyl-2-[(1R)-1-[3-(trifluoromethyl)phenyl]ethoxy]-4-morpholinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 170729-84-7 CAPLUS
CN 3H-1,2,4-Triazol-3-one, 5-[[[(2R,3S)-2-[(1R)-1-[3-fluoro-5-(trifluoromethyl)phenyl]ethoxy]-3-phenyl-4-morpholinyl]methyl]-1,2-dihydro- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




L12 ANSWER 8 OF 11 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 172673-17-5 CAPLUS
CN 3H-1,2,4-Triazol-3-one, 5-[[[(2R,3S)-2-[[[3,5-bis(trifluoromethyl)phenyl]methoxy]-4-oxido-3-phenyl-4-morpholinyl]methyl]-1,2-dihydro- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 172673-18-6 CAPLUS
CN 3H-1,2,4-Triazol-3-one, 5-[[[(2R,3S)-2-[[[3,5-bis(trifluoromethyl)phenyl]methoxy]-3-phenyl-4-morpholinyl]methyl]-4-[(ethoxycarbonyl)oxy]-2-ethyl-2,4-dihydro- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



L12 ANSWER 8 OF 11 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)


RN 170902-79-1 CAPLUS
CN 3H-1,2,4-Triazol-3-one, 5-[[[(2R,3S)-2-[(1S)-1-[3,5-bis(trifluoromethyl)phenyl]ethoxy]-3-phenyl-4-morpholinyl]methyl]-1,2-dihydro- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 170902-81-5 CAPLUS
CN 3H-1,2,4-Triazol-3-one, 5-[[[(2R,3S)-2-[(1S)-1-[3,5-bis(trifluoromethyl)phenyl]ethoxy]-3-phenyl-4-morpholinyl]methyl]-1,2-dihydro-, [2R-[2a(S*),3a]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 171242-94-7 CAPLUS
CN Morpholine, 2-[[[(1R)-1-[3,5-bis(trifluoromethyl)phenyl]ethoxy]-3-(4-fluorophenyl)-4-(1H-1,2,4-triazol-3-ylmethyl)-, (2R,3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



L12 ANSWER 8 OF 11 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)


RN 172673-19-7 CAPLUS
CN Phosphonic acid, [3-[[[(2R,3S)-2-[(1R)-1-[3,5-bis(trifluoromethyl)phenyl]ethoxy]-3-(4-fluorophenyl)-4-morpholinyl]methyl]-1,5-dihydro-5-oxo-4H-1,2,4-triazol-4-yl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 172673-20-0 CAPLUS
CN Phosphonic acid, [3-[[[(2R,3S)-2-[(1R)-1-[3,5-bis(trifluoromethyl)phenyl]ethoxy]-3-(4-fluorophenyl)-4-morpholinyl]methyl]-2,5-dihydro-5-oxo-1H-1,2,4-triazol-1-yl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 172673-21-1 CAPLUS
CN Phosphonic acid, [5-[[[(2R,3S)-2-[(1R)-1-[3,5-bis(trifluoromethyl)phenyl]ethoxy]-3-(4-fluorophenyl)-4-morpholinyl]methyl]-2,3-dihydro-5-oxo-1H-1,2,4-triazol-1-yl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.






RN 172673-22-2 CAPLUS
CN 1H-1,2,4-Triazol-3-ol, 5-[[2-[(2R,3S)-2-[(1R)-1-[3,5-bis(trifluoromethyl)phenyl]ethoxy]-3-(4-fluorophenyl)-4-morpholinyl]methyl]-, dihydrogen phosphate (ester) (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 172673-23-3 CAPLUS
CN 3H-1,2,4-Triazol-3-one, 5-[[2-[(1-[3,5-bis(trifluoromethyl)phenyl]ethoxy]-3-(4-fluorophenyl)-4-oxido-4-morpholinyl]methyl]-1,2-dihydro-, [2R-(2a(R*),3a)]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.




RN 172673-24-4 CAPLUS
CN Carbonic acid, 2-[3-[[2-[(1-[3,5-bis(trifluoromethyl)phenyl]ethoxy]-3-(4-fluorophenyl)-4-morpholinyl]methyl]-1,5-dihydro-5-oxo-4H-1,2,4-triazol-4-yl]-1-methylethyl ethyl ester (9CI) (CA INDEX NAME)




RN 172673-32-4 CAPLUS
CN Morpholine, 2-[[3-[[3,5-bis(trifluoromethyl)phenyl]methoxy]-3-phenyl-4-(1H-1,2,4-triazol-3-ylmethyl)- (9CI) (CA INDEX NAME)




RN 172673-33-5 CAPLUS
CN 3H-1,2,4-Triazol-3-one, 5-[[2-[(1-[3,5-bis(trifluoromethyl)phenyl]methoxy]-3-phenyl-4-morpholinyl]methyl]-1,2-dihydro- (9CI) (CA INDEX NAME)




RN 172673-34-6 CAPLUS
CN Morpholine, 2-[[3-[[3,5-bis(1,1-dimethylethyl)phenyl]methoxy]-3-phenyl-4-(1H-1,2,4-triazol-3-ylmethyl)- (9CI) (CA INDEX NAME)




RN 172673-35-7 CAPLUS
CN 3H-1,2,4-Triazol-3-one, 5-[[2-[[3-[[3,5-bis(1,1-dimethylethyl)phenyl]methoxy]-3-phenyl-4-morpholinyl]methyl]-1,2-dihydro- (9CI) (CA INDEX NAME)




RN 172673-36-8 CAPLUS
CN Morpholine, 2-[[3-[[3-[[3,5-bis(1,1-dimethylethyl)-5-methylphenyl]methoxy]-3-phenyl-4-(1H-1,2,4-triazol-3-ylmethyl)- (9CI) (CA INDEX NAME)




RN 172673-37-9 CAPLUS
CN 3H-1,2,4-Triazol-3-one, 5-[[2-[[3-[[3,5-bis(1,1-dimethylethyl)-5-methylphenyl]methoxy]-3-phenyl-4-morpholinyl]methyl]-1,2-dihydro- (9CI) (CA INDEX NAME)




RN 172673-38-0 CAPLUS
CN Morpholine, 2-[[3-methyl-5-(trifluoromethyl)phenyl]methoxy]-3-phenyl-4-(1H-1,2,4-triazol-3-ylmethyl)- (9CI) (CA INDEX NAME)




RN 172673-39-1 CAPLUS
CN 3H-1,2,4-Triazol-3-one, 1,2-dihydro-5-[[2-[[3-methyl-5-(trifluoromethyl)phenyl]methoxy]-3-phenyl-4-morpholinyl]methyl]- (9CI) (CA INDEX NAME)



RN 172673-40-4 CAPLUS
CN Morpholine, 2-[[3-[[3-[[3,5-bis(1,1-dimethylethyl)-5-(trifluoromethyl)phenyl]methoxy]-3-phenyl-4-(1H-1,2,4-triazol-3-ylmethyl)- (9CI) (CA INDEX NAME)




RN 172673-41-5 CAPLUS
CN 3H-1,2,4-Triazol-3-one, 5-([2-([3-(1,1-dimethylethyl)-5-(trifluoromethyl)phenyl]methoxy)-3-phenyl-4-morpholinyl]methyl)-1,2-dihydro- (9CI) (CA INDEX NAME)




RN 172673-51-7 CAPLUS
CN Morpholine, 2-([3,5-bis(trifluoromethyl)phenyl]methoxy)-5,6-dimethyl-3-phenyl-4-(1H-1,2,4-triazol-3-ylmethyl)-, 4-oxide, [2R-(2α,3β,5α,6α)]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 172673-52-8 CAPLUS
CN 3H-1,2,4-Triazol-3-one, 5-([2-([3,5-bis(trifluoromethyl)phenyl]methoxy)-5,6-dimethyl-4-oxido-3-phenyl-4-morpholinyl]methyl)-1,2-dihydro-, [2R-(2α,3β,5α,6α)]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 172673-57-3 CAPLUS
CN 3H-1,2,4-Triazol-3-one, 5-([2-([1-(3-fluoro-5-methylphenyl)ethoxy]-3-phenyl-4-morpholinyl]methyl)-1,2-dihydro-, [2R-(2α(R*),3α)]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 172673-58-4 CAPLUS
CN 3H-1,2,4-Triazol-3-one, 5-([2-([1-(3-chloro-5-methylphenyl)ethoxy]-3-phenyl-4-morpholinyl]methyl)-1,2-dihydro-, [2R-(2α(R*),3α)]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 172673-59-5 CAPLUS
CN 3H-1,2,4-Triazol-3-one, 5-([2-([1-(3-bromo-5-methylphenyl)ethoxy]-3-phenyl-4-morpholinyl]methyl)-1,2-dihydro-, [2R-(2α(R*),3α)]- (9CI) (CA INDEX NAME)




RN 172673-53-9 CAPLUS
CN Morpholine, 2-([1-(3-methyl-1-naphthalenyl)ethoxy]-3-phenyl-4-(1H-1,2,4-triazol-3-ylmethyl)-, [2R-(2α(R*),3α)]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 172673-55-1 CAPLUS
CN 3H-1,2,4-Triazol-3-one, 5-([2-([1-(3-chloro-5-(trifluoromethyl)phenyl)ethoxy]-3-phenyl-4-morpholinyl]methyl)-1,2-dihydro-, [2R-(2α(R*),3α)]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 172673-56-2 CAPLUS
CN 3H-1,2,4-Triazol-3-one, 5-([2-([1-(3,5-dimethylphenyl)ethoxy]-3-phenyl-4-morpholinyl]methyl)-1,2-dihydro-, [2R-(2α(R*),3α)]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


(CA INDEX NAME)

Absolute stereochemistry.




RN 172673-60-8 CAPLUS
CN 3H-1,2,4-Triazol-3-one, 5-([2-([1-(3-bromo-5-methylphenyl)ethoxy]-3-phenyl-4-morpholinyl]methyl)-1,2-dihydro-, [2R-(2α(R*),3α)]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 172673-61-9 CAPLUS
CN 3H-1,2,4-Triazol-3-one, 5-([2-([1-(3-chloro-5-methylphenyl)ethoxy]-3-phenyl-4-morpholinyl]methyl)-1,2-dihydro-, [2R-(2α(R*),3α)]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 172673-62-0 CAPLUS
CN 3H-1,2,4-Triazol-3-one, 5-([2-([1-(3-chloro-5-methylphenyl)ethoxy]-3-phenyl-4-morpholinyl]methyl)-1,2-dihydro-, [2R-(2α(R*),3α)]- (9CI) (CA INDEX NAME)




RN 172673-63-1 CAPLUS
CN 3H-1,2,4-Triazol-3-one, 5-[[2-[[1-(3-fluoro-5-(1-methylethyl)phenyl)ethoxy]-3-phenyl-4-morpholinyl]methyl]-1,2-dihydro-, [2R-[2a(R*),3a]]-(9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 172673-64-2 CAPLUS
CN Morpholine, 3-phenyl-4-((1H-1,2,4-triazol-3-ylmethyl)-2-[[1-(3-(trifluoromethyl)-1-naphthalenyl)ethoxy]-, [2R-[2a(R*),3a]]-(9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 172673-66-4 CAPLUS
CN 3H-1,2,4-Triazol-3-one, 5-[[2-[[1-(3-chloro-5-(1,1-dimethylethyl)phenyl)ethoxy]-3-phenyl-4-morpholinyl]methyl]-1,2-dihydro-, [2R-[2a(R*),3a]]-(9CI) (CA INDEX NAME)




RN 172673-70-0 CAPLUS
CN 3H-1,2,4-Triazol-3-one, 5-[[2-[[1-(3-fluoro-5-bis(trifluoromethyl)phenyl)ethoxy]-3-phenyl-4-morpholinyl]methyl]-1,2-dihydro-, [2R-[2a(R*),3a]]-(9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 172673-71-1 CAPLUS
CN 3H-1,2,4-Triazol-3-one, 5-[[2-[[1-(3-chloro-5-bis(trifluoromethyl)phenyl)ethoxy]-3-phenyl-4-morpholinyl]methyl]-1,2-dihydro-, [2R-[2a(R*),3a]]-(9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 172673-72-2 CAPLUS
CN 3H-1,2,4-Triazol-3-one, 5-[[2-[[1-(3,5-dichlorophenyl)ethoxy]-3-phenyl-4-morpholinyl]methyl]-1,2-dihydro-, [2R-[2a(R*),3a]]-(9CI) (CA INDEX NAME)




RN 172673-67-5 CAPLUS
CN 3H-1,2,4-Triazol-3-one, 5-[[2-[[1-(3-(1,1-dimethylethyl)-5-(trifluoromethyl)phenyl)ethoxy]-3-phenyl-4-morpholinyl]methyl]-1,2-dihydro-, [2R-[2a(R*),3a]]-(9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 172673-68-6 CAPLUS
CN 3H-1,2,4-Triazol-3-one, 5-[[2-[[1-(4-fluoro-3,5-dimethylphenyl)ethoxy]-3-phenyl-4-morpholinyl]methyl]-1,2-dihydro-, [2R-[2a(R*),3a]]-(9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 172673-69-7 CAPLUS
CN 3H-1,2,4-Triazol-3-one, 5-[[2-[[1-(4-chloro-3,5-dimethylphenyl)ethoxy]-3-phenyl-4-morpholinyl]methyl]-1,2-dihydro-, [2R-[2a(R*),3a]]-(9CI) (CA INDEX NAME)




RN 172673-73-3 CAPLUS
CN 3H-1,2,4-Triazol-3-one, 5-[[2-[[1-(3,5-difluorophenyl)ethoxy]-3-phenyl-4-morpholinyl]methyl]-1,2-dihydro-, [2R-[2a(R*),3a]]-(9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 172673-74-4 CAPLUS
CN 3H-1,2,4-Triazol-3-one, 1,2-dihydro-5-[[2-[[1-(1-naphthalenyl)ethoxy]-3-phenyl-4-morpholinyl]methyl]-, [2R-[2a(R*),3a]]-(9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 172673-75-5 CAPLUS
CN 3H-1,2,4-Triazol-3-one, 5-[[2-[[1-(4-fluoro-1-naphthalenyl)ethoxy]-3-phenyl-4-morpholinyl]methyl]-1,2-dihydro-, [2R-[2a(R*),3a]]-(9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 172673-76-6 CAPLUS
CN 3H-1,2,4-Triazol-3-one,
5-([2-([1-(3-fluoro-1-naphthalenyl)ethoxy]-3-phenyl-
4-morpholinyl)methyl]-1,2-dihydro-, [2R-[2a(R*),3a]]- (9CI)
(CA INDEX NAME)

Absolute stereochemistry.



RN 172673-77-7 CAPLUS
CN 3H-1,2,4-Triazol-3-one,
5-([2-([1-(3-chloro-1-naphthalenyl)ethoxy]-3-phenyl-
4-morpholinyl)methyl]-1,2-dihydro-, [2R-[2a(R*),3a]]- (9CI)
(CA INDEX NAME)


Absolute stereochemistry.



RN 172673-78-8 CAPLUS
CN 3H-1,2,4-Triazol-3-one, 1,2-dihydro-5-([2-([1-(3-methyl-1-
naphthalenyl)ethoxy]-3-phenyl-4-morpholinyl)methyl]-1,2-dihydro-, [2R-[2a(R*),3a]]- (9CI) (CA INDEX NAME)


RN 172673-81-3 CAPLUS
CN Morpholine, 3-([4-fluorophenyl]-2-([2-fluoro-5-(trifluoromethyl)phenyl]ethoxy)-3-phenyl-4-(1H-1,2,4-triazol-3-ylmethyl)-, (2S-cis)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 172673-82-4 CAPLUS
CN Morpholine, 3-([4-fluorophenyl]-2-([2-fluoro-5-(trifluoromethyl)phenyl]ethoxy)-3-phenyl-4-(1H-1,2,4-triazol-3-ylmethyl)-, (2S-cis)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 172673-83-5 CAPLUS
CN Morpholine, 2-([1-([2-fluoro-5-(trifluoromethyl)phenyl]ethoxy)-3-phenyl-4-(1H-1,2,4-triazol-3-ylmethyl)-, [2R-[2a(R*),3a]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




Absolute stereochemistry.




RN 172673-79-9 CAPLUS
CN 3H-1,2,4-Triazol-3-one,
1,2-dihydro-5-([3-phenyl-2-([1-([3-(trifluoromethyl)-
1-naphthalenyl]ethoxy)-4-morpholinyl)methyl]-1,2-dihydro-, [2R-[2a(R*),3a]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 172673-80-2 CAPLUS
CN 3H-1,2,4-Triazol-3-one,
5-([2-([3,5-bis(trifluoromethyl)phenyl]methoxy)-3-(4-hydroxyphenyl)-4-morpholinyl)methyl]-1,2-dihydro-, (2S-cis)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 172673-84-6 CAPLUS
CN Morpholine, 3-([4-fluorophenyl]-2-([2-fluoro-5-(trifluoromethyl)phenyl]ethoxy)-3-phenyl-4-(1H-1,2,4-triazol-3-ylmethyl)-, [2R-[2a(R*),3a]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 172673-85-7 CAPLUS
CN 3H-1,2,4-Triazol-3-one,
5-([2-([2-fluoro-5-(trifluoromethyl)phenyl]methoxy
)-3-phenyl-4-morpholinyl)methyl]-1,2-dihydro-, (2S-cis)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 172673-86-8 CAPLUS
CN 3H-1,2,4-Triazol-3-one, 5-([3-([4-fluorophenyl]-2-([2-fluoro-5-(trifluoromethyl)phenyl]ethoxy)-3-phenyl-4-(1H-1,2,4-triazol-3-ylmethyl)-, [2R-[2a(R*),3a]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.





RN 172673-87-9 CAPLUS
CN 3H-1,2,4-Triazol-3-one,
5-[(2-{[1-[2-chloro-5-(trifluoromethyl)phenyl]ethoxy]-3-phenyl-4-morpholinyl)methyl]-1,2-dihydro-, [2R-[2α(R*),3α]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 172673-88-0 CAPLUS
CN 3H-1,2,4-Triazol-3-one, 5-[(2-{[1-[2-chloro-5-(trifluoromethyl)phenyl]ethoxy]-3-phenyl-4-morpholinyl)methyl]-1,2-dihydro-, [2R-[2α(R*),3α]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 172674-12-3 CAPLUS
CN Morpholine, 2-[(1-[2-chloro-5-(trifluoromethyl)phenyl]ethoxy]-3-(4-fluorophenyl)-4-(1H-1,2,4-triazol-3-ylmethyl)-, [2R-[2α(R*),3α]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 172674-13-4 CAPLUS
CN 3H-1,2,4-Triazol-3-one,
5-[(2-{[1-[2-chloro-5-(trifluoromethyl)phenyl]ethoxy]-3-phenyl-4-morpholinyl)methyl]-1,2-dihydro-, (2S-cis)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 172674-14-5 CAPLUS
CN 3H-1,2,4-Triazol-3-one,
5-[(2-{[1-[2-chloro-5-(trifluoromethyl)phenyl]ethoxy]-3-(4-fluorophenyl)-4-morpholinyl)methyl]-1,2-dihydro-, (2S-cis)- (9CI)


RN 172674-09-8 CAPLUS
CN Morpholine,
2-[(2-chloro-5-(trifluoromethyl)phenyl)methoxy]-3-phenyl-4-(1H-1,2,4-triazol-3-ylmethyl)-, (2S-cis)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 172674-10-1 CAPLUS
CN Morpholine, 2-[(2-chloro-5-(trifluoromethyl)phenyl)methoxy]-3-(4-fluorophenyl)-4-(1H-1,2,4-triazol-3-ylmethyl)-, (2S-cis)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 172674-11-2 CAPLUS
CN Morpholine, 2-[(1-[2-chloro-5-(trifluoromethyl)phenyl]ethoxy]-3-phenyl-4-(1H-1,2,4-triazol-3-ylmethyl)-, [2R-[2α(R*),3α]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




(CA INDEX NAME)

Absolute stereochemistry.




RN 172674-15-6 CAPLUS
CN 3H-1,2,4-Triazol-3-one,
5-[(2-{[1-[2-chloro-5-(trifluoromethyl)phenyl]ethoxy]-3-phenyl-4-morpholinyl)methyl]-1,2-dihydro-, [2R-[2α(R*),3α]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 172674-16-7 CAPLUS
CN 3H-1,2,4-Triazol-3-one,
5-[(2-{[1-[2-chloro-5-(trifluoromethyl)phenyl]ethoxy]-3-(4-fluorophenyl)-4-morpholinyl)methyl]-1,2-dihydro-, [2R-[2α(R*),3α]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 172674-37-2 CAPLUS
CN Morpholine, 2-[(3-methylphenyl)methoxy]-3-phenyl-4-(1H-1,2,4-triazol-3-ylmethyl)-, (2S-cis)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 172674-38-3 CAPLUS
CN Morpholine, 3-(4-fluorophenyl)-2-[(3-methylphenyl)methoxy]-4-(1H-1,2,4-triazol-3-ylmethyl)-, (2S-cis)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 172674-39-4 CAPLUS
CN Morpholine, 2-[1-(3-methylphenyl)ethoxy]-3-phenyl-4-(1H-1,2,4-triazol-3-ylmethyl)-, (2R-[2α(R*),3α])- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 172674-43-0 CAPLUS
CN 3H-1,2,4-Triazol-3-one, 1,2-dihydro-5-[[2-[1-(3-methylphenyl)ethoxy]-3-phenyl-4-morpholinylmethyl]-, (2R-[2α(R*),3α])- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 172674-44-1 CAPLUS
CN 3H-1,2,4-Triazol-3-one, 5-[[3-(4-fluorophenyl)-2-[(3-methylphenyl)ethoxy]-4-morpholinylmethyl]-1,2-dihydro-, (2R-[2α(R*),3α])- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 172674-63-6 CAPLUS
CN Morpholine, 2-[1-(3-bromophenyl)methoxy]-3-phenyl-4-(1H-1,2,4-triazol-3-ylmethyl)-, (2S-cis)- (9CI) (CA INDEX NAME)




RN 172674-40-7 CAPLUS
CN Morpholine, 3-(4-fluorophenyl)-2-[1-(3-methylphenyl)ethoxy]-4-(1H-1,2,4-triazol-3-ylmethyl)-, (2R-[2α(R*),3α])- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 172674-41-8 CAPLUS
CN 3H-1,2,4-Triazol-3-one, 1,2-dihydro-5-[[2-[(3-methylphenyl)methoxy]-3-phenyl-4-morpholinylmethyl]-, (2S-cis)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 172674-42-9 CAPLUS
CN 3H-1,2,4-Triazol-3-one, 5-[[3-(4-fluorophenyl)-2-[(3-methylphenyl)methoxy]-4-morpholinylmethyl]-1,2-dihydro-, (2S-cis)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

Absolute stereochemistry.




RN 172674-66-7 CAPLUS
CN Morpholine, 2-[(3-bromophenyl)methoxy]-3-(4-fluorophenyl)-4-(1H-1,2,4-triazol-3-ylmethyl)-, (2S-cis)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 172674-67-8 CAPLUS
CN Morpholine, 2-[1-(3-bromophenyl)ethoxy]-3-phenyl-4-(1H-1,2,4-triazol-3-ylmethyl)-, (2R-[2α(R*),3α])- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 172674-68-9 CAPLUS
CN Morpholine, 2-[1-(3-bromophenyl)ethoxy]-3-(4-fluorophenyl)-4-(1H-1,2,4-triazol-3-ylmethyl)-, (2R-[2α(R*),3α])- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 172674-69-0 CAPLUS
CN 3H-1,2,4-Triazol-3-one, 5-[[2-[(3-bromophenyl)methoxy]-3-phenyl-4-morpholinylmethyl]-1,2-dihydro-, (2S-cis)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 172674-70-3 CAPLUS
CN 3H-1,2,4-Triazol-3-one, 5-[[2-[(3-bromophenyl)methoxy]-3-(4-fluorophenyl)-4-morpholinylmethyl]-1,2-dihydro-, (2S-cis)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 172674-71-4 CAPLUS
CN 3H-1,2,4-Triazol-3-one, 5-[[2-[(3-bromophenyl)methoxy]-3-phenyl-4-morpholinylmethyl]-1,2-dihydro-, [2R-[2α(R*),3α]]- (9CI) (CA INDEX NAME)




RN 172674-95-2 CAPLUS
CN Morpholine, 2-[[1-[(3-chlorophenyl)ethoxy]-3-phenyl-4-(1H-1,2,4-triazol-3-yl)methyl]-, [2R-[2α(R*),3α]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 172674-96-3 CAPLUS
CN Morpholine, 2-[[1-[(3-chlorophenyl)ethoxy]-3-(4-fluorophenyl)-4-(1H-1,2,4-triazol-3-yl)methyl]-, [2R-[2α(R*),3α]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 172674-97-4 CAPLUS
CN 3H-1,2,4-Triazol-3-one, 5-[[2-[(3-chlorophenyl)methoxy]-3-phenyl-4-morpholinylmethyl]-1,2-dihydro-, (2S-cis)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 172674-72-5 CAPLUS
CN 3H-1,2,4-Triazol-3-one, 5-[[2-[(3-bromophenyl)methoxy]-3-(4-fluorophenyl)-4-morpholinylmethyl]-1,2-dihydro-, [2R-[2α(R*),3α]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 172674-93-0 CAPLUS
CN Morpholine, 2-[[1-[(3-chlorophenyl)methoxy]-3-phenyl-4-(1H-1,2,4-triazol-3-yl)methyl]-, (2S-cis)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 172674-94-1 CAPLUS
CN Morpholine, 2-[[1-[(3-chlorophenyl)methoxy]-3-(4-fluorophenyl)-4-(1H-1,2,4-triazol-3-yl)methyl]-, (2S-cis)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 172674-98-5 CAPLUS
CN 3H-1,2,4-Triazol-3-one, 5-[[2-[(3-chlorophenyl)methoxy]-3-(4-fluorophenyl)-4-morpholinylmethyl]-1,2-dihydro-, (2S-cis)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 172674-99-6 CAPLUS
CN 3H-1,2,4-Triazol-3-one, 5-[[2-[(3-chlorophenyl)methoxy]-3-phenyl-4-morpholinylmethyl]-1,2-dihydro-, [2R-[2α(R*),3α]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 172675-00-2 CAPLUS
CN 3H-1,2,4-Triazol-3-one, 5-[[2-[(3-chlorophenyl)methoxy]-3-(4-fluorophenyl)-4-morpholinylmethyl]-1,2-dihydro-, [2R-[2α(R*),3α]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 172675-21-7 CAPLUS
CN Morpholine, 4-[(2,5-dihydro-1H-1,2,4-triazol-3-yl)methyl]-3-phenyl-2-[[3-(trifluoromethyl)phenyl]methoxy]-, (2S-cis)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 172675-22-8 CAPLUS
CN Morpholine, 4-[(2,5-dihydro-1H-1,2,4-triazol-3-yl)methyl]-3-(4-fluorophenyl)-2-[[3-(trifluoromethyl)phenyl]methoxy]-, (2S-cis)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 172675-23-9 CAPLUS
CN Morpholine, 4-[(2,5-dihydro-1H-1,2,4-triazol-3-yl)methyl]-3-phenyl-2-[[3-(trifluoromethyl)phenyl]methoxy]-, (2R-[2a(R*),3a])- (9CI) (CA INDEX NAME)




RN 172675-27-3 CAPLUS
CN 3H-1,2,4-Triazol-3-one, 5-[[3-(4-fluorophenyl)-2-[[3-(trifluoromethyl)phenyl]ethoxy]-4-morpholinyl]methyl]-1,2-dihydro-, [2R-[2a(R*),3a]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 172675-48-8 CAPLUS
CN Morpholine, 2-[[3-(1,1-dimethylethyl)phenyl]ethoxy]-3-phenyl-4-(1H-1,2,4-triazol-3-ylmethyl)-, (2S-cis)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 172675-49-9 CAPLUS
CN Morpholine, 2-[[3-(1,1-dimethylethyl)phenyl]ethoxy]-3-(4-fluorophenyl)-4-(1H-1,2,4-triazol-3-ylmethyl)-, (2S-cis)- (9CI) (CA INDEX NAME)




RN 172675-24-0 CAPLUS
CN Morpholine, 4-[(2,5-dihydro-1H-1,2,4-triazol-3-yl)methyl]-3-(4-fluorophenyl)-2-[[1-[3-(trifluoromethyl)phenyl]ethoxy]-, [2R-[2a(R*),3a]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 172675-25-1 CAPLUS
CN 3H-1,2,4-Triazol-3-one, 1,2-dihydro-5-[[3-phenyl-2-[[3-(trifluoromethyl)phenyl]ethoxy]-4-morpholinyl]methyl]-, (2S-cis)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 172675-26-2 CAPLUS
CN 3H-1,2,4-Triazol-3-one, 5-[[3-(4-fluorophenyl)-2-[[3-(trifluoromethyl)phenyl]ethoxy]-4-morpholinyl]methyl]-1,2-dihydro-, (2S-cis)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 172675-50-2 CAPLUS
CN Morpholine, 2-[[1-[3-(1,1-dimethylethyl)phenyl]ethoxy]-3-phenyl-4-(1H-1,2,4-triazol-3-ylmethyl)-, [2R-[2a(R*),3a]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 172675-51-3 CAPLUS
CN Morpholine, 2-[[1-[3-(1,1-dimethylethyl)phenyl]ethoxy]-3-(4-fluorophenyl)-4-(1H-1,2,4-triazol-3-ylmethyl)-, [2R-[2a(R*),3a]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 172675-52-4 CAPLUS
CN 3H-1,2,4-Triazol-3-one, 5-[[2-[[3-(1,1-dimethylethyl)phenyl]ethoxy]-3-phenyl-4-morpholinyl]methyl]-1,2-dihydro-, (2S-cis)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 172675-53-5 CAPLUS
CN 3H-1,2,4-Triazol-3-one, 5-[[2-[[1-(1,1-dimethylethyl)phenyl]ethoxy]-3-(4-fluorophenyl)-4-morpholinyl]methyl]-1,2-dihydro-, (2S-cis)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 172675-54-6 CAPLUS
CN 3H-1,2,4-Triazol-3-one, 5-[[2-[[1-(1,1-dimethylethyl)phenyl]ethoxy]-3-phenyl-4-morpholinyl]methyl]-1,2-dihydro-, [2R-[2a(R*),3a]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 172675-55-7 CAPLUS
CN 3H-1,2,4-Triazol-3-one, 5-[[2-[[1-(1,1-dimethylethyl)phenyl]ethoxy]-3-(4-fluorophenyl)-4-morpholinyl]methyl]-1,2-dihydro-, [2R-[2a(R*),3a]]- (9CI) (CA INDEX NAME)




RN 172675-81-9 CAPLUS
CN Morpholine, 2-[[1-[[3-(methylthio)-5-(trifluoromethyl)phenyl]ethoxy]-3-phenyl-4-(1H-1,2,4-triazol-3-ylmethyl)-, [2R-[2a(R*),3a]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 172675-83-1 CAPLUS
CN 3H-1,2,4-Triazol-3-one, 5-[[2-[[1-(2,3-dihydro-2,2-dimethyl-5-(methylthio)-7-benzofuranyl]ethoxy)-3-phenyl-4-morpholinyl]methyl]-1,2-dihydro-, [2R-[2a(R*),3a]]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 172675-84-2 CAPLUS
CN Morpholine, 2-[[1-[[2,3-dihydro-2,2-dimethyl-5-(methylthio)-7-benzofuranyl]ethoxy]-3-phenyl-4-(1H-1,2,4-triazol-3-ylmethyl)-, [2R-[2a(R*),3a]]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

Absolute stereochemistry.




RN 172675-77-3 CAPLUS
CN 3H-1,2,4-Triazol-3-one, 1,2-dihydro-5-[[2-[[1-(3-(methylthio)phenyl)ethoxy]-3-phenyl-4-morpholinyl]methyl]-, [2R-[2a(R*),3a]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 172675-78-4 CAPLUS
CN Morpholine, 2-[[1-[[3-(methylthio)phenyl]ethoxy]-3-phenyl-4-(1H-1,2,4-triazol-3-ylmethyl)-, [2R-[2a(R*),3a]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 172675-80-8 CAPLUS
CN 3H-1,2,4-Triazol-3-one, 1,2-dihydro-5-[[2-[[1-(3-(methylthio)-5-(trifluoromethyl)phenyl]ethoxy)-3-phenyl-4-morpholinyl]methyl]-, [2R-[2a(R*),3a]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 172675-86-4 CAPLUS
CN 3H-1,2,4-Triazol-3-one, 5-[[2-[[1-(3,5-dimethoxyphenyl)ethoxy]-3-phenyl-4-morpholinyl]methyl]-1,2-dihydro-, [2R-[2a(R*),3a]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 172675-87-5 CAPLUS
CN Morpholine, 2-[[1-[[3-(methylthio)-5-(trifluoromethyl)phenyl]ethoxy]-3-phenyl-4-(1H-1,2,4-triazol-3-ylmethyl)-, [2R-[2a(R*),3a]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 172675-89-7 CAPLUS
CN 3H-1,2,4-Triazol-3-one, 5-[[3-(4-fluorophenyl)-2-[[1-(3'-fluoro-5-(trifluoromethyl)[1,1'-biphenyl]-3-yl]ethoxy]-4-morpholinyl]methyl]-1,2-dihydro-, [2R-[2a(R*),3a]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 172675-90-0 CAPLUS
CN Morpholine, 3-(4-fluorophenyl)-2-[[1-[3'-fluoro-5-(trifluoromethyl)]1,1'-biphenyl]-3-yl]ethoxy]-4-(1H-1,2,4-triazol-3-ylmethyl)-, [2R-[2 α (R*),3 α]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 172675-92-2 CAPLUS
CN 3H-1,2,4-Triazol-3-one, 5-[[2-[1-[3'-chloro-5-(trifluoromethyl)]1,1'-biphenyl]-3-yl]ethoxy]-3-(4-fluorophenyl)-4-morpholinylmethyl]-1,2-dihydro-, [2R-[2 α (R*),3 α]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 172675-93-3 CAPLUS
CN Morpholine, 2-[1-[3'-chloro-5-(trifluoromethyl)]1,1'-biphenyl]-3-yl]ethoxy]-3-(4-fluorophenyl)-4-(1H-1,2,4-triazol-3-ylmethyl)-, [2R-[2 α (R*),3 α]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 172675-95-5 CAPLUS
CN 3H-1,2,4-Triazol-3-one, 5-[[2-[1-(3,5-dimethylphenyl)ethoxy]-3-(4-fluorophenyl)-4-morpholinylmethyl]-1,2-dihydro-, [2R-[2 α (R*),3 α]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 172675-96-6 CAPLUS
CN Morpholine, 2-[1-(3,5-dimethylphenyl)ethoxy]-3-(4-fluorophenyl)-4-(1H-1,2,4-triazol-3-ylmethyl)-, [2R-[2 α (R*),3 α]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 172675-98-8 CAPLUS
CN 3H-1,2,4-Triazol-3-one, 5-[[2-[1-(3-fluoro-5-methylphenyl)ethoxy]-3-(4-fluorophenyl)-4-morpholinylmethyl]-1,2-dihydro-, [2R-[2 α (R*),3 α]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 172676-00-5 CAPLUS
CN 3H-1,2,4-Triazol-3-one, 5-[[2-[1-(3-chloro-5-methylphenyl)ethoxy]-3-(4-fluorophenyl)-4-morpholinylmethyl]-1,2-dihydro-, [2R-[2 α (R*),3 α]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 172676-01-6 CAPLUS
CN Morpholine, 2-[1-[3-chloro-5-methylphenyl]ethoxy]-3-(4-fluorophenyl)-4-(1H-1,2,4-triazol-3-ylmethyl)-, [2R-[2 α (R*),3 α]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 172676-03-8 CAPLUS
CN 3H-1,2,4-Triazol-3-one, 5-([2-([1-(3-bromo-5-methylphenyl)ethoxy]-3-(4-fluorophenyl)-4-morpholinyl)methyl]-1,2-dihydro-, [2R-[2α(R*),3α]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 172676-04-9 CAPLUS
CN Morpholine, 2-[1-([3-(4-fluorophenyl)ethoxy]-3-(4-fluorophenyl)-4-(1H-1,2,4-triazol-3-ylmethyl)-, [2R-[2α(R*),3α]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


RN 172676-09-4 CAPLUS
CN 3H-1,2,4-Triazol-3-one, 5-([3-([4-fluorophenyl]-2-[1-([3-(1-methylethoxy)-5-(trifluoromethyl)phenyl]ethoxy)-4-morpholinyl)methyl]-1,2-dihydro-, [2R-[2α(R*),3α]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 172676-10-7 CAPLUS
CN Morpholine, 3-([4-fluorophenyl]-2-[1-([3-(1-methylethoxy)-5-(trifluoromethyl)phenyl]ethoxy)-4-(1H-1,2,4-triazol-3-ylmethyl)-, [2R-[2α(R*),3α]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 172676-12-9 CAPLUS
CN 3H-1,2,4-Triazol-3-one, 5-([2-([1-([3-chloro-5-(1-methylethoxy)phenyl]ethoxy)-3-(4-fluorophenyl)-4-morpholinyl)methyl]-1,2-dihydro-, [2R-[2α(R*),3α]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.





RN 172676-06-1 CAPLUS
CN 3H-1,2,4-Triazol-3-one, 5-([3-([4-fluorophenyl]-2-[1-([3-methyl-5-(1-methylethoxy)phenyl]ethoxy)-4-morpholinyl)methyl]-1,2-dihydro-, [2R-[2α(R*),3α]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 172676-07-2 CAPLUS
CN Morpholine, 3-([4-fluorophenyl]-2-[1-([3-methyl-5-(1-methylethoxy)phenyl]ethoxy)-4-(1H-1,2,4-triazol-3-ylmethyl)-, [2R-[2α(R*),3α]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 172676-13-0 CAPLUS
CN Morpholine, 2-[1-([3-chloro-5-(1-methylethoxy)phenyl]ethoxy)-3-(4-fluorophenyl)-4-(1H-1,2,4-triazol-3-ylmethyl)-, [2R-[2α(R*),3α]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 172676-15-2 CAPLUS
CN Morpholine, 2-[1-([3-fluoro-5-(1-methylethoxy)phenyl]ethoxy)-3-(4-fluorophenyl)-4-(1H-1,2,4-triazol-3-ylmethyl)-, [2R-[2α(R*),3α]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 172676-17-4 CAPLUS
CN 3H-1,2,4-Triazol-3-one, 5-([2-[1-[3-chloro-5-(1,1-dimethylethyl)phenyl]ethoxy]-3-(4-fluorophenyl)-4-morpholinyl]methyl)-1,2-dihydro-, [2R-[2 α (R*),3 α]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 172676-18-5 CAPLUS
CN Morpholine, 2-[1-[3-chloro-5-(1,1-dimethylethyl)phenyl]ethoxy]-3-(4-fluorophenyl)-4-(1H-1,2,4-triazol-3-ylmethyl)-, [2R-[2 α (R*),3 α]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 172676-20-9 CAPLUS
CN 3H-1,2,4-Triazol-3-one, 5-([2-[1-[3-(1,1-dimethylethyl)-5-(trifluoromethyl)phenyl]ethoxy]-3-(4-fluorophenyl)-4-morpholinyl]methyl)-1,2-dihydro-, [2R-[2 α (R*),3 α]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 172676-21-0 CAPLUS
CN Morpholine, 2-[1-[3-(1,1-dimethylethyl)-5-(trifluoromethyl)phenyl]ethoxy]-3-(4-fluorophenyl)-4-(1H-1,2,4-triazol-3-ylmethyl)-, [2R-[2 α (R*),3 α]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 172676-23-2 CAPLUS
CN 3H-1,2,4-Triazol-3-one, 5-([2-[1-(4-fluoro-3,5-dimethylphenyl)ethoxy]-3-(4-fluorophenyl)-4-morpholinyl]methyl)-1,2-dihydro-, [2R-[2 α (R*),3 α]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 172676-24-3 CAPLUS
CN Morpholine, 2-[1-(4-fluoro-3,5-dimethylphenyl)ethoxy]-3-(4-fluorophenyl)-4-(1H-1,2,4-triazol-3-ylmethyl)-, [2R-[2 α (R*),3 α]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 172676-26-5 CAPLUS
CN 3H-1,2,4-Triazol-3-one, 5-([2-[1-(4-chloro-3,5-dimethylphenyl)ethoxy]-3-(4-fluorophenyl)-4-morpholinyl]methyl)-1,2-dihydro-, [2R-[2 α (R*),3 α]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 172676-27-6 CAPLUS
CN Morpholine, 2-[1-(4-chloro-3,5-dimethylphenyl)ethoxy]-3-(4-fluorophenyl)-4-(1H-1,2,4-triazol-3-ylmethyl)-, [2R-[2 α (R*),3 α]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 172676-29-8 CAPLUS
CN 3H-1,2,4-Triazol-3-one, 5-([2-[1-(4-fluoro-3,5-bis(trifluoromethyl)phenyl)ethoxy]-3-(4-fluorophenyl)-4-morpholinyl]methyl)-1,2-dihydro-, [2R-[2 α (R*),3 α]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 172676-30-1 CAPLUS
CN Morpholine, 2-[1-[4-fluoro-3,5-bis(trifluoromethyl)phenyl]ethoxy]-3-(4-fluorophenyl)-4-(1H-1,2,4-triazol-3-ylmethyl)-, [2R-[2α(R*),3α]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 172676-32-3 CAPLUS
CN 3H-1,2,4-Triazol-3-one, 5-[[2-[1-[4-chloro-3,5-bis(trifluoromethyl)phenyl]ethoxy]-3-(4-fluorophenyl)-4-morpholinyl]methyl]-1,2-dihydro-, [2R-[2α(R*),3α]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 172676-33-4 CAPLUS
CN Morpholine, 2-[1-[4-chloro-3,5-bis(trifluoromethyl)phenyl]ethoxy]-3-(4-fluorophenyl)-4-(1H-1,2,4-triazol-3-ylmethyl)-, [2R-[2α(R*),3α]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 172676-35-6 CAPLUS
CN 3H-1,2,4-Triazol-3-one, 5-[[2-[1-(3,5-dichlorophenyl)ethoxy]-3-(4-fluorophenyl)-4-morpholinyl]methyl]-1,2-dihydro-, [2R-[2α(R*),3α]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 172676-36-7 CAPLUS
CN Morpholine, 2-[1-[3,5-dichlorophenyl]ethoxy]-3-(4-fluorophenyl)-4-(1H-1,2,4-triazol-3-ylmethyl)-, [2R-[2α(R*),3α]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 172676-38-9 CAPLUS
CN 3H-1,2,4-Triazol-3-one, 5-[[2-[1-(3,5-difluorophenyl)ethoxy]-3-(4-fluorophenyl)-4-morpholinyl]methyl]-1,2-dihydro-, [2R-[2α(R*),3α]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 172676-39-0 CAPLUS
CN Morpholine, 2-[1-(3,5-difluorophenyl)ethoxy]-3-(4-fluorophenyl)-4-(1H-1,2,4-triazol-3-ylmethyl)-, [2R-[2α(R*),3α]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 172676-41-4 CAPLUS
CN 3H-1,2,4-Triazol-3-one, 5-[[3-(4-fluorophenyl)-2-[1-(1-naphthalenyl)ethoxy]-4-morpholinyl]methyl]-1,2-dihydro-, [2R-[2α(R*),3α]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 172676-42-5 CAPLUS
CN Morpholine, 3-(4-fluorophenyl)-2-[(1-(1-naphthalenyl)ethoxy)-4-(1H-1,2,4-triazol-3-ylmethyl)-, [2R-[2 α (R*),3 α]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 172676-44-7 CAPLUS
CN 3H-1,2,4-Triazol-3-one, 5-[[2-[(1-(4-fluoro-1-naphthalenyl)ethoxy)-3-(4-fluorophenyl)-4-morpholinyl]methyl]-1,2-dihydro-, [2R-[2 α (R*),3 α]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 172676-45-8 CAPLUS
CN Morpholine, 2-[1-(4-fluoro-1-naphthalenyl)ethoxy]-3-(4-fluorophenyl)-4-(1H-1,2,4-triazol-3-ylmethyl)-, [2R-[2 α (R*),3 α]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 172676-46-9 CAPLUS
CN 3H-1,2,4-Triazol-3-one, 5-[[2-[(1-(3-fluoro-1-naphthalenyl)ethoxy)-3-(4-fluorophenyl)-4-morpholinyl]methyl]-1,2-dihydro-, [2R-[2 α (R*),3 α]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 172676-47-0 CAPLUS
CN Morpholine, 2-[1-(3-fluoro-1-naphthalenyl)ethoxy]-3-(4-fluorophenyl)-4-(1H-1,2,4-triazol-3-ylmethyl)-, [2R-[2 α (R*),3 α]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 172676-49-2 CAPLUS
CN 3H-1,2,4-Triazol-3-one, 5-[[2-[(1-(3-chloro-1-naphthalenyl)ethoxy)-3-(4-fluorophenyl)-4-morpholinyl]methyl]-1,2-dihydro-, [2R-[2 α (R*),3 α]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 172676-50-5 CAPLUS
CN Morpholine, 2-[1-(3-chloro-1-naphthalenyl)ethoxy]-3-(4-fluorophenyl)-4-(1H-1,2,4-triazol-3-ylmethyl)-, [2R-[2 α (R*),3 α]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 172676-52-7 CAPLUS
CN 3H-1,2,4-Triazol-3-one, 5-[[3-(4-fluorophenyl)-2-[1-(3-methyl-1-naphthalenyl)ethoxy]-4-morpholinyl]methyl]-1,2-dihydro-, [2R-[2 α (R*),3 α]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 172676-53-8 CAPLUS
CN Morpholine, 3-(4-fluorophenyl)-2-[1-(3-methyl-1-naphthalenyl)ethoxy]-4-(1H-1,2,4-triazol-3-ylmethyl)-, [2R-[2a(R*),3a]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 172676-55-0 CAPLUS
CN 3H-1,2,4-Triazol-3-one, 5-[[3-(4-fluorophenyl)-2-[1-[3-(trifluoromethyl)-1-naphthalenyl]ethoxy]-4-morpholinyl]methyl]-1,2-dihydro-, [2R-[2a(R*),3a]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 172676-59-4 CAPLUS
CN Morpholine, 3-(4-fluorophenyl)-2-[1-[3-(methylthio)phenyl]ethoxy]-4-(1H-1,2,4-triazol-3-ylmethyl)-, [2R-[2a(R*),3a]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 172676-61-8 CAPLUS
CN 3H-1,2,4-Triazol-3-one, 5-[[3-(4-fluorophenyl)-2-[1-[3-(methylthio)-5-(trifluoromethyl)phenyl]ethoxy]-4-morpholinyl]methyl]-1,2-dihydro-, [2R-[2a(R*),3a]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 172676-56-1 CAPLUS
CN Morpholine, 3-(4-fluorophenyl)-4-(1H-1,2,4-triazol-3-ylmethyl)-2-[1-[3-(trifluoromethyl)-1-naphthalenyl]ethoxy]-, [2R-[2a(R*),3a]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 172676-58-3 CAPLUS
CN 3H-1,2,4-Triazol-3-one, 5-[[3-(4-fluorophenyl)-2-[1-[3-(methylthio)phenyl]ethoxy]-4-morpholinyl]methyl]-1,2-dihydro-, [2R-[2a(R*),3a]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 172676-62-9 CAPLUS
CN Morpholine, 3-(4-fluorophenyl)-2-[1-[3-(methylthio)-5-(trifluoromethyl)phenyl]ethoxy]-4-(1H-1,2,4-triazol-3-ylmethyl)-, [2R-[2a(R*),3a]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 172676-64-1 CAPLUS
CN 3H-1,2,4-Triazol-3-one, 5-[[2-[1-[2-(3-dihydro-2,2-dimethyl-5-(methylthio)-7-benzofuranyl]ethoxy]-3-(4-fluorophenyl)-4-morpholinyl]methyl]-1,2-dihydro-, [2R-[2a(R*),3a]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 172676-65-2 CAPLUS
CN Morphinolone, 2-[[1-(2,3-dihydro-2,2-dimethyl-5-(methylthio)-7-benzofuranylethoxy)-3-(4-fluorophenyl)-4-(1H-1,2,4-triazol-3-ylmethyl)-, [2R-[2 α (R*),3 α]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 172676-67-4 CAPLUS
CN 3H-1,2,4-Triazol-3-one, 5-[[2-[[1-(3,5-dimethoxyphenyl)ethoxy]-3-(4-fluorophenyl)-4-morpholinylmethyl]-1,2-dihydro-, [2R-[2 α (R*),3 α]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 172676-73-2 CAPLUS
CN 3H-1,2,4-Triazol-3-one, 5-[[3-(4-fluorophenyl)-2-(1-phenylethoxy)-4-morpholinylmethyl]-1,2-dihydro-, [2R-[2 α (R*),3 α]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 172676-74-3 CAPLUS
CN Morphinolone, 3-(4-fluorophenyl)-2-(1-phenylethoxy)-4-(1H-1,2,4-triazol-3-ylmethyl)-, [2R-[2 α (R*),3 α]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 172676-76-3 CAPLUS
CN 3H-1,2,4-Triazol-3-one, 5-[[2-[[1-(3-fluorophenyl)ethoxy]-3-phenyl-4-morpholinylmethyl]-1,2-dihydro-, [2R-[2 α (R*),3 α]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 172676-68-5 CAPLUS
CN Morphinolone, 2-[[1-(3,5-dimethoxyphenyl)ethoxy]-3-(4-fluorophenyl)-4-(1H-1,2,4-triazol-3-ylmethyl)-, [2R-[2 α (R*),3 α]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 172676-70-9 CAPLUS
CN 3H-1,2,4-Triazol-3-one, 1,2-dihydro-5-[[3-phenyl-2-(1-phenylethoxy)-4-morpholinylmethyl]-, [2R-[2 α (R*),3 α]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 172676-71-0 CAPLUS
CN Morphinolone, 3-phenyl-2-(1-phenylethoxy)-4-(1H-1,2,4-triazol-3-ylmethyl)-, [2R-[2 α (R*),3 α]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 172676-77-6 CAPLUS
CN Morphinolone, 2-[[1-(3-fluorophenyl)ethoxy]-3-phenyl-4-(1H-1,2,4-triazol-3-ylmethyl)-, [2R-[2 α (R*),3 α]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 172676-79-8 CAPLUS
CN 3H-1,2,4-Triazol-3-one, 5-[[3-(4-fluorophenyl)-2-(1-(3-fluorophenyl)ethoxy)-4-morpholinylmethyl]-1,2-dihydro-, [2R-[2 α (R*),3 α]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 172676-80-1 CAPLUS
CN Morphinolone, 3-(4-fluorophenyl)-2-(1-(3-fluorophenyl)ethoxy)-4-(1H-1,2,4-triazol-3-ylmethyl)-, [2R-[2 α (R*),3 α]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 172676-82-3 CAPLUS
CN 3H-1,2,4-Triazol-3-one, 5-([2-[1-(4-fluorophenyl)ethoxy]-3-phenyl-4-morpholinyl]methyl)-1,2-dihydro-, [2R-[2a(R*),3a]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 172676-83-4 CAPLUS
CN Morpholine, 2-[1-(4-fluorophenyl)ethoxy]-3-phenyl-4-(1H-1,2,4-triazol-3-ylmethyl)-, [2R-[2a(R*),3a]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 172676-85-6 CAPLUS
CN 3H-1,2,4-Triazol-3-one, 5-([3-(4-fluorophenyl)-2-[1-(4-fluorophenyl)ethoxy]-4-morpholinyl]methyl)-1,2-dihydro-, [2R-[2a(R*),3a]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


RN 172676-89-0 CAPLUS
CN Morpholine, 2-[1-[3,5-bis(trifluoromethyl)phenyl]ethoxy]-3-(3-fluorophenyl)-4-(1H-1,2,4-triazol-3-ylmethyl)-, [2R-[2a(R*),3a]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 172676-91-4 CAPLUS
CN 3H-1,2,4-Triazol-3-one, 5-([2-[1-[3,5-bis(trifluoromethyl)phenyl]ethoxy]-3-(3,4-difluorophenyl)-4-morpholinyl]methyl)-1,2-dihydro-, [2R-[2a(R*),3a]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 172676-92-5 CAPLUS
CN Morpholine, 2-[1-[3,5-bis(trifluoromethyl)phenyl]ethoxy]-3-(3,4-difluorophenyl)-4-(1H-1,2,4-triazol-3-ylmethyl)-, [2R-[2a(R*),3a]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 172676-86-7 CAPLUS
CN Morpholine, 3-(4-fluorophenyl)-2-[1-(4-fluorophenyl)ethoxy]-4-(1H-1,2,4-triazol-3-ylmethyl)-, [2R-[2a(R*),3a]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 172676-88-9 CAPLUS
CN 3H-1,2,4-Triazol-3-one, 5-([2-[1-[3,5-bis(trifluoromethyl)phenyl]ethoxy]-3-(3-fluorophenyl)-4-morpholinyl]methyl)-1,2-dihydro-, [2R-[2a(R*),3a]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 172676-94-7 CAPLUS
CN 3H-1,2,4-Triazol-3-one, 5-([2-[1-[3,5-bis(trifluoromethyl)phenyl]ethoxy]-3-(3,4-dichlorophenyl)-4-morpholinyl]methyl)-1,2-dihydro-, [2R-[2a(R*),3a]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 172676-95-8 CAPLUS
CN Morpholine, 2-[1-[3,5-bis(trifluoromethyl)phenyl]ethoxy]-3-(3,4-dichlorophenyl)-4-(1H-1,2,4-triazol-3-ylmethyl)-, [2R-[2a(R*),3a]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 172676-97-0 CAPLUS
CN 3H-1,2,4-Triazol-3-one, 5-([2-([1-[3,5-bis(trifluoromethyl)phenyl]ethoxy]-3-(3,4-dimethylphenyl)-4-morpholinyl)methyl]-1,2-dihydro-, [2R-[2α(R*),3α]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 172676-98-1 CAPLUS
CN Morpholine, 2-[1-[3,5-bis(trifluoromethyl)phenyl]ethoxy]-3-(3,4-dimethylphenyl)-4-(1H-1,2,4-triazol-3-ylmethyl)-, [2R-[2α(R*),3α]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 172677-00-8 CAPLUS
CN 3H-1,2,4-Triazol-3-one, 5-([3-(1,3-benzodioxol-5-yl)-2-[1-[3,5-bis(trifluoromethyl)phenyl]ethoxy]-4-morpholinyl)methyl]-1,2-dihydro-, [2R-[2α(R*),3α]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 172677-01-9 CAPLUS
CN Morpholine, 3-(1,3-benzodioxol-5-yl)-2-[1-[3,5-bis(trifluoromethyl)phenyl]ethoxy]-4-(1H-1,2,4-triazol-3-ylmethyl)-, [2R-[2α(R*),3α]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 172677-03-1 CAPLUS
CN 3H-1,2,4-Triazol-3-one, 5-([2-([1-[3,5-bis(trifluoromethyl)phenyl]ethoxy]-3-(2-naphthalenyl)-4-morpholinyl)methyl]-1,2-dihydro-, [2R-[2α(R*),3α]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 172677-04-2 CAPLUS
CN Morpholine, 2-[1-[3,5-bis(trifluoromethyl)phenyl]ethoxy]-3-(2-naphthalenyl)-4-(1H-1,2,4-triazol-3-ylmethyl)-, [2R-[2α(R*),3α]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 172677-06-4 CAPLUS
CN Morpholine, 2-[1-[3-fluoro-5-(trifluoromethyl)phenyl]ethoxy]-3-phenyl-4-(1H-1,2,4-triazol-3-ylmethyl)-, [2R-[2α(R*),3α]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 172677-08-6 CAPLUS
CN Morpholine, 2-[1-[3-chloro-5-(trifluoromethyl)phenyl]ethoxy]-3-phenyl-4-(1H-1,2,4-triazol-3-ylmethyl)-, [2R-[2α(R*),3α]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 172677-10-0 CAPLUS
CN Morpholine, 2-[1-[3,5-dimethylphenyl]ethoxy]-3-phenyl-4-(1H-1,2,4-triazol-3-ylmethyl)-, [2R-[2α(R*),3α]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 172677-12-2 CAPLUS
 CN Morpholine, 2-[(1-(3-fluoro-5-methylphenyl)ethoxy)-3-phenyl-4-(1H-1,2,4-triazol-3-ylmethyl)-, [2R-[2 α (R*),3 α]]- (9CI) (CA INDEX NAME)]

Absolute stereochemistry.




RN 172677-14-4 CAPLUS
 CN Morpholine, 2-[(1-(3-chloro-5-methylphenyl)ethoxy)-3-phenyl-4-(1H-1,2,4-triazol-3-ylmethyl)-, [2R-[2 α (R*),3 α]]- (9CI) (CA INDEX NAME)]

Absolute stereochemistry.




RN 172677-16-6 CAPLUS
 CN Morpholine, 2-[(1-(3-bromo-5-methylphenyl)ethoxy)-3-phenyl-4-(1H-1,2,4-triazol-3-ylmethyl)-, [2R-[2 α (R*),3 α]]- (9CI) (CA INDEX NAME)]

Absolute stereochemistry.




RN 172677-24-6 CAPLUS
 CN Morpholine, 4-[(2,5-dihydro-1H-1,2,4-triazol-3-yl)methyl]-2-[(1-(3-fluoro-5-(1-methylethoxy)phenyl)ethoxy)-3-phenyl-, [2R-[2 α (R*),3 α]]- (9CI) (CA INDEX NAME)]

Absolute stereochemistry.




RN 172677-26-8 CAPLUS
 CN Morpholine, 2-[(1-(3-chloro-5-(1,1-dimethylethyl)phenyl)ethoxy)-4-[(2,5-dihydro-1H-1,2,4-triazol-3-yl)methyl]-3-phenyl-, [2R-[2 α (R*),3 α]]- (9CI) (CA INDEX NAME)]

Absolute stereochemistry.




RN 172677-28-0 CAPLUS
 CN Morpholine, 4-[(2,5-dihydro-1H-1,2,4-triazol-3-yl)methyl]-2-[(1-(4-fluoro-3,5-bis(trifluoromethyl)phenyl)ethoxy)-3-phenyl-, [2R-[2 α (R*),3 α]]- (9CI) (CA INDEX NAME)]

Absolute stereochemistry.




RN 172677-18-8 CAPLUS
 CN Morpholine, 2-[(1-(3-(1-methylethoxy)phenyl)ethoxy)-3-phenyl-4-(1H-1,2,4-triazol-3-ylmethyl)-, [2R-[2 α (R*),3 α]]- (9CI) (CA INDEX NAME)]

Absolute stereochemistry.




RN 172677-20-2 CAPLUS
 CN Morpholine, 2-[(1-(3-(1-methylethoxy)-5-(trifluoromethyl)phenyl)ethoxy)-3-phenyl-4-(1H-1,2,4-triazol-3-ylmethyl)-, [2R-[2 α (R*),3 α]]- (9CI) (CA INDEX NAME)]

Absolute stereochemistry.




RN 172677-22-4 CAPLUS
 CN Morpholine, 2-[(1-(3-chloro-5-(1-methylethoxy)phenyl)ethoxy)-4-[(2,5-dihydro-1H-1,2,4-triazol-3-yl)methyl]-3-phenyl-, [2R-[2 α (R*),3 α]]- (9CI) (CA INDEX NAME)]

Absolute stereochemistry.




RN 172677-30-4 CAPLUS
 CN Morpholine, 2-[(1-(4-fluoro-3,5-dimethylphenyl)ethoxy)-3-phenyl-4-(1H-1,2,4-triazol-3-ylmethyl)-, [2R-[2 α (R*),3 α]]- (9CI) (CA INDEX NAME)]

Absolute stereochemistry.




RN 172677-32-6 CAPLUS
 CN Morpholine, 2-[(1-(4-chloro-3,5-dimethylphenyl)ethoxy)-4-[(2,5-dihydro-1H-1,2,4-triazol-3-yl)methyl]-3-phenyl-, [2R-[2 α (R*),3 α]]- (9CI) (CA INDEX NAME)]

Absolute stereochemistry.




RN 172677-34-8 CAPLUS
 CN Morpholine, 4-[(2,5-dihydro-1H-1,2,4-triazol-3-yl)methyl]-2-[(1-(4-fluoro-3,5-bis(trifluoromethyl)phenyl)ethoxy)-3-phenyl-, [2R-[2 α (R*),3 α]]- (9CI) (CA INDEX NAME)]

Absolute stereochemistry.




RN 172677-36-0 CAPLUS
CN Morpholine, 2-[[1-(4-chloro-3,5-bis(trifluoromethyl)phenyl)ethoxy]-4-[(2,5-dihydro-1H-1,2,4-triazol-3-yl)methyl]-3-phenyl-, [2R-[2 α (R*),3 α]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 172677-38-2 CAPLUS
CN Morpholine, 2-[[1-(3,5-dichlorophenyl)ethoxy]-4-[(2,5-dihydro-1H-1,2,4-triazol-3-yl)methyl]-3-phenyl-, [2R-[2 α (R*),3 α]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 172677-40-6 CAPLUS
CN Morpholine, 2-[[1-(3,5-difluorophenyl)ethoxy]-4-[(2,5-dihydro-1H-1,2,4-triazol-3-yl)methyl]-3-phenyl-, [2R-[2 α (R*),3 α]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 172677-48-4 CAPLUS
CN Morpholine, 2-[[1-(3-chloro-1-naphthalenyl)ethoxy]-3-phenyl-4-[(1H-1,2,4-triazol-3-yl)methyl]-, [2R-[2 α (R*),3 α]]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.




RN 172822-01-4 CAPLUS
CN Phosphonic acid, [3-[[[(2R,3S)-2-[(1R)-1-[3,5-bis(trifluoromethyl)phenyl]et

hoxyl]-3-(4-fluorophenyl)-4-morpholinyl]methyl]-2,5-dihydro-5-oxo-1H-1,2,4-triazol-1-yl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 172822-02-5 CAPLUS
CN Phosphonic acid, [3-[[[(2R,3S)-2-[(1R)-1-[3,5-bis(trifluoromethyl)phenyl]ethoxy]-3-(4-fluorophenyl)-4-morpholinyl]methyl]-1,5-dihydro-5-oxo-4H-1,2,4-triazol-4-yl]-, dipotassium salt, [2R-[2 α (R*),3 α]]- (9CI) (CA INDEX NAME)




RN 172677-42-8 CAPLUS
CN Morpholine, 2-[[1-(1-naphthalenyl)ethoxy]-3-phenyl-4-[(1H-1,2,4-triazol-3-yl)methyl]-, [2R-[2 α (R*),3 α]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 172677-44-0 CAPLUS
CN Morpholine, 2-[[1-(4-fluoro-1-naphthalenyl)ethoxy]-3-phenyl-4-[(1H-1,2,4-triazol-3-yl)methyl]-, [2R-[2 α (R*),3 α]]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 172677-46-2 CAPLUS
CN Morpholine, 2-[[1-(3-fluoro-1-naphthalenyl)ethoxy]-3-phenyl-4-[(1H-1,2,4-triazol-3-yl)methyl]-, [2R-[2 α (R*),3 α]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


Absolute stereochemistry.



● 2 K


RN 172822-03-6 CAPLUS
CN Phosphonic acid, [3-[[[(2R,3S)-2-[(1R)-1-[3,5-bis(trifluoromethyl)phenyl]et hoxyl]-3-(4-fluorophenyl)-4-morpholinyl]methyl]-2,5-dihydro-5-oxo-1H-1,2,4-triazol-1-yl]-, dipotassium salt (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● 2 K


RN 172822-04-7 CAPLUS
CN 1H-1,2,4-Triazol-3-ol, 5-[[[(2R,3S)-2-[(1R)-1-[3,5-bis(trifluoromethyl)phenyl]ethoxy]-3-(4-fluorophenyl)-4-morpholinyl]methyl]-, dihydrogen phosphate (ester), dipotassium salt (9CI) (CA INDEX NAME)



● 2 K

RN 172822-05-8 CAPLUS
CN Phosphonic acid, 5-([2-([3,5-bis(trifluoromethyl)phenyl]ethoxy)-3-(4-fluorophenyl)-4-morpholinyl)methyl]-2,3-dihydro-3-oxo-1H-1,2,4-triazol-1-yl)-, dipotassium salt, [2R-(2α(R*),3α)]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● 2 K

RN 172822-07-0 CAPLUS
CN Morpholine, 2-([3,5-bis(trifluoromethyl)phenyl]methoxy)-5,6-dimethyl-3-phenyl-4-(1H-1,2,4-triazol-3-ylmethyl)-, 4-oxide, [2R-(2α,3β,5β,6β)]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

Absolute stereochemistry.




IT 172822-11-6P 172822-12-7P 172822-28-5P
172822-29-6P 173405-07-7P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses) (preparation of morpholine tachykinin receptor antagonist prodrugs)
RN 172822-11-6 CAPLUS
CN 3H-1,2,4-Triazol-3-one, 5-([2-([3,5-bis(trifluoromethyl)phenyl]ethoxy)-3-(4-fluorophenyl)-4-morpholinyl)methyl]-1,2-dihydro-, [2S-(2α,3α,5β,6β)]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 172822-12-7 CAPLUS
CN 3H-1,2,4-Triazol-3-one, 5-([2-([3,5-bis(trifluoromethyl)phenyl]ethoxy)-3-(4-fluorophenyl)-4-morpholinyl)methyl]-1,2-dihydro-, [2S-(2α,3α,5β,6β)]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 172822-08-1 CAPLUS
CN 3H-1,2,4-Triazol-3-one, 5-([2-([3,5-bis(trifluoromethyl)phenyl]ethoxy)-3-(4-fluorophenyl)-4-morpholinyl)methyl]-1,2-dihydro-, [2R-(2α,3β,5β,6β)]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 172822-09-2 CAPLUS
CN Morpholine, 2-([3,5-bis(trifluoromethyl)phenyl]methoxy)-5,6-dimethyl-3-phenyl-4-(1H-1,2,4-triazol-3-ylmethyl)-, 4-oxide, [2S-(2α,3α,5β,6β)]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 172822-10-5 CAPLUS
CN Morpholine, 2-([3,5-bis(trifluoromethyl)phenyl]methoxy)-5,6-dimethyl-3-phenyl-4-(1H-1,2,4-triazol-3-ylmethyl)-, 4-oxide, [2S-(2α,3α,5β,6β)]- (9CI) (CA INDEX NAME)




RN 172822-28-5 CAPLUS
CN 3H-1,2,4-Triazol-3-one, 5-([2-([3,5-bis(trifluoromethyl)phenyl]ethoxy)-3-(4-fluorophenyl)-4-morpholinyl)methyl]-1,2-dihydro-, [2S-(2α,3α,5β,6β)]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 172822-29-6 CAPLUS
CN 3H-1,2,4-Triazol-3-one, 5-([2-([3,5-bis(trifluoromethyl)phenyl]ethoxy)-3-(4-fluorophenyl)-4-morpholinyl)methyl]-1,2-dihydro-, [2S-(2α,3α,5β,6β)]- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).




RN 173405-07-7 CAPLUS
 CN 3H-1,2,4-Triazol-3-one, 5-[[2-[1-[3-fluoro-5-(1-methylethoxy)phenyl]ethoxy]-3-(4-fluorophenyl)-4-morpholinyl]methyl]-1,2-dihydro-, [2R-[2a(R*),3a]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.





IT 159706-40-8P 159706-76-0P 170729-75-6P
 172678-16-9P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (preparation of morpholine tachykinin receptor antagonist prodrugs)
 RN 159706-40-8 CAPLUS
 CN Hydrazinecarboxylic acid, 2-[2-[2-[[3,5-bis(trifluoromethyl)phenyl]methoxy]-3-phenyl-4-morpholinyl]-1-iminoethyl]-, methyl ester, (2S-cis)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 172678-16-9 CAPLUS
 CN Morpholine, 2-[1-[3-fluoro-5-methylphenyl]ethoxy]-3-(4-fluorophenyl)-4-(1H-1,2,4-triazol-3-ylmethyl)-, [2R-[2a(R*),3a]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 159706-76-0 CAPLUS
 CN Hydrazinecarboxylic acid, 2-[2-[2-[[3,5-dichlorophenyl]methoxy]-3-phenyl-4-morpholinyl]-1-iminoethyl]-, methyl ester, (2S-cis)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 170729-75-6 CAPLUS
 CN Hydrazinecarboxylic acid, 2-[2-[2-[[3,5-bis(trifluoromethyl)phenyl]ethoxy]-3-phenyl-4-morpholinyl]-1-iminoethyl]-, methyl ester, [2R-[2a(R*),3a]]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

ACCESSION NUMBER: 1995:943459 CAPLUS
 DOCUMENT NUMBER: 124:29769
 TITLE: Preparation of (thio)morpholines as tachykinin receptor antagonists
 INVENTOR(S): Dorn, Conrad P.; Finke, Paul E.; Hale, Jeffrey J.; MacCoss, Malcolm; Mills, Sander G.; Shah, Shrenik K.; Chambers, Mark Stuart; Harrison, Timothy; Ladduwahetty, Tamara; Williams, Brian John
 PATENT ASSIGNEE(S): Merck and Co., Inc., USA
 SOURCE: PCT Int. Appl., 319 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 3
 PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---|------|----------|------------------|----------|
| WO 9516679 | A1 | 19950622 | WO 1994-US14497 | 19941213 |
| W: AM, AU, BB, BG, BR, BY, CA, CN, CZ, EE, FI, GE, HU, JP, KG, KR, KZ, LK, LR, LT, LV, MD, NG, MN, NO, NZ, PL, RO, RU, SI, SK, TJ, TT, UA, US, UZ | | | | |
| RW: KE, MW, SD, SZ, AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG | | | | |
| IL 111960 | A | 19991222 | IL 1994-111960 | 19941212 |
| CA 2178949 | A1 | 19950622 | CA 1994-2178949 | 19941213 |
| CA 2178949 | C | 20060321 | | |
| AU 9514375 | A | 19950703 | AU 1995-14375 | 19941213 |
| AU 701862 | B2 | 19990204 | | |
| EP 734381 | A1 | 19961002 | EP 1995-905965 | 19941213 |
| EP 734381 | B1 | 20000705 | | |
| R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, NL, PT, SE | | | | |
| CN 1142819 | A | 19970212 | CN 1994-195008 | 19941213 |
| CN 1057296 | B | 20001011 | | |
| JP 19506628 | T | 19970630 | JP 1995-516959 | 19941213 |
| JP 3245424 | B2 | 20020115 | | |
| BR 9408351 | A | 19970826 | BR 1994-8351 | 19941213 |
| HU 76476 | A2 | 19970929 | HU 1996-1634 | 19941213 |
| HU 224014 | B1 | 20050428 | | |
| AT 194336 | T | 20000715 | AT 1995-905965 | 19941213 |
| ES 2147840 | T3 | 20001001 | ES 1995-905965 | 19941213 |
| PT 734381 | T | 20001229 | PT 1995-905965 | 19941213 |
| PL 182521 | B1 | 20020131 | PL 1994-315153 | 19941213 |
| SK 282800 | B6 | 20021203 | SK 1996-753 | 19941213 |
| RO 118203 | B1 | 20030328 | RO 1996-1239 | 19941213 |
| RU 2201924 | C2 | 20030410 | RU 1996-115181 | 19941213 |
| CZ 295381 | B6 | 20050713 | CZ 1996-1772 | 19941213 |
| TW 419471 | B | 20010121 | TW 1994-83111698 | 19941214 |
| ZA 9410008 | A | 19960715 | ZA 1994-10008 | 19941215 |
| HR 941000 | B1 | 20010430 | HR 1994-1000 | 19941215 |
| FI 9602489 | A | 19960813 | FI 1996-2489 | 19960614 |
| FI 109532 | B1 | 20020830 | | |
| NO 9602523 | A | 19960816 | NO 1996-2523 | 19960614 |
| NO 308742 | B1 | 20001023 | | |
| LV 11617 | B | 19970420 | LV 1996-201 | 19960625 |
| BG 64775 | B1 | 20060331 | BG 1996-100715 | 19960716 |
| US 5922706 | A | 19990713 | US 1997-969685 | 19971113 |
| HK 1009046 | A1 | 20010511 | HK 1998-109816 | 19980811 |
| US 6048859 | A | 20000411 | US 1999-251190 | 19990216 |

L12 ANSWER 9 OF 11 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
 US 6235735 B1 20010522 US 2000-526843 20000316
 GR 3034095 T3 20001130 GR 2000-401792 20000802
 US 2002002164 A1 20020103 US 2001-836716 20010417
 US 6638930 B2 20031028
 PRIORITY APPLN. INFO.:
 US 1993-169889 A 19931217
 US 1992-905976 B2 19920629
 US 1992-971448 B2 19921104
 US 1993-61914 B2 19930519
 WO 1994-US14497 W 19941213
 US 1995-525259 A3 19950908
 US 1997-959393 A3 19971028
 US 1999-251190 A3 19990216
 US 2000-526843 A3 20000316


OTHER SOURCE(S): MARPAT 124:29769
 GI



AB Title compds. [I: R = alkyl; R1 = H, (un)substituted alk(en)yl, -Ph, etc.; R2, R2 = H, (un)substituted alk(en)yl, -Ph, etc.; R1R2, R2R3 = atoms to form a ring; R6, R11 = (un)substituted Ph; X = O, SO₂-2; Z = bond, O, CO, CH₂, etc.) were prepared as tachykinin receptor antagonists (no data). Thus, PHCHBrCH(OMe)₂ was converted to PHCHBrCH(OCH₂C₆H₃(CF₃)₂-3,5)₂ which was aminated by H₂NCH₂CH₂OH to give, after N-protection, cyclization, and deprotection, title compound cis- and trans-II (R1 = H) as a mixture. The latter mixture was N-alkylated with ICH₂CONH₂ to give, after separation, cis- and trans-II (R1 = CH₂CONH₂).
 IT 159706-38-4P 159706-39-5P 159706-63-5P
 159706-64-6P 159706-67-9P 159706-75-9P
 159706-90-8P 170729-76-7P 170729-80-3P
 170729-82-5P 170729-84-7P 170729-88-1P
 170729-95-0P 170729-96-1P 170902-79-1P
 170902-81-3P
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses) (preparation of (thio)morpholines as tachykinin receptor antagonists)


L12 ANSWER 9 OF 11 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
 RN 159706-64-6 CAPLUS
 CN 3H-1,2,4-Triazol-3-one, 5-[[2-[[3,5-bis(trifluoromethyl)phenyl]methoxy]-6-methyl-3-phenyl-4-morpholinyl]methyl]-1,2-dihydro-, (2S-(2α,3α,6β))- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 159706-67-9 CAPLUS
 CN Morpholine, 2-[[3,5-bis(trifluoromethyl)phenyl]methoxy]-3-phenyl-4-[(1H-1,2,4-triazol-3-ylmethyl)-, (2S,3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 159706-75-9 CAPLUS
 CN 3H-1,2,4-Triazol-3-one, 5-[[2-[[3,5-dichlorophenyl]methoxy]-3-phenyl-4-morpholinyl]methyl]-1,2-dihydro-, (2S-cis)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 159706-90-8 CAPLUS


L12 ANSWER 9 OF 11 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
 RN 159706-38-4 CAPLUS
 CN Morpholine, 2-[[3,5-bis(trifluoromethyl)phenyl]methoxy]-3-phenyl-4-[(1H-1,2,4-triazol-3-ylmethyl)-, (2S,3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 159706-39-5 CAPLUS
 CN 3H-1,2,4-Triazol-3-one, 5-[[2-[[3,5-bis(trifluoromethyl)phenyl]methoxy]-3-phenyl-4-morpholinyl]methyl]-1,2-dihydro-, (2S,3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 159706-63-5 CAPLUS
 CN Morpholine, 2-[[3,5-bis(trifluoromethyl)phenyl]methoxy]-6-methyl-3-phenyl-4-[(1H-1,2,4-triazol-3-ylmethyl)-, (2S-(2α,3α,6β))- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




L12 ANSWER 9 OF 11 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
 CN 3H-1,2,4-Triazol-3-one, 5-[[2-[[3,5-bis(trifluoromethyl)phenyl]methoxy]-3-phenyl-4-morpholinyl]methyl]-1,2-dihydro-, (2S-(2α,3α,6β))- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 170729-76-7 CAPLUS
 CN 3H-1,2,4-Triazol-3-one, 5-[[2-[[3,5-bis(trifluoromethyl)phenyl]ethoxy]-3-phenyl-4-morpholinyl]methyl]-1,2-dihydro-, (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 170729-80-3 CAPLUS
 CN 3H-1,2,4-Triazol-3-one, 5-[[2-[[3,5-bis(trifluoromethyl)phenyl]ethoxy]-3-phenyl-4-morpholinyl]methyl]-1,2-dihydro-, (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).




RN 170729-82-5 CAPLUS
CN 3H-1,2,4-Triazol-3-one, 1,2-dihydro-5-[[2-(2R,3S)-3-phenyl-2-[(1R)-1-[3-(trifluoromethyl)phenyl]ethoxy]-4-morpholinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 170729-84-7 CAPLUS
CN 3H-1,2,4-Triazol-3-one, 1,2-dihydro-5-[[2-(2R,3S)-2-[(1R)-1-[3-fluoro-5-(trifluoromethyl)phenyl]ethoxy]-3-phenyl-4-morpholinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 170729-88-1 CAPLUS
CN 3H-1,2,4-Triazol-3-one, 1,2-dihydro-5-[[2-(2R,3S)-2-[(1R)-1-[3-fluoro-5-(trifluoromethyl)phenyl]ethoxy]-3-phenyl-4-morpholinyl]methyl]- (9CI) (CA INDEX NAME)





RN 170902-79-1 CAPLUS
CN 3H-1,2,4-Triazol-3-one, 1,2-dihydro-5-[[2-(2R,3S)-2-[(1R)-1-[3,5-bis(trifluoromethyl)phenyl]ethoxy]-3-phenyl-4-morpholinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 170902-81-5 CAPLUS
CN 3H-1,2,4-Triazol-3-one, 1,2-dihydro-5-[[2-(2R,3S)-2-[(1R)-1-[3,5-bis(trifluoromethyl)phenyl]ethoxy]-3-phenyl-4-morpholinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 170729-95-0 CAPLUS
CN 3H-1,2,4-Triazol-3-one, 1,2-dihydro-5-[[2-(2R,3S)-2-[(1R)-1-[3-(trifluoromethyl)phenyl]ethoxy]-3-phenyl-4-morpholinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 170729-96-1 CAPLUS
CN Morpholine, 2-[[2-(2R,3S)-2-[(1R)-1-[3-(trifluoromethyl)phenyl]ethoxy]-3-phenyl-4-morpholinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


IT 159706-40-8P 159706-76-0P 159706-84-0P
159706-85-1P 170729-75-6P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of (thio)morpholines as tachykinin receptor antagonists)
RN 159706-40-8 CAPLUS
CN Hydrazinecarboxylic acid, 2-[[2-[[2-[[3,5-bis(trifluoromethyl)phenyl]methoxy]-3-phenyl-4-morpholinyl]-1-iminoethyl]-, methyl ester, (2S-cis)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 159706-76-0 CAPLUS
CN Hydrazinecarboxylic acid, 2-[[2-[[2-[[3,5-dichlorophenyl]methoxy]-3-phenyl-4-morpholinyl]-1-iminoethyl]-, methyl ester, (2S-cis)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 159706-84-0 CAPLUS
CN Morpholine, 2-[[2-[[2-[[3,5-bis(trifluoromethyl)phenyl]methoxy]-5,6-dimethyl-3-phenyl-4-(1H-1,2,4-triazol-3-ylmethyl)- (9CI) (CA INDEX NAME)




RN 159706-85-1 CAPLUS
CN 3H-1,2,4-Triazol-3-one, 5-[[2-[[3,5-bis(trifluoromethyl)phenyl]methoxy]-5,6-dimethyl-3-phenyl-4-morpholinyl]methyl]-1,2-dihydro- (9CI) (CA INDEX NAME)



RN 170729-75-6 CAPLUS
CN Hydrazinecarboxylic acid, 2-[[2-[[1-[[3,5-bis(trifluoromethyl)phenyl]ethoxy]-3-phenyl-4-morpholinyl]-1-iminoethyl]-, methyl ester, [2R-[2α(R*),3α]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




g.g., coupling of 2-(S)-[3,5-bis(trifluoromethyl)benzyloxy]-3-(S)-phenylmorpholine with N-methylcarboxy-2-chloroacetamidrazone (prepn. given) afforded 4-[[2-(N-methylcarboxy)acetamidrazono]-2-(S)-[3,5-bis(trifluoromethyl)benzyloxy]-3-(S)-phenylmorpholine which upon cyclization and recrystn. from hexanes/ethyl acetate afforded I (Form A, 58% yield). Form A was suspended in 40 mL of deionized water and the resultant mixt. was sonicated for approx. 1 min, then stirred at room temp. for 48 h; the mixt. was transferred to a centrifuge tube and spun

at 2,700 G for 20 min; the supernatant was removed and the solid was placed on a piece of filter paper and allowed to air-dry for 4 days to afford Form B. A 3.0 mg sample of Form B was placed in a small aluminum pan and the unsealed pan was placed in a DSC instrument; the sample was heated at 1°/min under an inert nitrogen atm. from ambient temp. to 160°, then cooled back down to room temp.; the resulting solid is suitable for use as seed crystals in the large-scale prepn. of Form C. Pharmaceutical compns. were given.

IT 159706-39-5P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); PEP (Physical, engineering or chemical process); PRP (Properties); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); PROC (Process); USES (Uses) (polymorph; polymorphic form of 2-(S)-[3,5-

bis(trifluoromethyl)benzyloxy]-4-[[3-(5-oxo-1H,4H-1,2,4-triazolo)methyl]-3-(S)-phenylmorpholine, a tachykinin receptor antagonist)
RN 159706-39-5 CAPLUS
CN 3H-1,2,4-Triazol-3-one, 5-[[2-[[3,5-bis(trifluoromethyl)phenyl]methoxy]-3-phenyl-4-morpholinyl]methyl]-1,2-dihydro- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 159706-40-8P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent) (polymorphic form of 2-(S)-[3,5-bis(trifluoromethyl)benzyloxy]-4-[[3-(5-oxo-1H,4H-1,2,4-triazolo)methyl]-3-(S)-phenylmorpholine, a tachykinin receptor antagonist)
RN 159706-40-8 CAPLUS
CN Hydrazinecarboxylic acid, 2-[[2-[[3,5-bis(trifluoromethyl)phenyl]methoxy]-3-phenyl-4-morpholinyl]methyl]-1,2-dihydro- (9CI) (CA INDEX NAME)

ACCESSION NUMBER: 1995:913755 CAPLUS
DOCUMENT NUMBER: 124:117332
TITLE: Polymorphic form of 2-(S)-[3,5-


bis(trifluoromethyl)benzyloxy]-4-[[3-(5-oxo-1H,4H-1,2,4-triazolo)methyl]-3-(S)-phenylmorpholine, a tachykinin receptor antagonist

INVENTOR(S): Kaufman, Michael J.
PATENT ASSIGNEE(S): Merck and Co., Inc., USA
SOURCE: U.S., 10 pp.

DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|------------------------|------|----------|-----------------|------------|
| US 5457107 | A | 19951010 | US 1994-307962 | 19940916 |
| GB 2293168 | A | 19960320 | GB 1995-18113 | 19950906 |
| PRIORITY APPLN. INFO.: | | | US 1994-307962 | A 19940916 |


GI



AB A polymorphic form of the compound 2-(S)-[3,5-bis(trifluoromethyl)benzyloxy]-4-[[3-(5-oxo-1H,4H-1,2,4-triazolo)methyl]-3-(S)-phenylmorpholine (I, a tachykinin receptor antagonist (no data) useful in the treatment of inflammatory diseases, pain or migraine, asthma, and emesis) designated Form C is claimed, which is characterized by an endotherm of melting at an extrapolated onset temperature of 176-178°degree. when heated in a differential scanning calorimetric cell at a rate of 5°/min under a nitrogen atmospheric, which is characterized by an X-ray powder diffraction pattern with reflections at approx.: 11.5°, 12.6°, 15.5°, 16.8°, 20.1°, 21.3°, 25.4° and 28.5° (2 theta), and which is characterized by an aqueous solubility of 2.7 µg/mL in distilled water at room temperature. The instant polymorphic form has advantages over the other known forms of I in terms of thermodyn. stability

[3-phenyl-4-morpholinyl]-1-iminoethyl]-, methyl ester, (2S-cis)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



L12 ANSWER 11 OF 11 CAPLUS COPYRIGHT 2007 ACS on STN
 ACCESSION NUMBER: 1993:252333 CAPLUS
 DOCUMENT NUMBER: 122:56044
 TITLE: Morpholine and thiomorpholine tachykinin receptor antagonists
 INVENTOR(S): Dorn, Conrad P.; Hale, Jeffrey J.; Maccoss, Malcolm; Mills, Sander G.; Ladduwahetty, Tamara; Shah, Shrenik K.
 PATENT ASSIGNEE(S): Merck and Co., Inc., USA
 SOURCE: Eur. Pat. Appl., 96 pp.
 CODEN: EPKXDW
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 3
 PATENT INFORMATION:


| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|--|------|----------|-----------------|------------|
| EP 577394 | A1 | 19940105 | EP 1993-305086 | 19930629 |
| EP 577394 | B1 | 19991110 | | |
| R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, NL, PT, SE | | | | |
| CA 2099233 | A1 | 19931230 | CA 1993-2099233 | 19930625 |
| IL 106142 | A | 19970318 | IL 1993-106142 | 19930625 |
| AU 9341568 | A | 19940106 | AU 1993-41568 | 19930628 |
| AU 663595 | B2 | 19931012 | | |
| ZA 9304624 | A | 19940620 | ZA 1993-4624 | 19930628 |
| HR 931003 | B1 | 20001031 | HR 1993-1003 | 19930628 |
| WO 9400440 | A1 | 19940106 | WO 1993-US6181 | 19930629 |
| W: AU, BB, BG, BR, CA, CZ, FI, HU, JP, KR, KZ, LK, MG, MN, MW, NO, NZ, PL, RO, RU, SD, SK, UA, US | | | | |
| RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GH, ML, MR, NE, SN, TD, TG | | | | |
| AU 9346561 | A | 19940124 | AU 1993-46561 | 19930629 |
| CN 1087902 | A | 19940615 | CN 1993-109517 | 19930629 |
| CN 1049431 | B | 20000216 | | |
| JP 06172178 | A | 19940621 | JP 1993-212045 | 19930629 |
| JP 2634372 | B2 | 19970723 | | |
| HU 71809 | A2 | 19960228 | HU 1994-3804 | 19930629 |
| HU 219713 | B | 20010628 | | |
| PL 174506 | B1 | 19980831 | PL 1993-306840 | 19930629 |
| RO 114448 | B1 | 19990430 | RO 1994-2095 | 19930629 |
| RU 2140914 | C1 | 19991110 | RU 1994-46364 | 19930629 |
| AT 186532 | T | 19991115 | AT 1993-305086 | 19930629 |
| ES 2141133 | T3 | 20000316 | ES 1993-305086 | 19930629 |
| SK 281093 | B6 | 20001107 | SK 1994-1600 | 19930629 |
| CZ 288530 | B6 | 20010711 | CZ 1994-3330 | 19930629 |
| BG 62963 | B1 | 20001229 | BG 1994-99274 | 19941219 |
| FI 9406133 | A | 19941228 | FI 1994-6133 | 19941228 |
| FI 111363 | B1 | 20030715 | | |
| NO 9405064 | A | 19950228 | NO 1994-5064 | 19941228 |
| NO 305698 | B1 | 19990712 | | |
| HK 1009268 | A1 | 20010112 | HK 1998-109867 | 19980812 |
| GR 3031824 | T3 | 20000229 | GR 1999-402842 | 19991111 |
| LV 12568 | B | 20010420 | LV 2000-118 | 20000907 |
| PRIORITY APPLN. INFO.: | | | | |
| | | | US 1992-905976 | A 19920629 |
| | | | US 1992-971448 | A 19921104 |
| | | | US 1993-61914 | A 19930519 |
| | | | WO 1993-US6181 | A 19930629 |

L12 ANSWER 11 OF 11 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 159706-40-8 CAPLUS
 CN Hydrazinecarboxylic acid, 2-[[2-[[3,5-bis(trifluoromethyl)phenyl]methoxy]-1,3-phenyl-4-morpholinyl]-1-iminoethyl]-, methyl ester, (2S-cis)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 159706-63-5 CAPLUS
 CN Morpholine, 2-[[3,5-bis(trifluoromethyl)phenyl]methoxy]-6-methyl-3-phenyl-4-(1H-1,2,4-triazol-3-ylmethyl)-, (2S-(2α,3α,6β))- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




L12 ANSWER 11 OF 11 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
 OTHER SOURCE(S): MARPAT 122:56044
 GI



AB Substituted heterocycles I [R1-R3 = H, substituted (e.g., substituted-Ph, -amino, heterocyclyl, etc.) or unsubstituted-C1-6 alkyl; R1 and R2 may join together to form a heterocyclic ring; R4 = substituted-phenylalkyloxy; R5 = Ph, substituted-Ph, substituted (substituted-Ph, -amino, etc.) or unsubstituted-C1-8 alkyl; X = O, S] were prepd, and are tachykinin receptor antagonists useful in the treatment of inflammatory diseases, pain or migraine, and asthma and calcium channel blockers useful in the treatment of cardiovascular conditions such as angina, hypertension or ischemia (no data). A representative prepared example is (+/-)-2-(3,5-bis(trifluoromethyl)benzyloxy)-3-phenylmorpholine.
 IT 159706-38-4P 159706-39-5P 159706-40-8P
 159706-63-5P 159706-64-6P 159706-67-9P
 159706-68-0P 159706-75-9P 159706-76-0P
 159706-84-0P 159706-85-1P 159706-90-8P
 RL: SPN (Synthetic preparation); PREP (Preparation) (preparation of, as tachykinin receptor antagonists)

RN 159706-38-4 CAPLUS
 CN Morpholine, 2-[[3,5-bis(trifluoromethyl)phenyl]methoxy]-3-phenyl-4-(1H-1,2,4-triazol-3-ylmethyl)-, (2S,3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 159706-39-5 CAPLUS
 CN 3H-1,2,4-Triazol-3-one, 5-[[[(2S,3S)-2-[[3,5-bis(trifluoromethyl)phenyl]methoxy]-6-methyl-3-phenyl-4-morpholinyl]methyl]-1,2-dihydro- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L12 ANSWER 11 OF 11 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)


RN 159706-64-6 CAPLUS
 CN 3H-1,2,4-Triazol-3-one, 5-[[[(2S,3S)-2-[[3,5-bis(trifluoromethyl)phenyl]methoxy]-6-methyl-3-phenyl-4-morpholinyl]methyl]-1,2-dihydro-, [2S-(2α,3α,6β)]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 159706-67-9 CAPLUS
 CN Morpholine, 2-[[3,5-bis(trifluoromethyl)phenyl]methoxy]-3-phenyl-4-(1H-1,2,4-triazol-3-ylmethyl)-, (2S,3R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 159706-68-0 CAPLUS
 CN 3H-1,2,4-Triazol-3-one, 5-[[[(2S,3S)-2-[[3,5-bis(trifluoromethyl)phenyl]methoxy]-3-phenyl-4-morpholinyl]methyl]-1,2-dihydro-, (2S-trans)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 159706-75-9 CAPLUS
CN 3H-1,2,4-Triazol-3-one, 5-[[2-[(3,5-dichlorophenyl)methoxy]-3-phenyl-4-morpholinyl)methyl]-1,2-dihydro-, (2S-cis)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 159706-76-0 CAPLUS
CN Hydrazinecarboxylic acid, 2-[2-[[2-[(3,5-dichlorophenyl)methoxy]-3-phenyl-4-morpholinyl]-1-iminoethyl]-, methyl ester, (2S-cis)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 159706-84-0 CAPLUS
CN Morpholine, 2-[[3,5-bis(trifluoromethyl)phenyl]methoxy]-5,6-dimethyl-3-




RN 159706-85-1 CAPLUS
CN 3H-1,2,4-Triazol-3-one, 5-[[2-[[3,5-bis(trifluoromethyl)phenyl]methoxy]-5,6-dimethyl-3-phenyl-4-morpholinyl)methyl]-1,2-dihydro- (9CI) (CA INDEX NAME)



RN 159706-90-8 CAPLUS
CN 3H-1,2,4-Triazol-3-one, 5-[[2-[[3,5-bis(trifluoromethyl)phenyl]methoxy]-3-(4-fluorophenyl)-4-morpholinyl)methyl]-1,2-dihydro- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



=> fil reg

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

64.65

432.50

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)

SINCE FILE

TOTAL

ENTRY

SESSION

CA SUBSCRIBER PRICE

-9.36

-9.36

FILE 'REGISTRY' ENTERED AT 07:07:06 ON 15 MAY 2007

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2007 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 14 MAY 2007 HIGHEST RN 934733-40-1

DICTIONARY FILE UPDATES: 14 MAY 2007 HIGHEST RN 934733-40-1

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH December 2, 2006



Please note that search-term pricing does apply when conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

<http://www.cas.org/support/stngen/stndoc/properties.html>

=>

Uploading C:\Program Files\Stnexp\Queries\QUERIES\10511691.str



chain nodes :

13 14 25

ring nodes :

1 2 3 4 5 6 7 8 9 10 11 12 15 16 17 18 19 20

chain bonds :

1-25 13-14 14-15

ring bonds :

1-2 1-6 2-3 3-4 4-5 5-6 7-8 7-12 8-9 9-10 10-11 11-12 15-16 15-20
16-17 17-18 18-19 19-20

exact/norm bonds :

1-2 1-6 1-25 2-3 3-4 4-5 5-6 13-14 14-15

normalized bonds :

7-8 7-12 8-9 9-10 10-11 11-12 15-16 15-20 16-17 17-18 18-19 19-20

Match level :

1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:Atom

11:Atom 12:Atom 13:CLASS 14:CLASS 15:Atom 16:Atom 17:Atom 18:Atom 19:Atom


20:Atom 23:Atom 24:Atom 25:CLASS

L15 STRUCTURE UPLOADED

=> d

L15 HAS NO ANSWERS

L15 STR



Structure attributes must be viewed using STN Express query preparation.

=> s l15

SAMPLE SEARCH INITIATED 07:07:25 FILE 'REGISTRY'

SAMPLE SCREEN SEARCH COMPLETED - 13727 TO ITERATE

14.6% PROCESSED 2000 ITERATIONS

2 ANSWERS

INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)

SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**

BATCH **COMPLETE**

PROJECTED ITERATIONS: 267521 TO 281559

PROJECTED ANSWERS: 52 TO 496

L16

2 SEA SSS SAM L15

=> s l15 full
FULL SEARCH INITIATED 07:07:29 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 272024 TO ITERATE

100.0% PROCESSED 272024 ITERATIONS
SEARCH TIME: 00.00.02

183 ANSWERS

L17 183 SEA SSS FUL L15

=> s l17 and caplus/lc
54188266 CAPLUS/LC


L18 181 L17 AND CAPLUS/LC

=> s l17 not l18

L19 2 L17 NOT L18


=> d l19 1-2

L19 ANSWER 1 OF 2 REGISTRY COPYRIGHT 2007 ACS on STN
 RN 740019-95-8 REGISTRY
 ED Entered STN: 05 Sep 2004
 CN 2-Morpholinol, 2,3-diphenyl-, benzoate (ester) (9CI) (CA INDEX NAME)
 MF C23 H21 N O3
 CI COM
 SR CA



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L19 ANSWER 2 OF 2 REGISTRY COPYRIGHT 2007 ACS on STN
 RN 6312-38-5 REGISTRY
 ED Entered STN: 16 Nov 1984
 CN 2-Morpholinol, 2,3-diphenyl-, benzoate (ester), hydrochloride (9CI) (CA INDEX NAME)
 OTHER NAMES:
 CN NSC 33990
 CN NSC 40326
 MF C23 H21 N O3 . Cl H
 CRN (740019-95-8)



● HCl

=> fil caplus
COST IN U.S. DOLLARS

| SINCE FILE | TOTAL |
|------------|---------|
| ENTRY | SESSION |
| 180.95 | 613.45 |

FULL ESTIMATED COST

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)

| SINCE FILE | TOTAL |
|------------|---------|
| ENTRY | SESSION |
| 0.00 | -9.36 |

CA SUBSCRIBER PRICE

FILE 'CAPLUS' ENTERED AT 07:07:55 ON 15 MAY 2007
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2007 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 15 May 2007 VOL 146 ISS 21
FILE LAST UPDATED: 14 May 2007 (20070514/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply. They are available for your review at:

<http://www.cas.org/infopolicy.html>

=> d his

(FILE 'HOME' ENTERED AT 07:00:59 ON 15 MAY 2007)

FILE 'REGISTRY' ENTERED AT 07:01:12 ON 15 MAY 2007

| | |
|----|----------------------|
| L1 | STRUCTURE UPLOADED |
| L2 | 3 S L1 |
| L3 | 7 S L1 FULL |
| L4 | 7 S L3 AND CAPLUS/LC |

FILE 'CAPLUS' ENTERED AT 07:02:26 ON 15 MAY 2007

| | |
|----|---------|
| L5 | 12 S L4 |
|----|---------|

FILE 'REGISTRY' ENTERED AT 07:03:47 ON 15 MAY 2007

| | |
|-----|------------------------|
| L6 | STRUCTURE UPLOADED |
| L7 | 2 S L6 |
| L8 | 386 S L6 FULL |
| L9 | 380 S L8 AND CAPLUS/LC |
| L10 | 6 S L8 NOT L9 |

FILE 'CAPLUS' ENTERED AT 07:05:03 ON 15 MAY 2007

| | |
|-----|-----------------|
| L11 | 237 S L9 |
| L12 | 11 S L11 AND L5 |
| L13 | 0 S L12 NOT L5 |
| L14 | 1 S L5 NOT L12 |

FILE 'REGISTRY' ENTERED AT 07:07:06 ON 15 MAY 2007

L15 STRUCTURE UPLOADED
L16 2 S L15
L17 183 S L15 FULL
L18 181 S L17 AND CAPLUS/LC
L19 2 S L17 NOT L18

FILE 'CAPLUS' ENTERED AT 07:07:55 ON 15 MAY 2007

=> s l18
L20 47 L18

=> s l20 and l12
L21 10 L20 AND L12

| | SINCE FILE ENTRY | TOTAL SESSION |
|--|---------------------|------------------|
| => fil reg COST IN U.S. DOLLARS | | |
| FULL ESTIMATED COST | 1.41 | 614.86 |
| DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS) | | |
| CA SUBSCRIBER PRICE | 0.00 | -9.36 |

FILE 'REGISTRY' ENTERED AT 07:09:43 ON 15 MAY 2007
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2007 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES: 14 MAY 2007 HIGHEST RN 934733-40-1
DICTIONARY FILE UPDATES: 14 MAY 2007 HIGHEST RN 934733-40-1

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH December 2, 2006

Please note that search-term pricing does apply when
conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and
predicted properties as well as tags indicating availability of
experimental property data in the original document. For information
on property searching in REGISTRY, refer to:

<http://www.cas.org/support/stngen/stndoc/properties.html>

=>
Uploading C:\Program Files\Stnexp\Queries\QUERIES\105116912.str



chain nodes :
1 2 3 4 5 6 7 8 9
chain bonds :
1-2 2-3 2-8 3-4 4-5 5-6 5-7 8-9

exact/norm bonds :

1-2 2-3 2-8 3-4 4-5 5-6 5-7 8-9

Match level :


1:CLASS 2:CLASS 3:CLASS 4:CLASS 5:CLASS 6:CLASS 7:CLASS 8:CLASS 9:CLASS

L22 STRUCTURE UPLOADED

=> d

L22 HAS NO ANSWERS

L22 STR



Structure attributes must be viewed using STN Express query preparation.

=> s l22

SAMPLE SEARCH INITIATED 07:09:59 FILE 'REGISTRY'

SAMPLE SCREEN SEARCH COMPLETED - 20 TO ITERATE

100.0% PROCESSED 20 ITERATIONS

0 ANSWERS

SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**

BATCH **COMPLETE**

PROJECTED ITERATIONS: 132 TO 668

PROJECTED ANSWERS: 0 TO 0

L23 0 SEA SSS SAM L22

=> s l22 full

FULL SEARCH INITIATED 07:10:03 FILE 'REGISTRY'

FULL SCREEN SEARCH COMPLETED - 310 TO ITERATE

100.0% PROCESSED 310 ITERATIONS

23 ANSWERS

SEARCH TIME: 00.00.01

L24 23 SEA SSS FUL L22

=> s l24 and caplus/lc

54188266 CAPLUS/LC

L25 17 L24 AND CAPLUS/LC

=> s l24 not l25


L26 6 L24 NOT L25

=> d l26 1-6

$$\text{Cl}_3\text{C}-\overset{\text{NH}}{\underset{\parallel}{\text{C}}}-\text{NH}-\text{NH}-\overset{\text{O}}{\underset{\parallel}{\text{C}}}-\text{CH}_2-\text{S}-\text{CH}_2-\text{Ph}$$
CC(F)(F)c1nn(C(F)(F)F)c(C(F)(F)F)n1C(=O)N[N-]C(=O)C(F)(F)F
$$\text{F}_3\text{C}-\overset{\overset{\text{O}}{\parallel}}{\text{C}}-\text{NH}-\text{N}=\overset{\overset{\text{NHMe}}{\mid}}{\text{C}}-\text{CF}_3$$
$$\begin{array}{c} \text{O} \\ \parallel \\ \text{F}_3\text{C}-\text{C}-\text{NH}-\text{N}=\text{C}-\text{CF}_3 \\ | \\ \text{NH}-\text{CH}_2-\text{CH}=\text{CH}_2 \end{array}$$


..**PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT**

L26 ANSWER 3 OF 6 REGISTRY COPYRIGHT 2007 ACS on STN
 RN 121607-85-0 REGISTRY
 ED Entered STN: 14 Jul 1989
 CN Acetic acid, trifluoro-, 2-[2,2,2-trifluoro-1-[(1-methylpropyl)imino]ethyl]hydrazide (9CI) (CA INDEX NAME)
 MF C8 H11 F6 N3 O
 CI COM
 SR CA



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L26 ANSWER 6 OF 6 REGISTRY COPYRIGHT 2007 ACS on STN
 RN 121607-83-8 REGISTRY
 ED Entered STN: 14 Jul 1989
 CN Acetic acid, trifluoro-, 2-[1-(ethylimino)-2,2,2-trifluoroethyl]hydrazide (9CI) (CA INDEX NAME)
 MF C6 H7 F6 N3 O
 CI COM
 SR CA



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

=> fil reg

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

188.75

803.61

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)

SINCE FILE

TOTAL

ENTRY

SESSION

CA SUBSCRIBER PRICE

0.00

-9.36

FILE 'REGISTRY' ENTERED AT 07:10:30 ON 15 MAY 2007

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2007 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 14 MAY 2007 HIGHEST RN 934733-40-1

DICTIONARY FILE UPDATES: 14 MAY 2007 HIGHEST RN 934733-40-1

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH December 2, 2006

Please note that search-term pricing does apply when conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

<http://www.cas.org/support/stngen/stndoc/properties.html>

=> d his

(FILE 'HOME' ENTERED AT 07:00:59 ON 15 MAY 2007)

FILE 'REGISTRY' ENTERED AT 07:01:12 ON 15 MAY 2007

L1 STRUCTURE UPLOADED

L2 3 S L1

L3 7 S L1 FULL

L4 7 S L3 AND CAPLUS/LC

FILE 'CAPLUS' ENTERED AT 07:02:26 ON 15 MAY 2007

L5 12 S L4

FILE 'REGISTRY' ENTERED AT 07:03:47 ON 15 MAY 2007

L6 STRUCTURE UPLOADED

L7 2 S L6

L8 386 S L6 FULL

L9 380 S L8 AND CAPLUS/LC

L10 6 S L8 NOT L9

FILE 'CAPLUS' ENTERED AT 07:05:03 ON 15 MAY 2007

L11 237 S L9

L12 11 S L11 AND L5

L13 0 S L12 NOT L5

L14 1 S L5 NOT L12

FILE 'REGISTRY' ENTERED AT 07:07:06 ON 15 MAY 2007

L15 STRUCTURE UPLOADED
L16 2 S L15
L17 183 S L15 FULL
L18 181 S L17 AND CAPLUS/LC
L19 2 S L17 NOT L18

FILE 'CAPLUS' ENTERED AT 07:07:55 ON 15 MAY 2007

L20 47 S L18
L21 10 S L20 AND L12

FILE 'REGISTRY' ENTERED AT 07:09:43 ON 15 MAY 2007

L22 STRUCTURE UPLOADED
L23 0 S L22
L24 23 S L22 FULL
L25 17 S L24 AND CAPLUS/LC
L26 6 S L24 NOT L25

FILE 'REGISTRY' ENTERED AT 07:10:30 ON 15 MAY 2007

=> s l25
 54188266 CAPLUS/LC
L27 17 L24 AND CAPLUS/LC

=> s l27 and l12
L28 0 L27 AND L12

=> s l27 and l21
L29 0 L27 AND L21

=> log y

COST IN U.S. DOLLARS

| SINCE FILE | TOTAL |
|------------|---------|
| ENTRY | SESSION |
| 5.40 | 809.01 |

FULL ESTIMATED COST

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)

| SINCE FILE | TOTAL |
|------------|---------|
| ENTRY | SESSION |
| 0.00 | -9.36 |

CA SUBSCRIBER PRICE

STN INTERNATIONAL LOGOFF AT 07:10:55 ON 15 MAY 2007